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Abstract
The slow clinical application of genomic medicine and Pharmacogenomics (PGx) is
attributed mainly to lack of knowledge of genomic medicine and PGx and confidence
among healthcare professionals, scarcity of infrastructure, and absence of
stakeholders’ interest. The objective of this study is to lay out a strategic plan for the
implementation of genomic medicine and PGx in the United Arab Emirates (UAE) by
exploring multiple areas: (1) the educational environment of genomic medicine and
PGx in colleges and universities; (2) knowledge, and attitude of the medical and health
sciences students, academics, and the healthcare providers; (3) the current
infrastructure of genetic and genomic services; (4) the views and vision of the
stakeholders. These areas were explored using a mixed method approach of qualitative
and quantitative research designs besides mapping the educational environment of
genomics and PGx as well as genetic and genomic services. The assessment of
university curricula resulted in “genetics” being included in the majority of universities
syllabus. PGx was taught in six universities but only for pharmacy majors. The mean
knowledge score of the surveyed healthcare providers was 5.2 (± 2.3) out of nine,
which shows a fair level of knowledge. However, 92% showed a positive attitude
regarding availability of genetic testing. The top identified barrier for implementation
for genomics and PGx was the cost of testing (62%), followed by lack of training or
education of genomics and PGx (58%) and lack of health insurance coverage (57%).
Moreover, the mean knowledge score for medical and health sciences students was 5.4
(± 2.7). Regarding genetic and genomic services, prenatal testing was the most offered
genetic service among the laboratories included in the study, and blood samples was
the main sample type for genetic testing followed by saliva. There was no
standardization of the accreditation bodies, health insurance coverage. Most of the
interviewed stakeholders emphasized the clinical demand for genomic medicine in
UAE. However, many were less inclined to articulate the need for PGx at present.
Most of stakeholders were in favour of building infrastructure for better genetic
services in the country. However, stakeholder from health insurance sector had a
contradicting stance about the cost-effectiveness of genomic medicine. The majority
were concerned with the legal and ethical aspects of genomic medicine and had an
opposing stance on direct-to-consumer kits. In addition, based on these findings, this
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thesis conceptualizes a pharmacogenomics’ literacy framework alongside a roadmap
for the implementation of genomic medicine and PGx in UAE.

Keywords: Genomics, pharmacogenomics, framework, knowledge, attitude,
stakeholders, education, healthcare providers, literacy, medical students, health
sciences students, genetic and genomic services.

ix

)Title and Abstract (in Arabic

خريطه لتطبيق طب الجينوم وعلم الجينوم الصيدالني في دولة االمارات العربية المتحدة
الملخص

يُعزى التطبيق السريري البطيء للطب الجينومي وعلم الجينوم الصيدالني ( )PGxبشكل أساسي
إلى نقص المعرفة الجينية والثقة بين المتخصصين في الرعاية الصحية ،وندرة البنية التحتية،
وغياب اهتمام أصحاب المصلحة .الهدف من هذه الدراسة هو وضع خطة استراتيجية لتطبيق
الطب الجينومي وعلم الصيدلة الجيني في دولة اإلمارات العربية المتحدة من خالل استكشاف
وتحليل مجاالت متعددة بما فيها )1( :البيئة التعليمية للطب الجينومي وعلم الجينوم الصيدالني في
الكليات والجامعات؛ ( )2معرفة وموقف طالب الطب والعلوم الطبية والصحية واألكاديميين
ومقدمي الرعاية الصحية؛ ( )3البنية التحتية الحالية للخدمات الجينية في الدولة؛ ( )4وجهات نظر
ورؤية أصحاب المصلحة والمسؤلين .تم استكشاف هذه المجاالت باستخدام نهج مختلط من تصاميم
البحوث النوعية والكمية إلى جانب رسم خرائط البيئة الحالية للتعليم واالختبار الجيني .أدى تقييم
المناهج الجامعية إلى إدراج "علم الوراثة" في معظم مناهج الجامعات ولكن يتم تدريس الجينوم
الصيدالني في ست جامعات ولطالب تخصصات الصيدلة فقط .ان متوسط درجة المعرفة الجينية
لمقدمي الرعاية الصحية الذين شملهم االستطالع  )2.3 ±( 5.2من تسعة ،مما يدل على مستوى
معقول من المعرفة ،أظهر  %92موقفًا إيجابيًا فيما يتعلق بتوافر االختبارات الجينية .كان العائق
األعلى الذي تم تحديده للتنفيذ هو تكلفة االختبار ( ،)%62يليه نقص التدريب أو التعليم ()%58
والتأمين الصحي ( .)%57عالوة على ذلك ،كان متوسط درجة المعرفة للطالب .)2.7 ±( 5.4
ضا بين المختبرات المشمولة في
كانت اختبارات ما قبل الوالدة هي الخدمة الجينية األكثر عر ً
الدراسة ،وكانت عينات الدم هي نوع العينة الرئيسي لالختبار الجيني يليها اللعاب .لم يكن هناك
توحيد لهيئات االعتماد ،تغطية التأمين الصحي .أكد معظم أصحاب المصلحة الذين تمت مقابلتهم
على الطلب السريري على الطب الجيني في اإلمارات العربية المتحدة .ومع ذلك ،كان الكثيرون
أقل ميال إلى التعبير عن الحاجة إلى علم الصيدلة الجيني في الوقت الحاضر .كان معظم أصحاب
المصلحة يؤيدون بناء البنية التحتية لتحسين الخدمات الجينية في البالد .ومع ذلك ،كان ألصحاب
ضا حول فعالية تكلفة الطب الجيني .كانت الغالبية
المصلحة من قطاع التأمين الصحي موقفًا متناق ً
معنية بالجوانب القانونية واألخالقية للطب الجينومي وكان لها موقف معارض من مجموعات
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تصورا إلطار محو األمية
األدوات الموجهة للمستهلكين .بنا ًء على هذه النتائج ،وضعت الدراسة
ً
في علم الصيدلة الجيني جنبًا إلى جنب مع خارطة طريق لتطبيق الطب الجيني وعلم الجينوم
الصيدالني في اإلمارات العربية المتحدة.
مفاهيم البحث الرئيسية :الطب الجيني ،علم الجينوم الصيدالني ،هيكلة ،المعرفة ،موقف ،صناع
القرار ،التعليم ،الكادر الصحي ،محو االمية ،طلبة الطب ،طلبة العلوم الصحية ،الخدمات الجينية
والجينومية.
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Chapter 1: Introduction
1.1 Overview
The overall aim of this research is to evaluate the current status of applying genomic
medicine and pharmacogenomics in the United Arab Emirates and construct a
roadmap for fully implementing these modern disciplines in the healthcare systems.
1.2 Statement of the Problem
The United Arab Emirates (UAE) is a rapidly developing cosmopolitan country
consisting of a mixture of multinational populations with varying educational
backgrounds, religious beliefs, and cultural practices. Although it has not been
accurately measured, it is believed that the health burden imposed by genetic and
genomic variations on the UAE national population is very high. For example,
according to the 2006 March of Dimes report, the UAE is ranked sixth out of 193
countries in terms of prevalence of birth defects, mainly caused by genetic disorders
(Christianson et al., 2006). In addition, at least 400 genetic diseases have been reported
among the UAE national population with over 250 of these disorders are caused by
mutations in single genes (Al-Gazali & Ali, 2010). In fact, the majority (> 60%) of the
reported single gene disorders are caused by homozygous mutations in recessive genes
due to the high rates of inbreeding and consanguinity (Al‐Gazali & Ali, 2010).
Furthermore, the incidence of multifactorial diseases that are partly caused by genetic
predisposition variations and interactions with the environment are very common. This
include diseases such as type 2 diabetes, obesity, hypertension, cancer,
neurodegenerative and cardiovascular diseases, and they have been steadily rising in
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the UAE over the past few decades. This is mainly due to the rapid socioeconomic
growth and a significant rise in life expectancy because of improved health care
systems (Al‐Gazali & Ali, 2010). However, the rapid increase in the prevalence of
these multifactorial diseases also suggest genetic predisposition to those diseases
revealed by rapid changes in lifestyle including diet. In addition, it has been
extensively documented that responses to medications used for the treatments of
various conditions such as diabetes, cancer, cardiovascular etc. are largely influenced
by genetic variation. These responses include therapy failure and/or adverse drug
reactions and negative side effects. Scholars in UAE have made major advances in the
understanding of the genetic causes of single genes disorders (Al-Gazali & Ali, 2010)
and are currently active in identifying genetic biomarkers that influence response to
some of the most commonly used medications (Al-Mahayri et al., 2020). This was
hugely facilitated by significant and recent advances in genotyping technologies such
as the advent of next generation sequencing technologies and bioinformatics tools
(Knaup et al., 2004). Despite these advances, the burden of genetic aberrations and
side effects or therapy failure is still high in UAE and therefore efforts (including
public health efforts) should be made to reduce them.
In recent years, translation of genomic discoveries into mainstream medical practice
and public health has gained significant attention and importance. However, there are
often major discrepancies in the pace of implementation of genomic medicine and
pharmacogenomics between different countries. The main reason does not only lie in
the limitation of resources but also in the slow pace of adoption of the new findings
and the poor understanding of the potential that this new discipline offers to rationalize
medical treatment and diagnosis. There are several examples from the successful
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implementation of genomic medicine in resource-limited and or developing countries,
particularly in the field of public health genomics, emphasizing in the latter case in
genomic education, stakeholder analysis and economics in pharmacogenomics
(Zgheib et al., 2020). These examples can be considered as model cases and be readily
replicated for the wide implementation of pharmacogenomics and genomic medicine
in other countries such as the UAE.
The researcher believes that in order to advance genomic medicine utility into the UAE
healthcare system, the public health aspects of genomics medicine and
pharmacogenomics has to be addressed. In other words, the investigator must
understand the current state-of-the-art healthcare environment for implementing
genomic medicine and pharmacogenomics in the clinic, including the available genetic
and genomic provisions, the educational and knowledge environments, and the stance
of stakeholders. This will set the scene for mapping the roadmap for the full
implementation of genomics medicine and pharmacogenomics in UAE with possible
adoption by other countries in the gulf or MENA region.
1.3 Relevant Literature
In the UAE, pharmacogenomics research started in 1996, initially involving
erythrocyte Glucose-6-Phosphate Dehydrogenase Deficiency (G6PD) related with
drug induced hemolytic anemia (Bayoumi, 1996), and later N-Acetyltransferase 2
(NAT2) (Woolhouse et al., 1997). In addition, the Cytochrome P450 2D6 (CYP2D6)
pharmacogenomic biomarker allele frequencies were investigated in the Emirati
population, including reporting of four novel CYP2D6 variants (Qumsieh et al., 2011),
and warfarin pharmacogenomics for the Emirati population (Al-Mahayri et al., 2019),
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as well as the pharmacogenomics of cancer in UAE (Al-Jaibeji et al., 2016). In
addition, significant advances had been made in understanding the molecular and
cellular basis of single disorders in the UAE (Akawi et al., 2016; Al-Gazali & Ali,
2010; Kizhakkedath et al., 2014; Komara et al., 2016).
Public Health Genomics: As defined in a review by Roberts et al. (2014), is a
comprehensive interdisciplinary initiative that defies succinct description or definition.
It includes within its purview many longstanding disciplines, such as genetic
epidemiology, biostatistics, health policy, and health education, as well as state-funded
programs focused on surveillance and prevention of birth defects and heritable
disorders. A study by Mitropoulou and co-workers undertook an initiative to assess
the level of support or opposition to pharmacogenomics and genomic medicine in
Greece (Mitropoulou et al., 2014). This survey indicated that the majority of the key
stakeholders, namely academic institutions and research organizations, the bioethics
council, private genetic laboratories, citizens, pharmaceutical and biotechnology
companies, genetics and genomics professional associations, the private health
insurance industry, pharmacists, and physicians (both geneticists and other
specialties), are highly supportive of pharmacogenomics and genomic medicine in
Greece. On the contrary, the Ministry of Health and the public health insurance funds
are opposed to the implementation of genomic medicine, while the Greek National
Medicines Organization displays a neutral stance, possibly since the cost-effectiveness
of a pharmacogenomics approach is not yet fully proven, the proper legislation to
oversee the operation of private genetic testing laboratories is not yet in place or simply
because they fear that reimbursement of genetic testing could increase rather than
decrease the overall healthcare expenditure. These latter stakeholders have high
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intervention potential against the implementation of pharmacogenomics and genomic
medicine into mainstream clinical practice. Subsequently, several opportunities and
obstacles in the pharmacogenomics and genomic medicine policymaking in Greece
derived from this analysis, based on the current position and intervention potential of
the key stakeholders. Similar analysis could also be conducted in the Gulf Cooperation
Council (GCC) countries particularly in the UAE, which will positively impact on the
pace of implementation of genomic medicine.
Moreover, insufficient genomics education and lack of genomics awareness among
healthcare professionals and the general public are two perspectives of the same issue,
which hinders the smooth incorporation of genomic medicine into clinical practice
(Mai et al., 2014; Reydon et al., 2012; Syurina et al., 2011). On one hand, the vast
majority of healthcare professionals declare that they feel insufficiently trained in
genomics to be able to engage with the delivery of genomics services, while on the
other hand, patients and the broader public tend to have low genomic literacy, which
impairs their capacity to meaningfully integrate genomic-based information into their
lifestyle decision-making, which is a challenge for public health genomics. On top of
this, pharmacogenomics education is not uniformly provided in the various academic
institutions worldwide, with the United States and Western European countries leading
the way and the Southeastern European countries lagging behind. A survey in 175
departments from 98 universities from 11 Southeastern European countries indicated
that

for

a

significant

number

of

universities

the

topic

of

pharmacogenetics/pharmacogenomics is not included at all in their undergraduate and
postgraduate curricula in health sciences (Pisanu et al., 2014). Additionally, studies
that surveyed Greek and Italian physicians indicated that only a small fraction of those
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feel competent enough either to propose a genetic test for their patients and/or to
interpret the results from such a test. These findings are in sharp contrast with the
current reality of pharmacogenomics education in North European countries, where
pharmacogenomics is more uniformly and extensively taught and highlight the need
for a more in-depth genomics education, either with the incorporation of
pharmacogenomics and genomic medicine in their undergraduate or graduate training,
or in the form of continuous medical education seminars. These studies might provide
the basis to harmonize pharmacogenomics education in Southeast European countries
with those of Northwestern European countries, such that it would directly impact on
a smoother integration of pharmacogenomics into mainstream medical practice.
As in other resource-limited regions, in Latin America for example, there are very few
postgraduate programs focused on genomics (Palacios & Collado-Vides, 2007). In
Africa, the high cost of genomics and low private investment is compounded by a
relatively low level of medical professionals with understanding of genomics
(Wonkam et al., 2006). In addition, another attempt in sub-Saharan Africa to
triangulate the views of multiple stakeholders related to Sickle-Cell Disease (SCD)
(doctors, parents with SCD-affected children and adult SCD patients) towards prenatal
diagnosis of SCD showed several discrepancies. The majority accepted the principle
of prenatal genetic diagnosis for SCD (78.7%, 89.8%, and 89.2% respectively);
however, parents (62.5%) were more in favor of termination of SCD-affected
pregnancy, than doctors and adults’ patients (36.1% and 40.9% acceptance,
respectively). These differential attitudes signal potential value-based conflicts on the
horizon and can usefully inform the future policy actions on the African continent, as
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OMICS technologies are increasingly employed in global health (Wonkam & Hurst,
2014).
1.3.1 The Educational Environment of Genomics
Pharmacogenomics (PGx) is the study of the impact genetic variation has on a person’s
drug response (Aneesh et al., 2009). PGx can play an important role in the future of
personalized medicine (Pisanu et al., 2014). PGx aims to minimize drug toxicity and
improve drug efficacy (Gurwitz et al., 2003; Pisanu et al., 2014).
The slow clinical application of PGx is mainly attributed to the lack of genomic
knowledge and lack of confidence among healthcare professionals (Pisanu et al.,
2014). Therefore, PGx education is essential, especially for pharmacists, in order to
support the delivery of PGx services (Talwar et al., 2019). Pharmacists have a unique
role due to their extensive knowledge in pharmacokinetics and pharmacodynamics of
drugs placing them in an integral position in which they can accelerate the
implementation of PGx (Elewa & Awaisu, 2019).
Several studies demonstrate that, despite their belief in the PGx importance in
pharmacy, pharmacists and healthcare providers perceive themselves to have low
confidence in their knowledge and application of PGx testing, indicating the need for
extensive PGx education in order to optimally guide patients (Formea et al., 2013;
McCullough et al., 2011; Pisanu et al., 2014). A survey by Formea et al. (2013)
assessed the pharmacist’s educational exposure to PGx pointed out that 67.1% reported
that PGx should be a focal point in school education yet 80.1% reported that it was not
an integral part of their education. In a larger context, a survey evaluating PGx
education in Southeast Europe reported that 85% of students and residents and 95% of
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specialized physicians believe PGx should be taught more extensively during medical
and surgery curriculums (Pisanu et al., 2014).
In 2005, The International Society of Pharmacogenomics (ISP) published
recommendations directed to the deans of Education at medical, pharmaceutical and
health schools worldwide (Gurwitz et al., 2005). It included a recommendation with
an urgency to implement PGx in core pharmacology curricula. Therefore, many
studies conducted evaluations and assessments of PGx education using the ISP’s
recommendations as the reference point (Green et al., 2010; Higgs et al., 2008; Karas
Kuželički et al., 2019).
The ISP recognized PGx to be crucial in integrating personalized medicine into clinical
practice and recommended that curricula of medical, health and pharmaceutical
schools include at least 4 hours, ideally 8 hours, of PGx teaching (Gurwitz et al., 2005).
A survey conducted on PGx education in British medical schools found that only 4 out
of the 14 respondents (29%) adhered to the ISP’s recommendation of the minimum 4
hours of teaching with the majority teaching for 1-2 hours during the degree’s
curriculum. However, the majority of respondents (84%) did teach the main elements
recommended by the ISP addressing the core elements of PGx (Higgs et al., 2008) . A
survey completed in 2010 showed that 74.4% of respondents of US and Canadian
medical schools have incorporated PGx into the degree’s curriculums but still less than
the 89.3% of US pharmacy schools and the 84% of British medical schools (Green et
al., 2010).
A study in 2014 concluded that PGx educational programs were not uniformly
provided. The study contrasted survey results from Northern and Southern European
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countries. It showed that Northern European countries, such as the United Kingdom,
Germany and Netherlands’s PGx education at undergraduate and postgraduate studies
level is more uniform than South Eastern countries where PGx is either not at all
included (Bosnia and Herzegovina, Cyprus and Malta), or included in some (Bulgaria,
Albania, Croatia, Serbia and Turkey), or extensively taught (Greece and Italy) (Pisanu
et al., 2014).
Little is known and studied regarding PGx educational environment and healthcare
professionals’ knowledge and attitudes towards the practice in the Gulf Cooperation
Council (GCC) countries. Nevertheless, two studies have been conducted in Qatar and
Kuwait and presented similar findings to the above-mentioned studies (Albassam et
al., 2018; Elewa et al., 2015). Lack of knowledge was highlighted as a top barrier in
both Qatar and Kuwait respondents despite their positive attitudes towards PGx.
Pharmacists exhibited more positive overall perceptions than doctors or physicians in
Qatar and Kuwait, respectively. This supports the importance and advocating of
pharmacists’ roles in pharmacogenetic services. In both studies, the majority of survey
respondents were aware of the importance of PGx in individualized medicine.
Moreover, both Qatar and Kuwait, pharmacists’ felt a higher sense of responsibility
and a more positive attitude than physicians in regard to PGx’s relevance in their
practice. Lack of confidence in applying PGx testing in practice was also evident in
Kuwait’s study with only 16% of respondents claiming high confidence. The high selfconfidence was significantly common in those with 10 or more years of experience
and previous exposure to PGx. Altogether, these findings contribute to the urgency
needed to offer effective PGx teaching programs.
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Another presented viewpoint in several studies is the provision of continuing educating
to interested pharmacists and healthcare providers (Green et al., 2010; Karas Kuželički
et al., 2019; Tsermpini et al., 2019). It can be deemed essential for the healthcare
professionals with insufficient genomic education and knowledge to implement PGx
into practice. There have been efforts to bridge this knowledge gap with providing
online e-learning and training courses (Tsermpini et al., 2019). In addition, low genetic
literacy of the public has been noted to be a problem that should be explored so as to
facilitate lifestyle decision-making based on genomic information (Karas Kuželički et
al., 2019; Pisanu et al., 2014; Tsermpini et al., 2019).
There is necessity to map the educational environment of genomics and PGx in the
UAE and to assess the readiness and willingness of the higher education system in
UAE to move forward with the implementation of genomic medicine and PGx.
1.3.2 The Knowledge and Attitude of the Healthcare Providers
There has been a substantial amount of investigation on genes and medications
detailing variations in drug response in individuals. An individual’s genetic makeup
significantly influences their reaction to the medication, accounting for an estimated
20 – 95% of variations in drug response (Bush et al., 2016; Chanfreau-Coffinier et al.,
2019a). These results give the premise to PGx and pharmacogenetics testing. The
utilization of genetic tests to determine the ideal pharmaceutical therapy for a patient
will enhance drug efficacy and will lower adverse drug responses (Haga et al., 2012;
Muzoriana et al., 2017; Pisanu et al., 2014). The expressions PGx and
pharmacogenetics are often used interchangeably; however, PGx has a greater
emphasis on the entire genome’s influence on drug response (Jarrar et al., 2019).
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Amongst 193 countries, the UAE is positioned sixth in the prevalence of birth defects,
predominantly due to genetic roots (Al-Gazali & Ali, 2010; Christianson et al., 2006).
PGx and genetic testing can act as a vital tool in comprehending genetic makeup,
diagnosing disease-causing genes, and delivering protective and supportive measures
to these diseases. The prospect of PGx implementation in medical practice is vastly
reliant on healthcare workers’ acceptance and the application of pharmacogenetics
tests (Mai et al., 2014; Pisanu et al., 2014; Rogausch et al., 2006). Pharmacists are
proposed to be at the heart of PGx implementation due to their integral and unique
roles as educators to healthcare workers and patients (Formea et al., 2013; Jarrar et al.,
2019; McCullough et al., 2011; Muzoriana et al., 2017). In fact, pharmacists expressed
more positive perceptions than physicians toward PGx, as stated in two previous
studies in Qatar and Kuwait (Albassam et al., 2018; Elewa et al., 2015). In these
studies, the majority of survey respondents were aware of the significance of PGx in
individualized medicine. As the largest group in the healthcare workforce, nurses also
assume a central role in patient advocacy as defined by the American Nursing
Association. Therefore, they are anticipated to be acquainted on this type of genetic
testing to assume responsibility in incorporating it in clinical setting (Dodson, 2011).
The laborious implementation of genetic testing and PGx can be associated to many
reasons, including but not limited to, a lack of evidence in clinical use, costing, and
ethical concerns (Dodson, 2011; Muzoriana et al., 2017). Despite the limited
widespread implementation of PGx testing, it is currently being applied and used to
model treatments for certain cancers, diabetes, and cardiovascular diseases (Nishant et
al., 2012). Cardiovascular Disease (CVD) represents one of the foremost health threats
in the UAE. According to the World Health Organization (WHO) report on the UAE,
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40% of all deaths were due to cardiovascular diseases. The Department of Health in
the emirate of Abu Dhabi (DOH) reported that 71% of the population has at least 1
CVD risk factor, foreseeing a rapid increase in future CVD events. Moreover, 12% of
all deaths were due to cancers and 5% to diabetes (Department of Health, 2018; World
Health Organization, 2018). Many hurdles to PGx application have also been reported;
however, lack of genomic knowledge and lack of healthcare professionals’ confidence
in decision-making are widely prominent factors affecting the practice of PGx (Abdela
et al., 2017; Muzoriana et al., 2017; Pisanu et al., 2014). Therefore, it has been
underscored that more concentrated and advance PGx education and training is crucial
for healthcare professionals, especially pharmacists, for better the delivery of PGx and
personalized medicine services (Abdela et al., 2017; Kudzi et al., 2015; Muzoriana et
al., 2017; Talwar et al., 2019). Moreover, to successfully translate the discipline of
PGx into clinical practice, all members of the healthcare workforce need to be
knowledgeable and educated on the subject. There are no current research studies, to
date, in the UAE assessing health professionals’ stance and attitudes towards PGx and
genomic medicine.
1.3.3 The Knowledge and Attitudes of Health Science Students
The accomplishment of the Human Genome Project in 2003 boosted personalized
medicine and made the concept more prevalent between clinicians, and it encouraged
the implementation of genomics education (Giri et al., 2018; Karas Kuželički et al.,
2019; McCullough et al., 2011). This was presented in a global survey performed to
gauge the education progress of PGx, showing that 82.1% of the programs began the
implementation of PGx topics after the completion of the Human Genome project
(Karas Kuželički et al., 2019). In 2007, four years after the Human Genome Project
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was completed, the Food and Drug Administration (FDA) executed pharmacogenetics,
labeling changes to warfarin to indicate that genetic makeup can affect dosage
requirements and risks (Formea et al., 2013; McCullough et al., 2011). This change,
among several others, was deemed an important tangible step in PGx and personalized
medicine (AlEjielat et al., 2016; Formea et al., 2013; McCullough et al., 2011). Future
advances in genomic medicine and PGx will require health professionals to be
equipped with the knowledge and tools in order to fully apply and implement PGx in
clinical practice as best as possible (Green et al., 2010; Gurwitz et al., 2005; Higgs et
al., 2008; Tsermpini et al., 2019). In spite of the emphasis and evidence on the
importance of genomic medicine and PGx in clinical practice, many healthcare
professionals articulate a lack of confidence in the implementation of PGx in practice
(Abdela et al., 2017; McCullough et al., 2011). This is fairly attributed to lack of
education, a widely highlighted barrier, which can lead to knowledge gaps and
difficulty in interpreting and communicating PGx results (Abdela et al., 2017).
Medical and health science students represent future health professionals, and their
perceptions are essential to expanding awareness on personalized medicine and PGx
(Abdela et al., 2017; Green et al., 2010; Gurwitz et al., 2005; Gurwitz et al., 2003).
Particularly, pharmacists, as drug experts, are considered fundamental in the clinical
implementation of PGx due to the nature of their education and background (AlEjielat
et al., 2016; McCullough et al., 2011; McMahon & Tucci, 2011; Muzoriana et al.,
2017). In order to increase genomic medicine and PGx awareness and competency
among medical and health science students, their knowledge, attitudes, and practice
towards genomic medicine and PGx should be evaluated. Very little is known and
studied regarding the genomic medicine and PGx educational environment and
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Eastern and, more specifically, Gulf Cooperation Council (GCC) countries. Three
studies have been conducted in Saudi Arabia, Qatar, and Kuwait. Synonymous with
other studies, respondents identified lack of knowledge to be one of the challenges,
despite the positive attitudes in PGx clinical implications (Albassam et al., 2018;
Algahtani, 2020; El Shanti et al., 2015). Assessment of the knowledge and attitudes
regarding genomic medicine and PGx among medical and health science students is
key. They are the future adopters of this field, therefore an attempt to assess and bridge
the knowledge gap and gain insight on their opinions and views on the practice of
personalized medicine and PGx will guide the stakeholders.
1.3.4 The Current State of Genetics Testing Services in UAE
The UAE is a federation of seven emirates situated in the southeast of the Arabian
Peninsula. It enjoys a unique strategic location that has made it a world-class and a
multicultural and multiracial country with diverse ethnic groups from Arabia, Persia,
Baluchistan, and Africa (Al-Gazali & Ali, 2010). The fast pace of economic
development is making the UAE one of the most ethnically diverse countries in the
world (Al-Gazali & Ali, 2010; Barakat-Haddad, 2013). Consanguineous marriages
within most UAE subpopulations are still the norm, leading to a high frequency of
recessive conditions and genetic disorders (Al-Gazali & Ali, 2010). The fields of
genetics and genomics are key for detecting and preventing genetic disorders.
Genomic medicine is defined as using an individual patient’s genotypic information
for their clinical care (Williams, 2019). Genetic testing is often crucial for accurate
diagnosis and effective prevention and treatment of human genetic diseases (Zhang &
Li, 2014). A few years back, genomic DNA sequencing in the UAE was restricted to
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research settings, but is now integrated into clinical settings, making it possible to
diagnose and treat diseases as well as to screen and prevent uncommon diseases
(Zhang & Li, 2014). The advent of next-generation sequencing technologies has
significantly reduced the cost and the time required for whole-human-genome
sequencing (Lappalainen et al., 2019). Beyond the widespread use and technical
requirements of genomic technology, there are real barriers that can impact the clinical
implementation of genomics into healthcare systems. The level of readiness of
healthcare systems to globally share clinical, epidemiological, and genomic data to
optimize clinical benefits is important. Over the next 5 years, it is expected that
genomic data from over 60 million patients will be generated within healthcare
systems worldwide (Stark et al., 2019a). Although limited data is available on
diagnostic yields, having population databases as a reference, and implementing,
building, and sharing them will improve the interpretation of variants globally (Landry
et al., 2018). The sharing of data on genomic variants and phenotypes globally will
provide useful information necessary to improve clinical care and empower device and
drug manufacturers who are promoting tests and treatments for patients (ACMG Board
Of Directors, 2017). Despite the expansion in genomic testing worldwide, it still has
major problems in many developing countries, where officials lack recognition of the
importance of integrating medical genetics into clinical settings. In other cases, there
is a shortage of trained personnel and laboratory infrastructure for genetic tests,
although the management of patients with genetic disorders relies heavily on the
laboratory infrastructure (Zhao et al., 2013). Despite the high frequency of genetic
disorders in the UAE, only a few major centers are providing genetic testing and
counseling. The Genetic and Thalassemia Center based in Dubai, the College of
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Medicine and Health Sciences based in Al Ain, and the Mother and Child Health
Department based in Abu Dhabi are among these centers. In addition, there is the
United Arab Emirates Genetic Diseases Association and the Center for Arab Genomics
Studies in Dubai (Al-Gazali & Ali, 2010). Within the UAE government, there is a
strong focus on improving and developing fundamental data on the genetic basis of
disease and diversity. Despite many genomic projects and other efforts made in the
Arab countries focused on understanding the unique genetic makeup of this region’s
citizens, information on the genomes of populations from these nations remains
limited. In addition, despite the progress made in recent years, many disorders in the
UAE are still unstudied (Al-Gazali et al., 2005). Therefore, the establishment of a
specific database would be valuable for planning and providing effective diagnosis and
prevention systems for healthcare providers and researchers in the UAE and the region.
In the literature, there is no precise information about the first genetic laboratory
established in the UAE; however, a total of three genetic centers were established at
an early stage in the country. A thalassemia and genetic center were established in
Dubai back in 1989 (Al-Gazali & Ali, 2010). This center provided services for
thalassemia patients from throughout the UAE and was equipped with cytogenetics,
biochemical, and molecular laboratories (Al‐Gazali & Ali, 2010). The second genetic
center is at the College of Medicine & Health Sciences at United Arab Emirates
University. It was established back in 1990 and has been providing services for patients
from all over the country. The third one was under the remit of the maternity and childcare unit at the Ministry of Health in Abu Dhabi and was established in 1999. Genetic
counseling was provided at the three centers by geneticists, who were not supported
by genetic counselors, health visitors, or social workers (Al-Gazali et al., 2005). More
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genetic centers are now being advertised across the UAE, but little is known about the
general landscape in which genetic testing is operating in the country. Furthermore,
there is no evidence of any assessment having been performed on the quality of genetic
analysis services provided across the country. There is a need to map the genetic
services in the UAE in order to establish a genomic infrastructure database that would
provide an opportunity to resource and promote best practices and help in establishing
a roadmap for implementing genomic medicine in the country.
1.3.5 Stakeholders’ Interest and Attitudes
It has been 18 years since the first milestone of genomic medicine and
pharmacogenomics occurred in 2004, when the FDA approved Gefitinib for the
treatment of genetic mutation metastatic non-small cell lung cancer (Shendure et al.,
2019). Cornucopia of studies had emphasized the evidence-based value of genomic
medicine and pharmacogenomics in breadth of spheres like oncology, neurology,
pediatric, nephrology (Evans et al., 2020; Geiersbach et al., 2020; Green et al., 2019;
Lucas et al., 2020; Monaghan et al., 2020; Neill et al., 2020; Riggs et al., 2020; Uddin
et al., 2020). For example, genomics took center stage in the COVID-19 pandemic and
proved its value with sequencing the coronavirus genome (Murray et al., 2020;
Randhawa et al., 2020; Uddin et al., 2020). Despite these leitmotif evidence, still there
is a chasm between research and the full implementation of genomic medicine and
pharmacogenomics in clinical practice (Brunette et al., 2020; Kochan et al., 2020;
Lauschke & Ingelman-Sundberg, 2020; McClaren et al., 2020b). Extensive research
efforts have investigated and diagnosed factors associated with the slow-uptake of the
full implementation of genomic medicine and pharmacogenomics, and they concluded
that knowledge gap of healthcare providers, current policy challenges, reimbursement
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of the cost of genetic tests, stance of stakeholders are some of the attributes that
hampered

the

full

pragmatic

implementation

of genomic

medicine

and

pharmacogenomics internationally (Best et al., 2020; Brunette et al., 2020; Klein,
2020; Kochan et al., 2020; McClaren et al., 2020a; McClaren et al., 2020b).
Directing the lens to the MENA region, additional and unique challenges are
introduced. A perspective paper by Zgheib et al. (2020) mapped the landscape of
precision medicine as well as the gap, challenges and needs in low- and middle-income
countries. The researchers projected the model of “fast-second winner” that
recommends pursuing country-specific genome wide association. This approach
claims to create rapport with stakeholders and accelerates the implementation of
genomic medicine in the region.
For effective introduction, set up and implementation of genomic medicine and
pharmacogenomics, the pivotal role of stakeholders cannot be overlooked (Chenoweth
et al., 2020; Mitropoulou et al., 2020; Mustapa et al., 2020; Rigter et al., 2020).
Fourteen stakeholders were identified as key players in the micro, meso and macro
levels of genomic medicine and pharmacogenomics (Mitropoulou et al., 2020).
Mapping the power, interest and stance of aforementioned stakeholders is a mainstay
in the endeavor of full genomic medicine and pharmacogenomics implementation
(Chenoweth et al., 2020; Mitropoulou et al., 2020; Mustapa et al., 2020; Rigter et al.,
2020).
Different tools, procedures, frameworks, and models are used to map the stakeholders’
interest, power, and stance. Mendelow’s matrix, PolicyMaker and PMP stakeholder
management are examples of these tools (Altahtooh, 2020; Bernstein et al., 2020;
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Mendelow, 1981; Mitropoulou et al., 2014; Potnis & Gala, 2020). Moreover, some of
these tools had been previously employed and validated on the stakeholders of
genomic medicine and pharmacogenomics to offer a vantage point for the systematic
implementation of genomic medicine and pharmacogenomics (Chanfreau-Coffinier et
al., 2019b; Esquivel-Sada et al., 2019; Faulkner et al., 2020; Mitropoulou et al., 2014).
There are several studies in UAE about genomic medicine (Al-Mahayri et al., 2019;
Alblooshi et al., 2019; AlSafar et al., 2019; Jithesh & Scaria, 2017; Osman et al., 2019).
Nevertheless, no studies about mapping the power, interest, and the attitude of the
various stakeholders in the UAE pertaining to the implementation of genomic
medicine and pharmacogenomics have been conducted. Therefore, mapping the
power/interest of various stakeholders in UAE using the Mendelow’s matrix is a
pivotal step to facilitate constructing a roadmap for the full implementation of genomic
medicine and pharmacogenomics in UAE.
1.4 Research Objectives
The overall aim of this research is to evaluate the current status of applying genomic
medicine and pharmacogenomics in the UAE and assemble a roadmap for fully
implementing these modern disciplines in the healthcare systems. The specific
objectives of this research are to:
1. Assess the readiness and willingness of the higher education system in UAE to move
forward with the implementation of genomic medicine and pharmacogenomics in the
UAE.

20

2. Assess the level of knowledge and attitude of healthcare providers about genomic
medicine and pharmacogenomics in addition to their perceived barriers toward full
implementation of genomic medicine and pharmacogenomics in UAE.
3. Assess the level of knowledge and attitude of medical and health science students
concerning genomic medicine and pharmacogenomics in supplement to their
perceived barriers toward full implementation of genomic medicine and
pharmacogenomics in UAE.
4. Map the current state of genetics and genomic testing services and regulatory aspects
in the UAE.
5. Establish a stakeholders’ matrix of power and interest toward genomic medicine and
pharmacogenomics to facilitate the implementation of genomic medicine and
pharmacogenomics in UAE.
1.5 Research Hypothesis
The research questions articulated as “Is the UAE ready to fully implement genomic
medicine and PGx? “What is the level of readiness of the UAE to implement genomic
medicine and PGx, and what would be of the most appropriate way to fully implement
these in the country?”
The null hypothesis:
UAE is not ready to fully implement genomic medicine and PGx in terms of
infrastructure, educational environment, stakeholder's stance, knowledge, and
attitudes of health care providers.
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Chapter 2: Methods
2.1 Research Design
To build the roadmap for the implementation of genomic medicine and
pharmacogenomics in UAE, multi-objectives ought to be explored: starting with the
current infrastructure of genetic services in UAE, the educational environment of
genomic medicine and pharmacogenomics in the colleges and universities in UAE.
Also, the knowledge and attitude of the medical and health sciences students,
academia, and the healthcare providers should be looked at. Moreover, the views and
vision of the stakeholders in UAE should also be taken into consideration.
To tackle these objectives, the researcher employed a mixed method approach of
qualitative research designs (focus group discussions and semi-structured interviews)
and quantitative research designs (cross-sectional survey) as well as mapping the
current environment of education and genetic testing using website surfing augmented
by site visit, questionnaires, and semi-structured interview. This is illustrated in Figure
1 in which the methods and stakeholders are represented by cars and buildings
respectively.
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Figure 1: Prototype of the employed methods and stakeholders

Researcher employed mixed method methodology to assess the readiness and
willingness of the higher education system in UAE to move forward with the
implementation of genomic medicine and pharmacogenomics in the UAE. This was
assessed by conducting semi-structured interviews with the academia and
commissioners and mapping the medical and health sciences curricula of UAE
universities. Moreover, to quantify the core of courses and assess the attitudes of
academia, the researcher distributed a validated survey. Mixed methodology was
adopted to assess the level of knowledge and attitude of healthcare providers about
genomic medicine and pharmacogenomics in addition to their perceived barriers
toward full implementation of genomic medicine and pharmacogenomics in UAE.
Focus group discussions were employed as a qualitative tool to explore the attitudes
and barriers of healthcare providers, namely pharmacists. Moreover, cross sectional
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methodology was employed to quantify these objectives. A validated survey was
distributed to assess the level of knowledge and attitude of medical and health science
students concerning genomic medicine and pharmacogenomics and their perceived
barriers toward full implementation of genomic medicine and pharmacogenomics in
UAE. To map the current state of genetics and genomic testing services and regulatory
aspects in the UAE, researcher exercised manual mapping of the websites of the
laboratories in complement with quantitative questionnaires. Qualitative semistructured interviews were conducted to establish a stakeholders’ matrix of power and
interest toward genomic medicine and pharmacogenomics. The compiled findings and
results guided the construction of the roadmap to implementation.
2.2 Data Collection
2.2.1 Assessing the Educational Environment in UAE
The researcher employed a mixed method triangulated approach to map the genomics
and PGx educational situation in the UAE. A qualitative approach was used, exploiting
interviews and content analysis of the educational curricula of different UAE
universities. This was coupled with interviews with teaching faculty members and
higher education experts from the Commission for Academic Accreditation (CAA) at
the Ministry of Educations in UAE, in addition to mapping the genomics and PGx
curricula in medical and health sciences degrees in the accredited universities in UAE.
Additionally, questionnaires had been distributed among the teaching faculty members
in UAE accredited universities to get an in-depth understanding of their needs and
vision of the future of genomics and PGx.
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Qualitative approach:
Mapping the genomics and pharmacogenomics curricula in medical and health
sciences degrees in the accredited universities in UAE:
The researcher identified all accredited universities, private and public, in the seven
emirates of UAE utilizing the official website of the UAE ministry of education.
Universities that do not offer health sciences, medical or dental programs were
excluded. The university’s latest syllabus and webpage were used to map the curricula
in medical and health sciences degrees in identified universities. The keywords used
were “genetics, genomics, molecular genetics, pharmacogenetics, pharmacogenomics,
public health genomics, medical genomics, and molecular diagnostics”. An excel sheet
used to record and code the collected data. Course modules were grouped into 11
course categories: genetics, genomics, pharmacogenetics, pharmacogenomics,
molecular diagnostics, molecular biology, molecular biology techniques, genetic
engineering, gene therapy, clinical genetics, and biotechnology. Total course credits
from all universities were summed up for each course category.
A total of four semi-structured interviews were conducted- two with teaching faculties
and two with commissioners in UAE. The interview guide was constructed and then
reviewed by experts in the field of genomic medicine, public health, qualitative study,
and epidemiology. All interviews were audio recorded and field notes were logged
during and after the interview. Each semi-structured interview took 40 to 60 minutes
and was performed at participants’ workplace. The interviews were transcribed in a
verbatim manner. Grounded theory guided the independent extraction of the codes and
themes by the two researchers. NVivo software version 12 was used for coding and
themes extractions.
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Quantitative Approach:
Assessing the current status of genomics and PGx teaching in medical and health
sciences degrees in the accredited universities in UAE and the attitude of academia
toward genomics implementation:
A validated and piloted questionnaire was used. The questionnaire was based on
validated and published questionnaires that were used to assess PGx in the Curricula
of Colleges and Schools of Pharmacy in the United States as well as other published
work (Murphy et al., 2010; Pisanu et al., 2014). The questionnaire had been piloted
among public health and pharmacy faculty members and amended accordingly. The
questionnaire was randomly emailed by an identified focal person (dean, secretary
identified from website of the colleges) to the academia teaching in the medical and
health sciences degrees in the accredited universities in UAE. The Statistical Package
for the Social Sciences (IBM SPSS) was used to perform descriptive statistics on the
data such as frequencies and means.
This study had been approved by the social science research ethics committee of
United Arab Emirates University (UAEU) ERS_2017_5671. Participants were asked
to read the information sheet of the study and sign the consent form before
participating in the study.
2.2.2 Assessing the Knowledge and Attitude of Healthcare Providers
A mixed method approach of both quantitative and qualitative methodology had been
commissioned to ensure deep and comprehensive assessment. A cross-sectional study
using a validated questionnaire was conducted (Albassam et al., 2018; Carver et al.,
2017; Mai et al., 2014). Inclusion criteria embodied registered healthcare workers
practicing in either public or private hospitals or clinics. Registered pharmacists,
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nurses, physicians, managers, and allied health practitioners were invited as they were
identified by literature as the stakeholders for the adoption of genetic testing and PGx.
The online Shafafiya portal of the DOH that contains a population frame for all the
healthcare providers working in the UAE had been accessed (data included: clinician
license, clinician name, major, profession, category, gender, facility name, facility
license, location, facility type, and the status). Facilities were stratified per location
and then contacted by the researcher either by email or by site visit to grant approval
and distribution of the questionnaire among the healthcare providers. Random
selection sampling and chain sampling techniques had been employed. The survey was
offered both in person and via the internet to accommodate the generally busy schedule
of healthcare providers, as some preferred answering the questionnaire on the spot
while others preferred filling it out online at a later time when they were less busy.
Moreover, some hospitals and clinics asked for the online survey so that they could
circulate it to their healthcare providers via email, while other clinics asked for printed
versions to be distributed by their human resources staff. Furthermore, the internetbased medium was used for snowball sampling. The survey was administered between
April and September 2019 in order to reach the calculated target sample size. The
survey was also kept open longer to accommodate the summer break period. This study
was approved by the Social Science Research Ethics Committee of United Arab
Emirates University (UAEU) ERS_2017_5671. Participants were asked to read the
study’s information sheet and sign a consent form before answering the survey. The
questionnaire was designed based on previously validated and used tools to explore
and identify knowledge, awareness, attitude, behavior, and interest in genetic testing
and PGx (Albassam et al., 2018; Carver et al., 2017; Mai et al., 2014). The
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questionnaire had been piloted among 50 medical and health sciences professionals
and amended accordingly. The questionnaire was administered in English and it was
divided into 3 sections. Section 1: Demographic data, e.g., age, gender, occupation,
years of experience, and nationality. Section 2: Knowledge; nine questions about
specific facts about genomic and PGx. A knowledge score was calculated from nine
true and false questions about genetics and PGx. Three knowledge levels were created
based on the number of correct answers: good (7–9 correct answers), fair (4–6 correct
answers) and poor (3 or less correct answers). Section 3: Attitudes of healthcare
workers with regard to the ethical, social, and economic implications of genetic testing
and PGx in addition to their perceived barriers for the full implementation of genetic
testing and PGx in the UAE. For the attitudes, a 5-point Likert scale of strongly agree,
agree, strongly disagree, disagree, and neutral was collapsed into agree, disagree, and
neutral for ease of analysis and interpretation. For statistical analysis, the sample size
had been estimated using the formula for cross-sectional studies; (1.962 × P (1 − P)/d2),
where P = 0.27 (27% is the prevalence reported in similar previous studies) and d =
0.05. Sample size = 3.84 × 0.27 (1 − 0.27)/0.0025 = 303 healthcare workers.
Accounting for an average response rate of 46% (reported in previous studies), the
calculated sample size needed for this analysis was 444 healthcare workers.
International Business Machines Corporation Statistical Package for the Social
Sciences (IBM SPSS) Statistics 26 was used for data analysis. Descriptive statistics
(means, standard deviation, SD) and frequencies (percentages) were used to represent
the data. Chi-squared test and Monte Carlo exact test were used to determine any
significant differences in the distribution of respondents’ characteristics between the
knowledge levels. Questions about genetics were selected from the literature with
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validated questions which recommended that the cutoff for good knowledge is 75%,
and we followed the analysis of the literature in giving all the questions of the
knowledge the same weights.
A qualitative inductive grounded theory approach informed by the Corbin and Strauss
(2008) methodological pathway was followed to develop a theory related to the field
of pharmacogenomics in the UAE. Four focus group discussions were conducted to
explore the knowledge, attitude and perception of registered pharmacists working in
the UAE toward genomics and pharmacogenomics. Pharmacists were invited through
hospitals, clinics and community pharmacies and using snowball techniques. Inclusion
criteria included any registered pharmacists of any nationality working in either private
or public settings and in any health care setting (tertiary hospitals, health clinics or
community pharmacies) as either outpatient, inpatient or clinical pharmacists.
Participants were invited in person, by telephone and via email. All who agreed to
participate received an official invitation via email including details of the meetings as
well as the information sheet of the study and time and location of the meeting. A
reminder email and messages were sent one week before the session and repeated 24
hours and 2 hours before the session. The sessions were conducted over weekends at
the College of Medicine and Health Sciences of the United Arab Emirates University
to ensure that participants attend the meeting. Each session lasted 90 min. Saturation
was reached after the fourth focus group discussion. Researchers followed an interview
guide with questions and prompts that had been revised by experts in the field of
qualitative studies, public health as well as genomic medicine. The Health Literacy
Skills theoretical framework guided the elements of interview guide (Squiers et al.,
2012). All four focus group sessions were audio taped during the sessions and field
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notes were recorded during and after the focus group sessions. Participants were asked
to read the information sheet of the study as well as to sign the consent form before
starting the discussion. A verbatim transcription for all focus group sessions was
reviewed by two researchers and then was returned for random participants for
comments and/or corrections to ensure credibility and reflexivity. All four focus group
sessions were coded, and themes were extracted. Inter-coder reliability was ensured.
The transcription was uploaded on NVivo 12 (Windows version) for analysis to extract
themes and visualize the findings.
2.2.3 Assessing the Knowledge and Attitude of Students in UAE
A cross-sectional study had been utilized. The targeted sample included undergraduate
and postgraduate medical and health science students (medicine, pharmacy,
laboratory, medical imaging, radiology, radiography, biochemistry, biomedical
sciences, dentistry, pharmacology, physiology, psychology, public health, and
occupational health) in the UAE, as they are the future adopters of genomic medicine
and PGx. Random selection sampling techniques had been employed, in which all the
universities and colleges in the UAE that offer degrees in medicine, pharmacy,
laboratory, and nursing had been contacted and asked to distribute the questionnaire
among their students. Furthermore, snowball sampling had been applied, where
existing students recruit future subjects from among their acquaintances that meet our
inclusion criteria. The survey was administered electronically between December
2018 and October 2019. The questionnaire was designed based on the literature to
explore and identify knowledge, awareness, attitudes, behavior, and interest in
genomic medicine and PGx among medical and health science students. It
encompassed validated questions used in the Public Understanding and Attitudes
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towards Genetics and Genomics (PUGGS) questionnaire (Carver et al., 2017), the
United States (Murphy et al., 2010), and Southeast Europe (Pisanu et al., 2014). The
questionnaire had been piloted among 50 medical and health science students and
consequently modified it. The questionnaire was administered in English and it was
divided into 3 sections: Section 1: Demographic data: age, gender, faculty, year of
study, major, and type of university (government or private). Section 2: Knowledge:
nine questions about basic genomic medicine and PGx facts. Section 3: Attitudes of
the students toward ethical, social, and economic implications of genomics and PGx
and their perceived barriers for the full implementation of genomic medicine and PGx
in the UAE. Sample size had been calculated using the formula for cross-sectional
study (1.962 × P (1−P) ÷ d 2), where: P = 48 (48% is the prevalence of the knowledge
of genomics among medical and health science students that was extracted from the
literature of similar studies) and d = 0.05. The sample size (students) = 3.84 × 0.48
(1−0.48) ÷ 0.0025 = 383 students. Similar regional studies showed an average response
rate of 84%, therefore an additional 61 students were needed to reach a final sample
size of 444 students. IBM SPSS Statistics version 26 had been applied to analyze the
data. Descriptive statistics (means, standard deviation, and frequencies) was used to
represent the data. The chi-squared test was used to determine any significant
differences in the distribution of the students’ characteristics between the knowledge
levels. A knowledge score was calculated from nine true or false questions about
genetics and PGx. Three knowledge levels were created based on the number of correct
answers: good (7–9 correct answers), fair (4–6 correct answers) and poor (3 or less
correct answers). For the attitudes, a 5-point Likert scale of strongly agree, agree,
strongly disagree, disagree and neutral was collapsed into agree, disagree and neutral
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for ease of analysis and interpretation. The frequency distribution of the Likert scale
results was reported as percentages to recognize the challenging areas of genomic
medicine and PGx that students identify with. This study had been approved by the
Social Science Research Ethics Committee of United Arab Emirates University
(UAEU) ERS_2017_5671. Participants were asked to read the information sheet of the
study as well as to sign the consent form before starting the survey.
2.2.4 Mapping Genetics Testing Services in UAE
This study was conducted using two pronged and complementary approaches: (1)
manual mapping of the laboratories in the UAE claiming to provide genetic and/or
genomic testing, and (2) handing out questionnaires in person onsite at these
laboratories in order to obtain information on the services that they provide and
identify contrast between website and onsite. Researcher relied on the definition of
genetic test of Holtzman (1999) as the analysis of human DNA, chromosomes,
proteins, and metabolites to discover heritable disease-associated genotypes,
mutations, phenotypes, or karyotypes for medical reasons. This study had been
approved by the social science research ethics committee of United Arab Emirates
University ERS_2017_5671. Participants were requested to read the information sheet
of the study as well as to sign the consent form before contributing to the study.
2.2.4.1 Website mapping
In a Google search engine, the following search terms were entered: “Genetic/genomic
testing,

UAE;

Genetic/genomic

counseling,

UAE;

pharmacogenomic/pharmacogenetic, UAE; Genetic screening, UAE; Genetic service,
UAE”. Such a wide range of search terms would allow capturing an accurate and
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comprehensive picture of the laboratories in the UAE offering genetic tests; hence this
is the first baseline in UAE. All websites were in English and/or Arabic. Using
Microsoft Excel, the following data had been collected: name of the laboratory,
location, contact number, type of services offered, availability of genomic biobank,
availability of bioinformatics analysis, DNA source, availability and type of genetic
counseling, accreditation, costs, insurance coverage, consent forms, and whether
samples are processed locally or abroad.
2.2.4.2 Onsite mapping
A validated questionnaire by Balasopoulou et al. (2017) with 33 questions was handed
onsite between June 2019 and the end of February 2020 to all the mapped laboratories
claiming to provide genetic testing services. The questionnaire captured: the technical
aspects of the provided services including availability of genomic biobank, availability
of bioinformatics analysis, DNA source, availability and type of genetic counseling,
accreditation, costs, insurance coverage, consent forms, and whether samples are
processed locally or abroad, gene-panel selection, logistics, reporting of results, and
cost / reimbursement. Responses were transcribed to Qualtrics survey software for
standardized analysis and reporting of findings. The fact that several laboratories have
more than two branches in more than two emirates was taken into consideration to
avoid duplicate responses. Results were reported using frequencies and percentages.
Percentages were calculated depending on the method of mapping: for the websitemapped laboratories the denominator was the total number of the mapped laboratories
using web search while the denominator for onsite was the total number of laboratories
that filled the survey. This distinction had been employed to avoid inflation and over
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estimation or duplication and to identify contrast between website and onsite mapping.
Qualtrics survey software was used to generate reports of onsite findings.
2.2.5 Establishing a Stakeholders’ Matrix of Power and Interest
A qualitative approach using in-depth interview had been used to explore the power,
interest, and the attitude of the stakeholders in the UAE toward pressing health
genomics aspects. Various stakeholders were identified by experts in the field of
epidemiology, genomic medicine and pharmacogenomics, and public health. The
criteria of selecting the stakeholders are mainly involved in the micro, meso and macro
pillars of the infrastructure of genomic implementation.
The interview guide had been constructed and then revised by experts in the field of
genomic medicine, public health, qualitative study, and epidemiology. The inverted
pyramid format had been selected for the interview guide and it composed blended of
open ended and closed ended questions and prompts that gauge the attitude,
commitment, power, and interest of the stakeholders toward genomic medicine and
pharmacogenomics in UAE, as well as their legal and ethical concerns. The following
are the focal points of the interview:
A- Clinical demand for genomic medicine and pharmacogenomics in UAE.
B- Infrastructure preference (in-house or outsource outside the country).
C- Opinion whether genomic medicine /pharmacogenomics is cost-effective.
D- Implementation approach: preemptive approach or gene-specific approach.
E- Attitude about their desire to undertake genetic test.
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F- Attitude toward online direct to consumer kits.
G- Concerns about the ethical and legal aspects of genomic medicine in UAE.
H- Their perceived barriers and challenges for the full implementation of genomic
medicine and pharmacogenomics in UAE.
The study sampling method was mainly purposive. Snowball technique was used to
connect with some stakeholders. Thirteen in-depth semi-structured interviews were
conducted with the identified stakeholders. All 13 interviews were audio recorded and
field notes were logged during and after the interview. This study had been approved
by social science research ethics committee of United Arab Emirates University
(UAEU) ERS_2017_5671. Participants were asked to read the information sheet of the
study as well as to sign the consent form before starting the interview. Each semistructured interview lasted from 40 - 60 minutes and was conducted in a location
convenient to the stakeholder.
A verbatim transcription for all interviews was reviewed by two researchers and then
was returned for random participants for comments and or corrections to ensure
credibility and reflexivity. The analysis of the qualitative research data was a hybrid
of inductive grounded theory approach informed by the Corbin and Strauss (2008) to
formulate the themes and concepts and deductive using the matrix framework of
Mendelow for mapping the interest and power of stakeholders (Corbin & Strauss,
2008; Thornberg et al., 2014).
Inter-coder reliability was ensured and transcription was uploaded on NVivo 12
software for analysis to extract themes and visualize the findings. A tally matrix was
created to signify the preponderance of categories and to isolate outliers and to provide
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decisive confidence (Groenland, 2018). The standards for reporting qualitative
research checklist by O’Brien et al. (2014) and COnsolidated criteria for REporting
Qualitative research (COREQ) checklist guided the presentation of findings.
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Chapter 3: Results
3.1 Assessing the Educational Environment in UAE
3.1.1 Mapping of Curricula for Genomics and PGx Courses
Out of the universities in all seven emirates, two universities were excluded as the
degrees did not match criteria. The assessment of university curricula included a total
of 21 universities: 7 in Abu Dhabi, 7 in Dubai, 3 in Ajman and 2 each in Ras Al
Khaimah and Sharjah. All courses’ credits in all universities were 368. Thorough
searching of the curricula and websites resulted in “genetics” having a total of 140
credits out of the 368 (38%). Genetics credits all belonged to stand-alone courses with
the exception being in medical and dental degrees, where only 8 out of 35 “genetics”
credits belonged to stand-alone courses. PGx and genomics courses accounted for 15
and 9 credits respectively out of 368. Figure 2 displays the number of total credits per
course category.
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Clinical Genetics
3, 1%

Biotechnology
28, 8%

Gene Therapy
24, 7%

Gene Engineering
26, 7%

Genetics
140, 38%

Molecular Biology
Techniques
17, 5%

Genomics
9, 2%
Molecular Biology
82, 22%
Molecular
Diagnostics
24, 6%

Pharmacogenetics
0, 0%
Pharmacogenomics
15, 4%

Figure 2: Total number of credits per course category (Total credits=368)

PGx was taught in the curriculum of 7 universities: United Arab Emirates University,
Fatima College of Health Sciences, Al-Ain University, City University College of
Ajman, Gulf Medical University, University of Sharjah, and Dubai Pharmacy College
for Girls. However, it was mostly for Pharmacy majors. Only 3 out of the 7 PGx
courses were stand-alone. When searching for “genomics”, 5 universities yielded
results. None of the genomics courses were stand-alone. When the keyword
“pharmacogenetics” was searched in all universities’ curricula, no results were found.
Figure 3 displays the results per university, degree, and course level when
“pharmacogenomics” and “genomics” was searched in the curricula.
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Figure 3: "PGx" and "genomics" search results

3.1.2 Findings of the Semi-Structured Interviews
The pinpointed main themes coded inductively from the iterative analysis of the semistructured interviews with the teaching faculties in UAE, and the commissioners and
higher education experts at the commission for academic accreditation at the Ministry
of Education are:


Recognizing the importance of genomic medicine and PGx to prepare the
future healthcare providers to the personalized medicine era.

Interviewee 2: “I graduated from the xxx medical school, so all what we had then was
basic molecular biology, so I went abroad to study, but when I came back to teach
here, I found there are courses about Genomic medicine and probably there is a
lecture or two about pharmacogenomics.”
Interviewee 3: “I’ve visited college of pharmacy just last week and they have a new
curriculum, and, in the curriculum, there was a pharmacogenetics course and they
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told us that they added this based on international reviews, I think the international
norms that there should be a pharmacogenetics course in pharmacy curriculum. “
Interviewee 4: “My personal experience of accreditation of medicine and pharmacy
programs is that if pharmacogenomics is insufficient in these programs, external
review teams normally do require that curricular content be added. This can be either
as separate courses but often better integrated into other courses.”


Calling for translational and implementational research along with recruiting
experts in the field.

Interviewee 1: “I think the main barrier is ignorance, I would say ignorance on many
levels, you know from healthcare workers who don’t know much about genomic
medicine, misconception in the community sometimes. Obviously, the decision makers
again they don’t have the full picture also studies or solid studies to implement
genomic medicine into healthcare systems more effectively.”
Interviewee 4: “I agree that many pharmacy colleges in the UAE do not have faculty
with much expertise in pharmacogenomics. This can be addressed through faculty
development and through use of visiting lecturers who do have the relevant expertise.”
3.1.3 Academia Survey Assessment
Respondents affiliated with the college of medicine constituted 70% of the sample,
and 13.8% from pharmacy or pharmacology. Respondents were 51.2% male with all
ages ranging between 28 and 70 with a mean age of 44. When asked on the current
state of PGx teaching in most universities and schools in UAE, 36.2% of the sample
considered it to be poor and 39.1% indicated that they do not know.
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According to the survey, only 34.3% of participants indicated that PGx coursework
was being taught within their curriculum. Respondents pointed out that 39.1% PGx
coursework was taught at a master’s level in their institution. Only 26.1% stated it was
a stand-alone required didactic course. Majority of respondents (81%) estimated 1-2
credit

hours

are

dedicated

to

PGx

in

their

curriculum

(Table

1).
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Table 1: PGx/pharmacogenetics coursework information in universities
Count
(N)

Percentage
(%)

Is PGx/ Pharmacogenetics coursework being taught within your
curriculum? (N=70)
24
34.3
Yes
No

26

37.1

I do not know

20

28.6

Where does the PGx/ pharmacogenetics coursework reside in the
curriculum? (N=23)
Stand-alone required didactic course in the area

6

26.1

Included as part of other required didactic
course(s)

13

56.5

Elective didactic coursework (stand-alone or
mixed)

3

13.0

Other

1

4.3

If you have a stand-alone PGx/ pharmacogenetics course, are there specific
prerequisite courses that are required? (N=21)
Yes

7

33.3

Maybe

9

42.9

No

5

23.8

I do not know

0

0.0

Please estimate the number of required credit hours dedicated to
PGx/pharmacogenetics in the curriculum. (N=21)
1-2 credit hours

17

81.0

3-4 credit hours

4

19.0

>5 credit hours

0

0.0

I do not know

0

0.0

At what academic level(s) is/are PGx/ pharmacogenetics coursework being
taught? (N=23)
PharmD

3

13.0

Master in Clinical Pharmacy

0

0.0

Master

9

39.1

Bachelor of Pharmacy

4

17.4

Other

7

30.4
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The top 3 topic areas currently covered in respondents’ PGx education is shown in
Table 2.
Table 2: Topics covered in respondents' PGx curricula (N=23)
Topic areas currently covered
PGX/Pharmacogenetics education

as

part

of

your Percent of
Cases (%)

The contribution of genetic variability to inter-individual
78.3
variations in drug response
Basic genetic concepts and terminology

73.9

The
drugs/drug
classes/clinical
situations
where
65.2
pharmacogenetic testing is likely to be most useful clinically
The influence (or lack thereof) of ethnicity in genetic
polymorphisms and associations of polymorphisms with drug 65.2
response
How identification of disease-associated genetic variations
facilitates development of prevention, diagnosis, and 60.9
treatment options
The ethical, legal and social issues related to pharmacogenetic/
genetic testing and recording of genetic information (e.g.,
52.2
privacy, the potential for genetic discrimination in health
insurance and employment)
The importance of family history in assessing predisposition
47.8
to disease
Specific methods of genotyping and phenotyping

39.1

Use of information technology to obtain credible, current
34.8
information about pharmacogenetics
Important issues in pharmacogenetic study design, particularly
30.4
those that differ from non-genetic clinical studies
The potential physical and/or psychosocial benefits,
limitations, and risks of genetic information for individuals, 30.4
family members, and communities
Pharmacogenetic testing is like all other clinical testing in that
it will not have 100 percent reliability, but rather is used along 21.7
with other clinical information
The resources available to assist clients seeking genetic
information or services, including the types of genetics 17.4
professionals available and their diverse responsibilities
Regulatory issues that may result from pharmacogenetics
being incorporated into Phase II and III testing

8.7
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Majority of respondents exhibited positive attitudes towards the availability and
accessibility of genetic testing with 89% agreeing that the government should invest
more money into its development. However, 74% agreed that the availability of
genetic tests could be problematic for insurance companies and future employers.
Figure 4 displays the results of the questions on genetic testing.

Figure 4: Views on genetic testing (N=73)
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Respondents had a positive outlook on the future of personalized medicine and PGx
(91.8%) with 82.2% agreeing that more study course time should be devoted to the
teaching of PGx. However, 69.9% believed insurance companies and employers could
exploit PGx. Confidentiality did not seem to be a top concern with only 35.6% not
willing to get their genome analyzed due to confidentiality issues. When asked if they
would prefer a physician or pharmacist to explain their genome report, 83.6% preferred
a physician. Respondents’ views on the concerns and outlook on the future is shown
in Figure 5.

Figure 5: Outlook of academia on the future of PGx in UAE (N=73)

Respondents exhibited positive attitudes when questioned on their desire to participate
in genetic research with 76.7% agreeing to participate and 74% interested in attending
a PGx course and/or educational seminar. Moreover, 63% agreed to donate genetic
materials for a bio-bank.
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Respondents identified the top 3 barriers for PGx implementation to be lack of training
or education (67.6%), lack of clinical guidelines on PGx/pharmacogenetics practice
(64.8%), and lack of testing services and shortage of personnel (52.1% each). When
asked on their preferred method to learning PGx, 56.3% chose workshops or seminars.
3.2 Assessing the Knowledge and Attitude of Healthcare Providers in UAE
Results presented here are for both quantitative and qualitative methods.
3.2.1 Quantitative
Table 3 presents the respondents’ demographic characteristics. Out of 552
respondents, 63.4% were females. The mean age (± SD) was 38 (± 9.6) years old, and
67.7% of the respondents were aged between 20 to 41 years old, and 26.9% between
20 to 30 years old. Most respondents had a pharmacy related occupation (42%)
followed by 52% belonging to either medicine or nursing occupations. More than half
(52.2%) had over 10 years of experience.
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Table 3: Demographic characteristics of healthcare providers in UAE (N=552)
Gender
Female
Male
Age Group
20-30
31-41
42-52
53-63
64-74
Occupation
Pharmacy Related
Nurse
Medicine
Business & Management
Administration
Allied Health
Governmental
Intern
Years of Experience
>10 years
<10 years
Nationality
Middle East
Asia
United Arab Emirates (UAE)
Africa
North America
UK
Gulf Cooperation Council (GCC) countries
Europe
Australia

Count (Percentage %)
350 (63.4)
202 (36.6)
148 (26.9)
225 (40.8)
124 (22.5)
53 (9.6)
1 (0.2)
232 (42)
153 (27.7)
134 (24.3)
14 (2.5)
5 (0.9)
5 (0.9)
5 (0.9)
2 (0.4)
265 (52.2)
149 (29.3)
226 (40.9)
179 (32.4)
68 (12.3)
34 (6.2)
14 (2.5)
11 (2.0)
8 (1.4)
4 (0.7)
1 (0.2)

3.2.1.1 Assessment of General Knowledge on Genetics and PGx
The mean knowledge score (SD) of the respondents was 5.2 (± 2.3) out of nine, which
shows a fair level of knowledge according to the scale. The mean knowledge score for
respondents of pharmacy related occupations was 5.1 (± 2.5), medicine 6.0 (± 2.0) and
nursing 4.8 (± 2.1). Respondents working in business and/or management positions
and allied health professionals both had scores of 5.6 (± 2.2 and ± 1.1, respectively).
Only 2 respondents out of 552 (0.4%) scored nine out of nine.
For the second question, regarding nucleotide pairing, the percentage of respondents
that answered correctly was only 1.7% higher than those who answered, “do not
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know”. A high percentage of 89.3% recognized correctly that genetic variances affect
drug response. Table 4 summarizes the results of the general knowledge questions on
genetics and PGx.

Table 4: Results of PGx knowledge questions of healthcare providers (N=552)
Do not
know
n (%)
28 (5.5)

Choose the correct answer:

Correct
answer

True
n (%)

False
n (%)

1. Humans have 48 chromosomes.

False

196 (38.8)

281 (55.6)

2. Adenine (A) only pairs with cytosine (C) and
Thymine (T) only pairs with Guanine (G).

False

148 (29.3)

183 (36.2)

174
(34.5)

3. Pharmacogenomics seeks to individualize
therapy based on patient’s genetic profile.

True

407 (80.6)

32 (6.3)

66 (13.1)

4. Genetic changes can cause adverse reactions.

True

395 (78.2)

45 (8.9)

65 (12.9)

5. Pharmacogenomics testing is recommended by
FDA for certain drugs.

True

335 (66.3)

16 (3.2)

154
(30.5)

6. Genetic changes can affect the patient’s
response to certain drug.

True

451 (89.3)

16 (3.2)

38 (7.5)

7. Genes can be activated or deactivated by other
genes.

True

379 (75.0)

38 (7.5)

88 (17.4)

8. Every cell of the body contains the whole
genome.

False

338 (66.9)

67 (13.3)

100
(19.8)

9. Environmental factors, such as cigarette smoke,
can affect gene activity.

True

379 (75.0)

52 (10.3)

74 (14.7)

Table 5 summarizes the distribution of the levels of knowledge between different
characteristics of the healthcare workers. The knowledge levels were significantly
different between men and women (p=0.01). Moreover, significant differences in
knowledge levels were found between occupation groups (p=0.00), completion status
of a PGx training or education (p=0.01) and having a patient who asked about taking
a genetic test in the last two years (p=0.02).
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Table 5: Comparison of the level of knowledge between different groups

Gender
Female
Male
Age Group
20–30
31–41
42–52
53–63
64–74
Years of Experience
<10
>10
Occupation Category
Administration
Pharmacy Related
Allied Health
Nurse
Governmental
Business &
Management

Level of Knowledge
Good
Fair
n (%)
n (%)

Poor
n (%)

95 (27.1)
74 (36.6)

196 (56.0)
87 (43.1)

59 (16.9)
41 (20.3)

46 (31.1)
63 (28.0)
34 (27.4)
25 (47.2)
1 (100)

73 (49.3)
119 (52.9)
71 (57.3)
19 (35.8)
0 (0.0)

29 (19.6)
43 (19.1)
19 (15.3)
9 (17.0)
0 (0.0)

72 (30.0)
97 (31.1)

126 (52.5)
157 (50.3)

42 (17.5)
58 (18.6)

0 (0.0)
69 (29.7)
1 (20.0)
31 (20.3)
0 (0.0)

3 (60.0)
117 (50.4)
4 (80.0)
88 (57.5)
3 (60.0)

2 (40.0)
46 (19.8)
0 (0.0)
34 (22.2)
2 (40.0)

5 (35.7)

7 (50.0)

2 (14.3)

59 (44.0)
1 (50.0)

14 (10.4)
0 (0.0)

75 (49.0)
208 (52.1)

24 (15.7)
76 (19.0)

0.01*

0.12**

0.88

0.00 **

Medicine
61 (45.5)
Intern
1 (50.0)
Previous Exposure to Genetic Issues
Yes
54 (35.3)
No
115 (28.8)
Completed PGx/ Pharmacogenetics
Training or Education
Yes
51 (41.5)
No
118 (27.5)

0.30

0.01 *
55 (44.7)
228 (53.1)

17 (13.8)
83 (19.3)

Have you ever advised any of your
patients to undertake a genetic test?
Yes
No

57 (38.0)
71 (34.6)

0.31
83 (55.3)
112 (54.6)

10 (6.7)
22 (10.7)

Have you had any patients who asked
about undertaking a genetic test in the
last two years?
Yes
No

59 (45.7)
74 (31.6)

0.02 *
62 (48.1)
132 (56.4)

8 (6.2)
28 (12.0)

Have you had any patients who asked
your advice about the results of a
genetic test in the last two years?
Yes
No

p-value

50 (41.7)
85 (34.1)

0.28
57 (47.5)
140 (56.2)

13 (10.8)
24 (9.6)

*significant value from Chi-square test ** significant value from Monte Carlo exact test
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3.2.1.2 Attitudes towards the genetic testing and the applications of PGx
Researcher found that 74% of respondents would consider having a genetic test
themselves performed at some point in their lives (Figure 6). The vast majority of
respondents (91.9%) exhibited a positive attitude regarding availability of genetic
testing. More than half (57.6%) reflected a positive response towards the accessibility
of genetic tests.
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Figure 6: Attitudes of healthcare providers on genetic testing (N=388)
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3.2.1.3 Concerns and Ethics
A common concern expressed by 74.4% of the recruited healthcare workers was that
genetic test results would affect the quality of the patient’s medical care. Among the
sample, 71.5% believed that PGx could be exploited and used as means of
discrimination (Figure 7).
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Figure 7: Concerns of healthcare providers on genetic testing (N=388)

3.2.1.4 Desire to Participate in Genetic Research
Statements questioning interest in genetic testing and PGx research was met with more
overall positive responses, where 68.2% of respondents expressed a desire to
participate in genetic research. Of the respondents, 83.7% indicated they would be
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interested in attending a course or educational seminar on PGx, and 43.4% would like
to donate genetic material to a biobank.
3.2.1.5 Current and Future Outlook on Genomics and PGx
On the subject of legal frameworks, only 47.7% agreed that policies and procedures
exist in the field of genetic tests in the UAE, with 44% taking a neutral stance. When
questioned on the future of medicine, 87.4% of respondents believed medicine will
become more personalized, and 85.3% agreed in thinking the government should
invest more money in genetic testing development. Moreover, 87.2% think more time
should be allocated to teaching PGx during studies. The majority of respondents
(83.9%) agreed that the expenses of genetic tests should be covered by insurance
companies.
3.2.1.6 Barriers to Implementation
Out of 474 respondents who answered the question on barriers to implementation, of
PGx testing in the UAE, 62% identified the cost of testing being a major barrier. Lack
of training or education and insurance coverage followed as the second and third
largest barriers (57.8% and 57.2% respectively). Only 6.3% thought there was no
clinical need for PGx testing.
3.2.1.7 Type of Preferred Education
Out of 472 respondents, a majority (73.9%) chose workshops or seminars as their
preferred learning method on PGx. Blended and internet-based learning received a
similar reception to each other (30.9% and 27.3% respectively).
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3.2.1.8 Assessment of Personal Knowledge and Attitudes
When questioned on their own personal experience with genetic testing and PGx,
39.9% stated that PGx was involved in their current work and 33.5% stating it was not.
Less than half (41.7%), agreed when asked on whether they would be able to explain
without external elaboration, the results of genetic tests to their patients. Only 38.4%
believed their undergraduate studies provided them with sufficient knowledge on
genetics and PGx. Only 31% of respondents reported advising at least one of their
patients to undertake a genetic test, as opposed to 43.2% of respondents reporting they
have not previously advised it. The majority (64.5%) reported that patients have not
asked about taking a genetic test in the last two years. Only 32.5% stated that patients
asked for their advice on genetic test results in the last two years. When asked on whom
they thought should provide counseling on genetic and pharmacogenetics testing and
results, 51.5% selected genetic counselor and 35.9% selected physician. Only 9.3%
believed a pharmacist should assume this role.
3.2.2 Qualitative
Participants’ demographics are presented in Table 6. More than half of the participants
were expatriates, females and above 30 years old. The sample included pharmacists
working in the inpatient setting and the outpatient setting as well as clinical
pharmacists and pharmacy residents. Some participants have postgraduate
qualifications, and some have experience working outside the UAE, with most of them
having more than 11 years of experience. The vast majority of the participants stated
that they did not receive formal education about genomics and pharmacogenomics at
a higher education level.
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Table 6: Demographics of pharmacists participated in FGD (N=38)
No.
of
participated
= 38
Age :
<30 years old

10

>31 years

28

Gender:
Male

14

Female

24

Total years of experiences:
<4 years

6

5- 10 years

4

> 11years

28

Studied Pharmacogenomics in college:
Yes

9

No

29

Current position:
Pharmacist (outpatient)

7

Pharmacist (inpatient)

15

Clinical Pharmacist

6

Pharmacy supervisor

5

Resident

4

Community pharmacist

1

Type of facility:
Tertiary care Hospital

34

Secondary care Hospital

0

Health clinic

3

Other

1

Facility operated by:
Government.

35

Non-Government

3

Nationality:
Locals (UAE citizen)

7

Non-locals

31

pharmacists
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Table 6: Demographics of pharmacists participated in FGD (N=38) (continued)

No.
of
participated

pharmacists

= 38
Qualification:*
BSc

18

Master

9

Pharm.D

8

Board Certified

12

Practiced outside UAE:
Yes

23

No

15

Number of declined participation

43

*Sum exceeds 100% as participants can pick more than one choice.

Themes extracted were based on the interview guide, which explored knowledge,
attitude and current practice, future direction and needs in the area of genomics and
pharmacogenomics. However, many themes have emerged from the focus group
sessions that have been classified as emerging themes. Below is the presentation of the
main themes in different sections (knowledge, attitude, practice, and future directions).
Followed by a presentation of the emerging themes: pharmacists’ role and power,
skills, trust and blame as well as cultural and religious beliefs.
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3.2.2.1 Main Themes
Knowledge:
The knowledge of pharmacists about genomic medicine and pharmacogenomics in
particular had been identified as a main theme. Moreover, sub-themes extracted
included

knowledge

about

the practice

and services of

genomics

and

pharmacogenomics, as well as sources of information and coverage of the costs of
testing as seen in Figure 8.

Knowledge

Knowledge
about fresh
graduates vs.
senior
pharmacists

Knowledge about
services

Knowledge about
practice and services
globally and
regionally

General knowledge
about
pharmacogenomics

Knowledge about
practice

Knowledge about
genetic and
pharmacogenomics tests
and its interpretation

Knowledge about
patient’s
involvement

Knowledge about
benefits of
pharmacogenomics

Laboratories

Knowledge about
source of information
related to genomics
and
pharmacogenomics

Cost and
coverage

Knowledge about their
role

Knowledge about
where to access
information related
to genomics and
pharmacogenomics

Figure 8: Main themes of the PGx knowledge of pharmacists in FGD
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Knowledge about the Science of Genomics and Pharmacogenomics, Practice, and
Services:
During the focus group discussion, participants were asked to rank their knowledge
about pharmacogenomics on a scale from 0 to 5 (0 is poor knowledge and 5 is excellent
knowledge) (Figure 9). More than third of the pharmacists rated their knowledge of
genomics and pharmacogenomics as poor; one pharmacist said: “Actually, we didn’t
hear about genomics and pharmacogenomics before this invitation” FG2M9.

Figure 9: The rating of the perceived pharmacists’ PGx knowledge

Most of the participants indicated that they are not sure where genetic testing is
conducted in the UAE. Moreover, most of them had no knowledge about where to
locate tests results in patients’ electronic records. In addition, they felt there is poor
dissemination of information from stakeholders to consumers and healthcare
providers. “They [stakeholders] are not sharing it with staff so we do not know”
FG4M12.
When asked if they are aware of the application of genomic medicine or
pharmacogenomics in their hospitals, they were unsure; one pharmacist pointed out
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that his hospital is conducting a test for Glucose-6-Phosphate Dehydrogenase (G6PD)
deficiency but was not sure if this is a pharmacogenetic test.
Knowledge about Sources of Information Related to Genomics and
Pharmacogenomics:
Most of the senior pharmacists in the sample did not receive formal education related
to genomics and pharmacogenomics at universities and the few (nine pharmacists)
who studied pharmacogenomics before classified their knowledge as being poor.
“we took a course on pharmacogenomics but did not benefit even professor was lost”
FG1F4.
Even some fresh graduates from a semi-governmental university in the UAE stated
that they did not receive formal education about genomics or pharmacogenomics at all
during their pharmacy bachelors’ years. As for the most frequently utilized sources of
information regarding genomics and pharmacogenomics among the participants,
Google search and YouTube videos were the most utilized sources. However, it was
noted that all clinical pharmacists in the focus group discussion indicated that
databases and trusted organizations (outside the UAE) are their sources of information,
believing that there is a gap in the available resources by the UAE health authorities.
A couple of participants indicated that the sources of their information are enough to
give

them

the

needed

knowledge.

“I watched a video on YouTube last night about pharmacogenomics, so I know what I
am talking about . . .” FG2M9.
Pharmacists agreed that they lack competency in interpreting genomics and
pharmacogenomics test reports, and they were not aware that the drug leaflets contain
sections related to pharmacogenomics.
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“if you did not invite me to this focus group, I wouldn’t know this piece of information
or any other knowledge discussed. So, I think there is no awareness” FG1M4.
Knowledge about Cost and Coverage of Genetic Tests:
Outpatient pharmacists in the focus group discussion were more aware about the cost
and coverage of genetic testing. An example used by participants is the case of patients
with cystic fibrosis and how the insurance companies are mandating and covering the
genetic tests before the initiation of the therapy. Another example is anticoagulant
coverage by health insurance.
“We know many cases where patient get stents and the inpatient cost is covered by
insurance, but when discharged and they have to pay they refuse to take their
anticoagulant medications (Plavix) and they are readmitted again with thrombosis”
FG4M13.
Attitudes:
The second major theme underscored is the attitude of pharmacists toward genomics
and pharmacogenomics. Researcher identified the following sub-themes: benefits of
pharmacogenomics, disclosure of genetic testing and biobanking, and the
implementation of pharmacogenomics within services (Figure 10).
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Figure 10: Themes and subthemes on the attitudes of pharmacists in FGD
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Pharmacists’ attitude about benefits of genomics and PGx:
Most participants showed an overall positive attitude toward PGx, despite their lack of
knowledge in the sciences of PGx and genomics. Nevertheless, some of them consider
pharmacogenomics as a science fiction and an area that lacks solid evidence.
“A lot of things was pending investigations, everything was not clear, as I just said
earlier it is uncharted territory, so a lot of new thing was introduced and nothing basic,
so I think it is a good branch and I am enthusiastic about it but still it is a new branch,
so no one had
solid things to give it to you, it was like watching something that will happen in the
future” FG2F8.
However, some had negative attitude toward the importance of learning and the use of
pharmacogenomics:
“What is the point of learning something that will be implemented 20 years later”
FG1M5.
“Why to waste money in something that will not benefit me” FG4M14.
“What is the point of knowing about it if we are not going to practice it. In UAE, there
is no market for genetics” FG1M2.
Pharmacists’ attitude toward disclosure of genetic test results and biobank:
Pharmacists had a mixed attitude toward knowing the results of their whole genome
sequencing; some wanted to know so they can lead a healthy lifestyle and keep an eye
on research, looking for interventions. The others did not want to know out of fear and
religious belief as well as its impact on their social and family life “Leave it to God”
FG2M9.
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“take the example of Angelina Jolie she was doing so fine before the test then after
that she lost weight and get divorced, so doing the test was bad for her!” FG3F13.
However, when it was related to their children, there was a consensus on the desire to
know how to protect their children.
“From my personal experience with vision problem and my mother have cancer
disease I want to protect my children from the disease I have, or my mother have it. I
see how my mother suffer with cancer and whatever it takes not to go through that
suffering will drive you to protect yourself or your children.” FG1M2.
When their attitude toward participating in biobanking had been explored, there were
mixed attitudes, with some being supportive of the idea as they believed it is vital to
research and consolidate community health, while others did not show any support for
it. For example, one expatriate pointed out that biobank should be directed only toward
UAE nationals, rather than expatriates since the expatriates may leave at any time,
affecting the follow up and research logistics.
Pharmacists’ attitude toward the implementation mechanism of genomic medicine
and PGx:
Pharmacists did not agree on the proper and ideal mechanism of implementing
genomic medicine and pharmacogenomics in the UAE. Some pharmacists advocated
a preemptive pharmacogenetic testing approach, which seeks proactive testing and
obtaining the results of the genetic test at the time of prescribing, and their arguments
were: “Test will be cost effective, because you will do it once, for example most of the
drugs are metabolized by the Cytochrome P450 (CYP450) enzyme. So, by doing this
test alone we will be able to identify poor or rapid metabolizers which will protect
them from the harm of certain medications. Let us say the test will cost 200 $ once per
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life and it will stay in the chart of the patients for long time, and this is for value for
expensive medications.” FG4M13.
On the other hand, other participants were advocates of the reactive pharmacogenetic
testing approach, in which specific drug–gene tests will be requested at the time of
dispensing:
“when the guidelines for hypertension was to use diuretics first, beta blockers second
etc the old guidelines, they said for Africans you should go for calcium channel
blockers. That was good, but do I need to do genome test that will cost me thousand
dollars to know? I do not think so. simply you can use the diuretics for couple of days
if it is not working then I will put beta blocker, if I have enough numbers of patient
that will prove the theory that this medication is not effective in this ethnicity at that
point I will go for genetic test, but I will not go before that.” FG4M12.
3.2.2.2 Emerging Themes
Power:
One emerging theme identified by this study was the lack of power and feeling of
powerlessness of pharmacists in making decisions related to pharmacogenomics.
“Even the stakeholders will not focus on pharmacists, their main focus is physicians.
Pharmacists are always out of the picture in any decision” FG1M2.
Moreover, they linked that attitude to stakeholders’ influence, no clear guidelines
about genomics and pharmacogenetics and their roles in the implementation.
“we can’t do it on our own, we cannot make decisions” FG3F14. Only clinical
pharmacists working in oncology services could envision their role, but they disclosed
that the knowledge gap hinders this role and that they do not have the power.
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Trust and responsibility:
Another emerging theme is the fear of losing their patients’ trust. Participants stated
that since they do not have the knowledge of genomics and pharmacogenomics, they
worry that they may lose the trust and rapport that they have with their patients.
“To be honest for us currently as a healthcare provider who don’t know much about
genomics and pharmacogenomics, so how we will initiate the talk with the patient”
FG3M11.
They also exhibited concerns about trusting the system in terms of confidentiality and
they worried that they may lose their jobs based on their genetic test results.
“I will never do the genetic test, if they find out that I have certain disease they may
fire me from my job, I will never do it even if they said there is confidentiality, there is
no law, and I will not take the risk” FG4M12.
Pharmacists declared that they do own patient counselling because they have the skills,
as well as being trained in their workplace about how to conduct counselling.
Nevertheless, they questioned their competency to do counselling about
pharmacogenomics to the patients when they do not have the knowledge of
pharmacogenomics. They worried that they may lose the trust and rapport that they
have with their patients.
Fatalism and stigma:
Pharmacists believed that it is all in God’s hand and nothing they can do will change
destiny. Some have revealed doubts that religion might constitute a barrier for the
implementation of genomic medicine in the UAE.
“who are we to interfere in destiny” FG2F8.
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Pharmacists assumed that culture had a powerful impact on the adoption of genomic
medicine more than religion.
“culture is one of the biggest challenges and barriers and should be factored in while
drafting laws and policies” FG2M6.
Nevertheless, they perceived culture as dynamic and they supported that by comparing
the era of genomic medicine to the era of organ transplant and in vitro fertilization and
how the community were opposers and now they are adopters. The fear of stigma was
not exclusive to the UAE; even pharmacists from other nationalities fear the labeling
and stigmatizing of their families with certain genetic diseases. One pharmacist stated:
“… …they change the law in Palestine, so the couples will not do the premarital test
at the same time, we will start with the man and based on the results of his test they
will decide if to do the test for the lady . . . . . . . . . . . . . . . see they change the law for
the effect of the culture and the fear of stigma” FG3F22.
The findings of the FGD lead to the conceptualizing of a personalized literacy
framework for the adoption of pharmacogenomics by pharmacists in UAE with
possible regional and global relevance. The researcher named the framework as
Pharmacogenomics Genomics Literacy for Pharmacists (PGLP). Figure 11 introduces
it.
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Figure 11: PGx Genomics Literacy Framework for Pharmacists (PGLP)
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3.3 Assessing the Knowledge and Attitude of Students in UAE
3.3.1 Students’ Demographic and Academic Characteristics
A total of 510 students consented and completed the questionnaire between December
2018 and October 2019. Of the participating students, 82.7% were female. The mean
(SD) age was 22 (± 4.7) years old and 76.1% were between the ages of 18 and 28.
Most responses (68.6%) came from students who were studying in universities located
in Al Ain city. Of the students, 52.2% were studying Medicine and 29.3% were
studying Pharmacy. Most of the students (73.9%) were in pursuit of a bachelor’s
degree and were in third and fourth year (22.2 and 23.4%, respectively). Table 7
summarizes the students’ demographic and academic characteristics.
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Table 7: Medical and health sciences students' demographics (N=510)
Count (%)
Gender
Female
421 (82.7)
Male
88 (17.3)
Age Group
<18
69 (13.5)
18-28
388 (76.1)
29-39
38 (7.5)
40-50
6 (1.2)
University Location
Al Ain
245 (68.6)
Dubai
83 (16.5)
Sharjah
55 (10.9)
Abu Dhabi
17 (3.4)
Ajman
1 (0.2)
Fujairah
1 (0.2)
Ras Al Khaimah
1 (0.2)
Program
Medicine
265 (52.2)
Pharmacy
149 (29.3)
Laboratory
35 (6.9)
Othera
59 (11.6)
a
medical imaging, radiology, radiography, biochemistry, biomedical sciences, dentistry,
pharmacology, physiology, psychology, public health, occupational health

3.3.2 Assessment of Students’ Knowledge on PGx
Only 4.2% responded correctly to all the knowledge questions. The highest proportion
of correct answers was for question 6 about the impact of genetics on drug response
and the lowest proportion of correct answers was for question 8 regarding cell
composition. Table 8 summarizes the results of the knowledge questions.
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Table 8: Results of PGx knowledge questions among students (N=506)

Knowledge questions

Correct
answer

Answered
“True”
n (%)
149
(29.4)

Answered
“False”
n (%)
350
(69.2)

Answered
“Do not
know” n (%)
7
(1.4)

1. Humans have 48 chromosomes.

False

2. Adenine (A) only pairs with cytosine
(C) and Thymine (T) only pairs with
Guanine (G).
3. Pharmacogenomics seeks to
individualize therapy based on
patient’s genetic profile.
4. Genetic changes can cause adverse
reactions.

False

79
(15.6)

385
(76.1)

42
(8.3)

True

418
(82.6)

12
(2.4)

76
(15)

True

426
(84.2)

20
(4.0)

60
(11.9)

5. Pharmacogenomics testing is
recommended by FDA for certain
drugs.
6. Genetic changes can affect the
patient’s response to certain drug.

True

261
(51.6)

25
(4.9)

220
(43.5)

True

455
(89.9)

11
(2.2)

40
(7.9)

7. Genes can be activated or deactivated
by other genes.

True

412
(81.4)

16
(3.2)

78
(15.4)

8. Every cell of the body contains the
whole genome.

False

314
(62.1)

112
(22.1)

80
(15.8)

9. Environmental factors, such as
cigarette smoke, can affect gene
activity.

True

423
(83.6)

43
(8.5)

40
(7.9)

Table 9 summarizes the distribution of the knowledge score and levels by the
demographic and academic characteristics of the students. The mean knowledge score
(SD) for all students was 5.4 (± 2.7). The mean knowledge scores for students studying
medicine and pharmacy were 5.5 (± 2.7) and 5.6 (± 2.7), respectively. The mean score
of students in pursuit of a bachelor’s was 6.4 (± 1.7), master’s 5.9 (± 1.5) and PhD 6.6
(± 1.2). A higher mean knowledge score was found in students who completed a PGx
or pharmacogenetics related training or education (6.5; ± 2.2) than those who did not
(5.6; ± 2.1).
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Table 9: Comparison of students’ knowledge with different groups (N=510)

Overall
Gender
Female
Male
Age group
<18
18-28
29-39
40-50
Program
Medicine
Pharmacy
Laboratory
Other
Degree
Bachelor
Master
PhD
Other
Year of study (Bachelor)
First
Second
Third
Fourth
Fifth
Sixth
Other
Year of study (Master)
First
Second
Third
Other
Year of study (PhD)
First
Second
Third
Fourth
Fifth

Mean score
(± SD)
5.4 (± 2.7)

Level of Knowledge
Good
Fair
n (%)
n (%)
219 (42.9)
191 (37.5)

Poor
n (%)
100 (19.6)

p-value
0.47

5.3 (± 2.7)
5.6 (± 2.6)

176 (41.8)
43 (48.9)

161 (38.2)
30 (34.1)

84 (20.0)
15 (17.0)

5.0 (± 2.5)
5.5 (± 2.8)
5.3 (± 2.8)
5.0 (± 2.6)

23 (33.3)
177 (45.6)
14 (36.8)
2 (33.3)

31 (44.9)
137 (35.3)
16 (42.1)
3 (50.0)

15 (21.7)
74 (19.1)
8 (21.1)
1 (16.7)

5.5 (± 2.7)
5.6 (± 2.7)
4.7 (± 2.9)
4.8 (± 2.4)

123 (46.4)
69 (46.3)
11 (31.4)
16 (27.1)

95 (35.8)
52 (34.9)
15 (42.9)
29 (49.2)

47 (17.7)
28 (18.8)
9 (25.7)
14 (23.7)

6.4 (± 1.7)
5.9 (± 1.5)
6.6 (± 1.2)
5.8 (± 1.0)

185 (44.5)
14 (33.3)
19 (40.4)
1 (25.0)

148 (35.6)
20 (47.6)
20 (42.6)
3 (75.0)

83 (20.0)
8 (19.0)
8 (17.0)
0 (0.0)

5.1 (± 2.0)
6.4 (± 1.7)
7.0 (± 1.4)
6.6 (± 1.6)
6.5 (± 1.5)
6.1 (± 1.3)
5.8 (± 1.2)

11 (5.9)
37 (20.0)
52 (28.1)
55 (29.7)
23 (12.4)
5 (2.7)
2 (1.1)

29 (19.6)
22 (14.9)
26 (17.6)
35 (26.3)
12 (8.1)
12 (8.1)
12 (8.1)

13 (15.7)
15 (18.1)
22 (26.5)
20 (24.1)
7 (8.4)
3 (3.6)
3 (3.6)

5.8 (± 1.4)
5.8 (± 1.6)
6.3 (± 1.2)
7.5 (± 0.7)

5 (35.7)
5 (35.7)
2 (14.3)
2 (14.3)

9 (45.0)
10 (50.0)
1 (5.0)
0 (0.0)

3 (37.5)
3 (37.5)
2 (25.0)
0 (0.0)

6.2 (± 1.1)
6.9 (± 1.2)
7.0 (± 1.3)
7.5 (± 0.6)
5.0 (± 0.0)

7 (36.8)
5 (26.3)
3 (15.8)
4 (21.1)
0 (0.0)

12 (60.0)
4 (20.0)
3 (15.0)
0 (0.0)
1 (5.0)

1 (12.5)
1 (12.5)
2 (25.0)
4 (50.0)
0 (0.0)

0.56

0.12

0.44

0.00*

0.35

0.08
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Table 9: Comparison of students’ knowledge levels with different groups (N=510)
(continued)
Level of Knowledge
Mean score
Good
(± SD)
n (%)
Previous
exposure
to
genetic issues
Yes
5.9 (± 2.1)
No
6.0 (± 2.2)
Completed
PGX/pharmacogenetics
training or education
Yes
6.5 (± 2.2)
No
5.6 (± 2.1)
Completed internship or
study abroad program
Yes
5.9 (± 2.2)
No
3.2 (± 3.4)
*significant p-value <0.05

Fair
n (%)

Poor
n (%)

p-value
0.56

94 (45.2)
125 (49.6)

92 (44.2)
99 (39.3)

22 (10.6)
28 (11.1)
0.00*

110 (62.5)
109 (38.4)

51 (29.0)
140 (49.3)

15 (8.5)
35 (12.3)
0.00*

191 (47.0)
29 (27.4)

169 (41.6)
22 (20.8)

46 (11.3)
55 (51.9)

There were significant differences in the levels of knowledge by the year of study of
bachelor’s degree students, the completion status of training or education in PGx or
pharmacogenetics and the completion of an internship or study abroad program (pvalues <0.05). Higher proportions of bachelor’s students in years 2-6 reported good to
fair levels of knowledge. Higher proportions of master’s students in years 1 and 2
reported

fair

levels

of

knowledge.

Of

the

students

who

completed

PGx/pharmacogenetics training or education, 62.5% reported a good level of
knowledge. Out of the 510 students, 406 (79.6%) reported to have completed an
internship or study abroad program; 47% and 41.6% of these students reported good
and fair levels of knowledge, respectively.
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3.3.3 Attitudes towards Genomic Medicine and PGx
Results on the attitudes towards genomic medicine and PGx were categorized into five
categories; views and considerations, desire to participate, accessibility and
availability of genetic tests, concerns, and ethics and, lastly, outlooks on the future.
3.3.4 Views and Considerations on Genomic Medicine and PGx
Majority of students (82.7%) would consider having genetic testing done at some point
in their life to find out their future risk of developing genetic diseases, whereas 74.7%
would only like to know their susceptibility to diseases that have current interventions
for protection (Figure 12).

Figure 12: Views and considerations of students on PGx (N=388)
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When asked if they prefer a pharmacist or physician to explain their genome report,
79.4% preferred a physician while 44.8% preferred a pharmacist (Figure 13).

Figure 13: Pharmacist vs. physician in genome report explaining (N=388)

3.3.5 Desire to Participate in Genetic Research
A high percentage of students (78.1%) stated to be interested in participating in genetic
research. The majority (79.4%) indicated that they would be interested in attending a
course or seminar for PGx education (Figure 14).
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Figure 14: Desire of students to participate in genetic activities (N=388)

3.3.6 Accessibility and Availability of Genetic Testing
The vast majority of students, respectively, 96.4% and 66.8%, reflected positive
attitudes towards the availability and accessibility of genetic tests. However, 57.5%
did agree that the availability of genetic tests could be problematic for insurance
companies and future employers (Figure 15).
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Figure 15: Students’ attitude on genetic testing (N=388)

3.3.7 Concerns and Ethics Regarding Genomic Medicine and PGx
The highest concern (66.8%) was that genomics could be exploited and used as means
of discrimination (Figure 16). The next concern by percentage (40.2%) was due to
issues of confidentiality and a similar percentage of 38.1% were skeptical toward PGx
testing due to a possibility of getting gene information unrelated to the treatment.
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Figure 16: Concerns and ethics of students regarding genomics (N=388)

3.3.8 Outlooks on the Future of Genomic Medicine and PGx
The majority of students were optimistic about the future; 87.1% believing medicine
will be more personalized. Most of them (89.9%) had a positive view on genetic testing
and agreed that the government should invest more money into its development.
Moreover, 73.2% thought more time should be dedicated towards studying PGx.
The top two barriers students identified to the implementation of genomic medicine
and PGx were lack of training or education (59.7%) and lack of clinical guidelines
(58.7%). The next two highly perceived barriers were cost of testing and lack of testing
services (46.3% and 44.7% respectively). Other answers included lack of awareness
and cultural/religious inhibitions. In order to improve future education on genomic
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medicine and PGx, students were asked for their preferred method of learning. The
majority (70.8%) preferred workshops or seminars while 34.2% and 30% preferred
internet-based learning and self-directed learning, respectively. Others preferred
learning during their internship year (37.6%).
3.4 Mapping the Current State of Genetics Testing Services in UAE
3.4.1 General Mapping of Private Genetic Services in the UAE
Twenty-seven laboratories were mapped through website search while 23 laboratories
responded to the onsite questionnaire. Their characteristics are presented in Table 10.
Most of the mapped laboratories that provide genetic services in UAE are located in
Dubai followed by Abu Dhabi, the capital of UAE. Only three laboratories claimed
that they have a genomic bank and stated that their consent form is tailored to such a
service.
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Table 10: Characteristics of the mapped laboratories in the UAE
Survey
(N = 23)

Website
(N = 27)

Location of the laboratory in the UAE by emirate: *
Abu Dhabi
Dubai
Sharjah
Ras Al-Khaimah
Ajman
Umm Al Quwain
Fujairah

4
15
3
1
0
0
0

7
21
3
2
1
1
1

Laboratories that have a genomic bank

3

3

analysis 6

2

Demographics

Laboratories

that

offer

bioinformatics

Type of stakeholders:
Directly to clients
3
Medical referrals (hospitals/clinics/doctors)
4
Both
11
Not mentioned/missing
5
Completeness or knowledge of completeness of the
information on the website:
Yes
9
No
3
I do not know/not mentioned/missing
11

1
0
5
21

2
23
2

Availability or knowledge of availability of the costs on
the website:
Yes
3
No
13
I do not know/not mentioned/missing
7

4
21
2

Accreditation by national or international bodies:
Yes
No
I do not know/not mentioned/missing

15
3
5

12
1
14

Location of the processing of the samples:
In-house within UAE
Sent out of the country
Both
I do not know/not mentioned/missing

15
7
0
1

4
2
3
18

* Some laboratories had multiple branches in different emirates.

With regard to the type of clients, 11 of the surveyed laboratories indicated that they
serve medical referrals from hospitals and clinics as well as directly providing services
to clients. However, such information was not disclosed on the websites of the 21
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mapped laboratories. Prenatal testing was the genetic service most commonly offered
among the laboratories included in the study, whereas onsite data revealed that blood
samples was the main sample type for genetic testing followed by saliva (Figure 17).
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Figure 17: Sources of the tested DNA at the mapped laboratories in UAE
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3.4.2 Inconsistency between Onsite and Website Mapping
There were inconsistencies between onsite-questionnaire responses and the findings
of the website search. For example, six laboratories claimed to provide bioinformatics
analysis, but analysis of their websites showed that only two of them stated that they
provide this service.
Another example of such discrepancy was detected upon assessing the sufficiency of
information provided on the laboratories’ websites. Interestingly, nine laboratories
claimed that their websites were accurate and comprehensive with regard to their
services; however, through website mapping, only two can be considered thorough
and comprehensive. Three of the surveyed laboratories considered the information
posted on their website to be incomplete and not representative of the services they
provide, while 11 of the surveyed laboratories did not annotate on the question.
The study identified a contrast with regard to the location of processing of samples, as
15 laboratories claimed to have an in-house facility for sample processing, but a
website search confirmed that only four of them do (Table 10).
3.4.3 Accreditation
One of the surprising findings in the mapping was that staff of three of the surveyed
laboratories stated that they did not seek any accreditation because they consider
themselves as window-laboratories (only a reception for a lab located abroad), where
the actual testing services are done abroad (Table 10). There was no standardization
of the accreditation bodies as different laboratories have different accreditations,
including, but not restricted to: ISO 15189, Joint Commission International, the
College of American Pathologists, and Health Authority of UAE.
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3.4.4 Genetic Counseling
Twelve laboratories coupled their genetic service with in-house genetic counseling,
while three laboratories refer their clients to an external counselor (Figure 18).
Unfortunately, half of the counseling provided by the facilities is limited. Few
laboratories provide in-house counseling services and the rest refer patients to external
counseling services.

Figure 18: Availability of genetic counseling services at the mapped laboratories

3.4.5 Coverage of the Cost
In the UAE, insurance companies are somewhat lagging in terms of covering genetic
tests, so only six laboratories claimed full coverage of the cost of genetic testing
through health insurance, mainly for UAE nationals. It was observed that websites did
not detail the cost of tests, and when asked about it on the onsite visit the personnel
responded that concealing such information would create market competition.
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3.4.6 Gene-panel Selection
Twelve laboratories stated that disease-specific panel is the most selected panel by
stakeholders, and nine of them stated that their laboratory can provide customized
panel of genes. Six of the mapped laboratories claimed providing pharmacogenomics
sequencing or genotyping tests.
3.4.7 Turnaround and Reporting of the Results
Turnaround of results ranged from 2 days to 8 weeks depending on the type of the
genetic tests and the destination of the shipping and processing of the samples (abroad
vs. in-house). The most common method of reporting results was through in-house
system followed by website and written reports. Additionally, 94% of the surveyed
personnel stated that their reports are easy to interpret by stakeholders (physicians and
patients). The majority of the laboratories (42%) follow the American guidelines and
database.
3.5 Establishing a Stakeholders’ Matrix of Power and Interest
Thirteen in-depth semi-structured interviews were conducted. The stakeholders
interviewed are presented in Figure 19.

Figure 19: Bubble representation of the interviewed stakeholders
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The identified main themes extracted inductively from the iterative analysis of the
aforementioned stakeholder’s interviews are the attitude of the stakeholders toward a
variety of facets of genomic medicine and pharmacogenomics. Besides the second
main theme which is their perceived barriers and challenges for the full
implementation of genomic medicine and pharmacogenomics in UAE. In addition, the
researcher underscored an emerging theme of the role of both genetic counselors and
the media in the implementation of genomic medicine and pharmacogenomics in UAE
which will be annotated under the emerging themes.
3.5.1 Main themes
3.5.1.1 Attitude of the stakeholders toward a Variety of Facets of Genomic
Medicine and Pharmacogenomics
Subthemes:
Attitude of stakeholders about the clinical demand for genomic medicine and
pharmacogenomics in UAE:
Most of the interviewed stakeholders emphasized the clinical demand for genomic
medicine in UAE due to arrays of justifications like the prevalence of consanguinity
in UAE, the high burden of genetic diseases, the urge to utilize the genomic technology
to personalized medications, and the raise in awareness among physicians about the
power of genetic services that motivated them to demand genomic medicine.
“Yes,, we need genomic medicine in the UAE because we have very young patients
with cancer, like from my own practice, the prevalence of breast cancer in very young
patients is higher in UAE than western world, I am trained in Germany and I didn’t
see this much.” Stakeholder #1
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“The opportunity here is unique, because once you identify one patient you are
actually serving a big family as they all share the DNA and that open the door for
prevention of the genetic disease.” Stakeholder #5
In terms of the demand to pharmacogenomics, many of the stakeholders were less
inclined to articulate the need for pharmacogenomics at the moment, however, they
believe that a shift in the demand may occur in the future.
“Pharmacogenomics currently is very limited, you know there are various factors to
that, you know it is not widely used but again there will be more demand in the future.”
Stakeholder #2
Inclination about the infrastructure to implement genomic medicine and
pharmacogenomics in UAE:
The majority of stakeholders in UAE favored building the genetic testing infrastructure
in UAE rather than sending the samples for testing abroad. They vindicated this stance
to variable factors of cost, confidentiality, building database and logistics. However,
few stakeholders opt to postpone building infrastructure in UAE until the demand
increases in order to have return on investment.
“It should be local. I think because one panel at a time will cost. because when you
send them outside you usually send them one at a time, so that will cost more and you
add more cost to the hospital and the patient, and those people are not geneticist they
do not speak the language, so you can’t talk directly to the lab, so that result in
communication gap and delay communication and hence diagnosis, that in the logistic
side.
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Another side, is when you have a lab in house you build your own database, currently
all testing is done in Portugal, in Germany, so no one knows what the most common
mutation in UAE is, having this database will help you plan where to put your
resources, treatment” Stakeholder #5
“I am here to build internal capacity in UAE, internal capacity means people,
infrastructure, science, international recognition and these elements are very
important. So whether we are going to have another genome sequencing center?
probably not, but those will have small scale, for example Al-Ain has the ability to
have breast cancer diagnostic center, so it would be more like diagnostic of focus
areas, but the diagnostic lab that we are building will have broader scale of tests and
will cover the population need, so I see it as constant collaboration between all of us,
we will not stand alone on high tower, we need to connect to meet the locals need.”
Stakeholder #9
“so, at the moment as you know, samples are sent-out, when you are doing enough
volume it is cheaper to do it in-house, doing few it is easier and cheaper to send it
out.” Stakeholder #8
Demeanor of stakeholders about the cost-effectiveness of genomic medicine and
pharmacogenomics:
Most of the stakeholders in UAE agreed that genomic medicine and
pharmacogenomics is cost-effective, and some were able to bring evidence from their
current practice or cited published papers that support that. One of the stakeholders is
in the process of studying this in UAE and has received approval from the institutional
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review board to do so. A stakeholder working in an insurance company had an opposite
stance about the cost-effectiveness of genomic medicine and pharmacogenomics.
Stance of the stakeholders’ strategy of the implementation of genomic medicine and
pharmacogenomics:
Albeit Preemptive approach or gene-specific approach:
The majority of the stakeholders favored preemptive approach, which seeks testing
proactively once in a lifetime and having the results of the genetic test ready at the
time of prescription.
“If you have proper equipment and proper screening then preemptive absolutely, as
you do more help there, right? you don’t wait for the patient to become patient to
react.” Stakeholder #5
However, they had two approaches; some supported newborn screening preemptive
approach while others preferred pre-marital screening preemptive approach. Genetic
counselors’ attitude was skewed toward gene-specific approach because they
anticipated the dilemma of incidental findings.
Attitude about their desire to undertake genetic test:
Mixed results were identified. Many agreed to undertake the genetic test to gain better
control of their life and to have a motive to lead a healthy lifestyle. On the other hand,
many disclosed that they will not take the test as they are scared of the consequences.
“I would not do it for myself, it will open a door I will not be able to close.” Stakeholder
#1
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Those who have children were more inclined to conduct the tests on their children but
not themselves.
Attitude toward online direct-to-consumer kit:
Most of the stakeholder’s attitude about online direct-to-consumer kit was skewed
toward rejecting it. Their justification is represented in the words of one of the genetic
counselors:
“I think it is misleading the consumer, it is not giving them correct and clear
information, and the client walking away thinking that he had been tested for
everything under the sun and he is immune now and that is not true. I really believe
that counseling should support the testing everywhere and every time.” Stakeholder
#4.
3.5.1.2 Stakeholders Perceived Concerns for the Full Implementation of
Genomic Medicine and Pharmacogenomics in UAE
Concerns about the ethical and legal aspects of genomic medicine:
Stakeholders exhibited blended views in regard to the ethical and legal aspects of
genomic medicine. Some of them did not voice any concern while others had concerns
related to confidentiality of the genetic tests results especially with the use of cloud for
bioinformatics. Many were worried about the ramifications of disclosing genetic tests
results to insurance companies. They are anxious that insurance companies may
increase the insurance price (this concern was confirmed by stakeholder from
insurance company) or cause discrimination by employer by denying jobs to those
with high probability of having a disease. Few of the stakeholders had not thought
about it nor consider it in their planning agenda.

92

3.5.1.3 Stakeholders Perceived Barriers and Challenges for the Full
Implementation of Genomic Medicine and Pharmacogenomics in UAE
The barriers and challenges perceived by the stakeholders in UAE can be categorized
using the PESTLE tool borrowed from the business model of risk management
(Rastogi & Trivedi, 2016) as follows:
P= Political: The slow pace of implementation, fragmented system and lack of unity,
and ineffective regulation of curriculum by professional bodies and health regulators.
E= Economic: Cost of bioinformatics support, coverage of the genetic tests to all
citizens.
S= Social: confidentiality, apathetic and latent stakeholders, ignorance, lack of
awareness about genomic medicine in the UAE community, role of media.
T=Technological: Bioinformatics.
L= Legal: Ineffective regulation of curriculum by professional bodies and health
regulators and lack of laws to protect confidentiality of genetic tests.
E=Environmental: Lack or the gap in education about genomic medicine and
pharmacogenomics, lack of evidence pertaining to the UAE population, ineffective
regulation of curriculum by professional bodies and health regulators, ineffective
curriculum, lack of experts in the field whether in the academic field or the health
setting, and limited numbers of well-trained genetic counselors.
3.5.2 Emerging Themes
The inductive methodology allowed researcher to code emerging themes. The
emerging themes are the added value of genetic counselor and the role of media as a
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stakeholder in the awareness of genetic diseases. Below is an elaboration on these
themes.
3.5.2.1 Stance of the stakeholders of the added value of genetic counselors
The added value of genetic counselors emerged when talking to stakeholders in the
health setting as well as academic fields. They pointed out that the genetic counselor
is the proposed model that will address the knowledge gap of genomics among
healthcare providers. Thus, their role is crucial for guiding physicians, saving cost and
timely intervention as well as their traditional role of counseling the index case and
their pedigree.
“Those physicians who are not competent in genomics, the genetic counselor will
actually go to the round with them, so she recommends microarrays or gene panel for
epilepsy for example or if it is a more complex case, she guides and navigates the
doctors to find the cost-effective route and test. When the results are back, all of them
need help with what does the result mean? so our genetic counselor will do both, she
will talk to the family and explain the result and its consequences, also the genetic
counselor will talk to the doctors to explain what these results mean in term of
management of the disease. For example, is the results diagnostic findings or not,
maybe they need axiom sequence instead of microarray. She will explain the etiology
as well. Some doctors can do that, but the current model even in the State they have
genetic counselor in every specialty to do that, and in UAE with the burden of disease
and lack of healthcare providers you need to depend on genetic counselor”
Stakeholder #5
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3.5.2.2 Role of media in the awareness about genomic medicine and genetic
diseases
The mother of the child with a genetic disease voiced that media is lagging behind in
spreading the awareness about genetic diseases and the value of genomic medicine.
“My daughter is a teenager now, and her peers are giving her a hard time at school,
most of the time she comes home crying and there is nothing I can do, I cannot educate
them or ask their families to do so. Unfortunately, the media did not bring justice to
children with genetic diseases, as they are always viewed as retarded. My daughter is
not retarded, and she should not go through all this pain and sadness. That added
extra weight on my shoulders” Stakeholder #13
3.5.3 Mendelow’s matrix
The interest and power (Mendelow’s matrix) of the stakeholders in UAE had been
mapped based on the preponderance of the emanated themes using a deductive
methodological approach. Figure 20 visualizes this mapping.
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Figure 20: Mendelow's matrix of the interviewed stakeholders

The Mendelow’s model of the stakeholders in UAE (Figure 20) is an essential and
validated strategic step in the business management that will empower policy makers
and interested parties to a full implementation of genomic medicine and
pharmacogenomics. The following categorization of the types of stakeholders
identified using Mendelow’s model will provide a systematic communication and
action plan strategy for future genomic medicine and pharmacogenomics
implementation (Mendelow, 1981). The first category identified is the promoters for
full implementation of genomic medicine and pharmacogenomics in UAE, which in
this study are the researchers, academics, and health-care administrative and
pharmaceutical companies. As per the stakeholders’ model, the strategy to deal with
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important and interested stakeholders is to manage closely as they are the key players.
The second category, on the contrary, is stakeholders with low interest and low power
(the apathetic); in this study, they are the commissions for academic accreditation.
According to Mendelow’s model, the recommended strategy is to keep them under
monitoring without engaging them in the plan of the implementation. The third
category is the stakeholders with high power but low interest; these are the real
challenge (the latent). In this study, they are the insurance company, so the solution is
to keep them satisfied and engaged. Finally, the last category is stakeholders with high
interest but low power (the defenders). In this study, they are the genetic counselors
and parents of the child with genetic disease; they ought to be informed and engaged.

97

Chapter 4: Discussion
The reiteration of discussion will be categorized according to the main objectives of
the study and follow the same pattern of the results.
4.1 Assessing the Genomics Educational Environment in UAE
In this part, the researcher attempted to navigate through the educational environment
of genomic medicine and PGx in UAE. The researcher did not limit the research to
specific field of genomics to allow broader mapping of the current educational
environment. This will act as a baseline for other researchers as well as a point of
comparison for the stakeholders.
Breadth of studies attributed the poor knowledge of healthcare providers toward
genomics and PGx to the dearth of official tutoring in the universities and
recommended incorporating genomics and PGx in the curriculum (Chair et al., 2019;
Rahma et al., 2020a; Rahma et al., 2020b; Sharoff, 2020; Stark et al., 2019a; Whitley
et al., 2020). The mapping of the medical and health sciences curriculum of the
accredited universities in UAE, pointed out that basic genetics is included in the
majority of universities’ syllabi both undergraduate and postgraduate, however PGx
and human genetics deviated from this inclusion. Even the curriculum was not
standardized among universities nor covering topics in the same significance. The
survey and the interviews of the academia disclosed that regulatory aspects and clinical
resources had less weight in the curriculum of PGx.
In the assessment of the knowledge of medical and health science students in the UAE
toward genomic medicine and PGx, only 4.2% responded correctly to all the
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knowledge questions which can be attributed to the scarce coverage of genomics in
the curriculum of the accredited universities in UAE.
The commissioners and higher education experts at the commission for academic
accreditation at the Ministry of Education in UAE ascribed this gap to the shortage of
the experts in the field of genomics and PGx in UAE as well as the paucity of
partnership with the specialists. A study by Shaffer et al. (2010) advocated the
genomics education partnership and concluded that it was fulfilling for both students
and faculty. This was also highlighted by Perkmann and Schildt (2015) in their review
of the structural Genomics Consortium case study, as well as in three-year case study
in genomics by LeBlanc and Dyer (2003).
A positive attitude was detected among academia and commissioners toward
harnessing genomics and PGx to prepare the future healthcare providers to the
personalized medicine era. The majority (82.2%) agreed that more room should be
allocated in the curriculum for genomics and PGx and 74% were interested in
attending PGx courses or seminars. These results are in consonance with the
international educational strategies (Adams et al., 2016; Frick et al., 2018; GálvezPeralta et al., 2018; Guy et al., 2020; Karas Kuželički et al., 2019; Perry et al., 2016;
Weitzel et al., 2016). Furthermore, the researcher contextualized the personal attitude
of the academia and commissioners toward conducting genetic tests and participating
in genetic research and biobanks, as researcher hypothesized that such positive attitude
would influence the pace of adoption of genomics in the curriculum. This area has not
been examined in the literature and warrants further research.
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Academia and education commissioners shared an optimistic view of the future. They
captured the strides that map the implementation of genomic medicine and PGx in the
UAE. The profound strategy is education. This finding is in line with literatures and
recommendations of international societies like the ISP and The International Society
of Nurses in Genetics (ISONG) (Beamer & Rosinski, 2019; Gurwitz et al., 2005;
Gurwitz et al., 2003; Hickey et al., 2018; Karas Kuželički et al., 2019; Lesko &
Johnson, 2012; Ziegelstein, 2015).
In the systematic review by Talwar et al. (2019), they analyzed the current genomics
courses offered to health professional students and concluded that the field of genomic
education incubates evolving pedagogical methods like self-genotyping, which can be
adopted by the academia in UAE.
The strength of this research is the overlapping mixed method approach that
countenances a comprehensive assessment and mapping of the educational
environment of genomics in UAE. Additionally, the triangulation with other results
about the assessment of knowledge of medical and health sciences students allows
attribution and postulation. Furthermore, assessing the attitude of the academia is a
novelty that fosters the implementation strategies. Including the commissioners and
higher education experts at the commission for academic accreditation at the Ministry
of Education delineated the stakeholders stand and fostered a top up viewpoint.
The limitations include the inherited bias of both quantitative and qualitative methods
involving lack of generalization, selection and information bias. To mitigate these
biases, the researcher employed random sampling and disseminated the questionnaires
to all the accredited health sciences universities in UAE. The snapshot feature of the
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research is another limitation that can be considered as a baseline for further research
comparison and analysis.
4.2 Assessing the Knowledge and Attitude of Healthcare Providers in UAE
4.2.1 Quantitative
Evaluating the knowledge and attitudes of the frontline workers of the health system
is imperative for the seamless implementation of genetic testing and PGx. In the UAE,
there are strides to implement genetic testing and pharmacogenomics; therefore, these
findings will delineate the stringent approach of implementation. The researcher
assessed the knowledge and attitudes of the entire cluster of the cohort healthcare
workers including physicians, pharmacists, nurses, allied health and administrative as
the stakeholders in UAE foresee a multidisciplinary approach for the implementation
of genetic testing and PGx. All participants in the cohort exhibited a fair knowledge
level about genetic testing and PGx. Most of the respondents showed a positive attitude
regarding availability of genetic testing. The top identified barrier to implementation
was the cost of testing followed by lack of training or education and insurance
coverage.
Advances in genetic testing facilitated discovering genetic variants, which guided the
drug prescription and tailored dose selection and replaced the trial-and-error approach.
In fact, several guidelines and algorithms are incorporating and adopting PGx in their
clinical pathways, which in turn paved the road to personalized medicine (Cavallari et
al., 2017b; Crews et al., 2012; Morash et al., 2018; Morganti et al., 2019; Relling et
al., 2010; Relling et al., 2011; Singh, 2020). Studies signify that physicians immersed
in PGx modules were more auspicious towards genetic testing as they sought it
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clinically beneficial. Furthermore, their awareness fueled their confidence in their
skills to implement personalized medicine into their patient-centered care (Owusu
Obeng et al., 2018). In her paper, Swan (2012) highlighted personalized medicine as
one of the plans and routes for the Health Vision of 2050 (Swan, 2012). Additionally,
Mason-Suares et al. (2016) highlighted the new spectrum of skills required from
healthcare providers in order to implement personalized medicine; some of these skills
include managing diagnostics facilities, gauging the relevance of tests and
implementing cost-effective procedures (Mason-Suares et al., 2016). In this research,
the investigator assessed the knowledge and attitude of healthcare workers in the UAE
to gauge their position within the personalized medicine spectrum. This aimed to
provide the stakeholders in UAE with the information needed to strategize their
implantation approaches. From these findings, stakeholders should prioritize
educating healthcare providers about basics of genetics and translational aspects.
Studies have consistently demonstrated a gap in the knowledge of healthcare workers
about genetic testing and PGx in almost all countries: United Kingdom, Greece,
Canada, USA, Japan, Germany, Netherlands, Egypt, Africa, Brazil, Qatar, Kuwait and
KSA (Algahtani, 2020; Alharbi et al., 2019; Bernhardt et al., 2012; De Denus et al.,
2013; Elewa et al., 2015; Feero & Green, 2011; Lopes‐Júnior et al., 2017; Mai et al.,
2014; Nagy et al., 2020; Owusu Obeng et al., 2018; Rahawi et al., 2020; Yau et al.,
2015). Similarly, these findings fall along the same line.
Interestingly, this research shows significant differences in the levels of theoretical
knowledge of genomics and PGx by gender. The proportion of healthcare workers with
good knowledge levels was higher in male than female workers, while more females
scored moderate or fair knowledge levels than male healthcare workers. One study by
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Powell et al. (2012) reported that the inconsistent levels of knowledge and
understanding is significantly associated with gender. Consequently, in their study,
male workers were two times more likely to feel prepared to answer questions related
to direct-to-consumer genetic tests than female workers (Powell et al., 2012). Gender
gap of knowledge had been addressed in other scientific domains, but not in genetic
testing and PGx. Many studies highlighted the reversed gender gap in education. This
disparity warrants in-depth investigation and further research; as such, it requires a
pivotal strategy (Quenzel & Hurrelmann, 2013; Van Bavel et al., 2018).
This research revealed significant statistical differences in the levels of genomics
knowledge between different occupations. Respondents working in the field of
medicine scored higher than those working in the field of pharmacy or nursing.
However, all exhibited a fair knowledge level. In part, this can be attributed to the
narrow application of genomics in the field of medicine in UAE (Abou Tayoun et al.,
2020; Akawi et al., 2012; Al-Ali et al., 2018; Al-Mahayri et al., 2019; Al-Mahayri et
al., 2020; AlSafar et al., 2019; Osman et al., 2018).
Remarkably, in the research sample, knowledge scores for genomic basics were
significantly associated with healthcare workers having patients asking them about
undertaking a genetic test in the last two years. Notably, this was not the case if the
patients asked them for advice about the results of a genetic test. This can potentially
be explained by the fact that healthcare workers felt responsible and duty-bound to
learn more about genomics and genetic tests to maintain the physician-patient rapport
(Gupta et al., 2020; Shaya et al., 2019). Another significant attribute to the knowledge
of the healthcare workers is completing a training or education in genetic testing or
PGx. A survey on Canadian physicians working in oncology, cardiology and family
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medicine concluded that physicians with prior training on genomics medicine had a
significantly higher mean knowledge score (Bonter et al., 2011). In fact, education and
training is the foundation of most of the platforms, frameworks and consortia that
coined the implementation of genetic testing and personalized medicine (Abu-Elmagd
et al., 2015; Korf et al., 2014; McClaren et al., 2020a; Nembaware et al., 2019).
Studies have repeatedly reported the positive attitude towards genetic testing and PGx
that resides among healthcare workers. This research is in line with this finding. The
vast majority of respondents in this cohort exhibited a positive attitude regarding
availability of genetic tests, biobank, and application of genetic testing and PGx. A
review by Yau et al. (2015) concluded that doctors working in USA, Canada, Japan,
Germany, and Netherlands had positive attitude toward pharmacogenetics despite the
poor knowledge. Another systematic literature review disclosed that healthcare
specialists saw merit in PGx (Dodson, 2011). Moreover, a study on pharmacists
working in Québec (Canada) voiced that pharmacists were very optimistic about the
prospective role of PGx (De Denus et al., 2013). In this cohort of healthcare workers
in the UAE, a genetic counselor was voted higher for assuming the role and
responsibilities of counseling on PGx and genomic test and results, followed by
physicians. Only 9.3% believed a pharmacist should assume this role, thereby
conflicting with the previous findings of pharmacists having significantly more
positive attitude than doctors toward assuming the roles and responsibilities of PGx
application and counseling (Elewa et al., 2015). This research’s findings fall along the
same line as the findings of pharmacists and physicians in Greece, wherein they
reported feeling incapable of clarifying the results of PGx tests to their customers or
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patients, and the authors tied that to the low level of undergraduate education in
genetics and PGx (Mai et al., 2014).
Most healthcare workers in UAE have considered having a genetic test performed at
some point in their career in order to make better informed decisions about their
respective interventions and treatments. Therefore, a positive attitude toward
perceived clinical utility of genomic results can be extrapolated. A mixed method
approach conducted by Stark et al. (2019b) on Australian health professionals echoed
that genetics professionals perceived higher clinical utility towards rapid genomic
testing in neonatal and pediatric intensive care than the intensivists themselves. More
than half of the healthcare workers in UAE reflected a positive attitude towards the
accessibility of online direct-to-consumer genetic tests. However, primary care
workers in Italy deemed the direct to customer genetic tests for chronic complex
diseases to not be clinically useful (Baroncini et al., 2015). A systematic review of the
literature regarding the standpoint of health professionals concluded that health
professionals specializing in genetics were most likely to express concerns toward
direct-to-consumer tests due to their deep knowledge in comparison with other
healthcare workers (Goldsmith et al., 2013). Another study by Patrinos et al. (2013)
exploring the good, bad, and ugly manifestation of direct-to-consumer genetic tests
concluded that pharmacists need to be presented with tutoring in genetic testing and
counseling (Patrinos et al., 2013).
The top barrier for the implementation of genetic testing and PGx in UAE identified
by the respondents was the cost of testing, followed by lack of training or education
and insurance coverage, lack of clinical guidelines, insufficient infrastructure, and lack
of laws governing privacy and confidentiality. Implementing genetic testing and PGx
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in UAE will first require addressing the aforementioned barriers on both individual
and systematic levels. Physicians in the USA echo similar opinions as those of
healthcare workers in this sample, whereby they rated costs of gene-based therapies
and genetic testing as the most significant barrier (Haga et al., 2011; Petersen et al.,
2014). A study by Najafzadeh et al. (2012) investigated the barriers to integrating
personalized medicine into clinical practice using a best–worst scaling choice
experiment and labeled both education and guidelines as barriers to the
implementation of genetic testing.
A variety of studies echoed the role of pharmacists in leading the implementation of
pharmacogenomics within their work settings (Bain et al., 2018; Bank et al., 2019;
Brown et al., 2018; Knapp & Ignoffo, 2020; Schuh & Crosby, 2019a; van der Wouden
et al., 2019). Given the UAE’s endeavors to follow a multidisciplinary approach for
project implementation, ensuring harmony, commitment and unity, including a large
variety of healthcare worker specialties in this cohort was very important (Alsaadi et
al., 2019; Antoniak, 2004; Haleeqa et al., 2020; Hawamdeh et al., 2013; Manda et al.,
2012; Rahmani & Afandi, 2015; Rowland-Jones, 2012). In the focus group discussion
conducted among pharmacists working in UAE, they voiced their preference to have
a multidisciplinary approach to implement pharmacogenomics (Rahma et al., 2020a).
Aggregating all healthcare workers in one pool is a limitation in this research;
therefore, researchers recommend conducting studies focusing on each specialty to
insure in-depth and tailored assessments of the gaps in knowledge, attitudes, and
existing challenges. Moreover, researchers recommend conducting qualitative studies
to physicians, nurses, and genetic counselors as that will lead to opening the door to a
more comprehensive understanding of the attitudes of healthcare workers in the UAE.
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4.2.2 Qualitative
Lessons from the implementation of genomic medicine and pharmacogenomics
worldwide suggest that gauging the knowledge and attitude of healthcare providers is
a prerequisite to exploring the road map for the implementation of pharmacogenomics
and possibly genomic medicine within the routine healthcare systems. Nevertheless, it
is not clear if this is happening now in the UAE. The novelty of these findings is that
it is the first qualitative research in the UAE that will allow stakeholders to follow a
clear pathway/framework for the adoption of genomics and pharmacogenomics in
clinical practice. The findings provide multilayers of factors and inputs like
knowledge, attitude, perception, sociocultural factors, and power that will be useful in
implementing pharmacogenomics in the UAE.
Several studies evaluated the knowledge and attitude of pharmacists toward genomics
and pharmacogenomics world-wide and this research is the first to do so in the UAE.
Despite the geographical spaces, pharmacists shared similar attitudes and concerns
toward pharmacogenomics (Abdela et al., 2017; Albassam et al., 2018; AlEjielat et al.,
2016; American Society of Health-System, 2015; Bush et al., 2019; Muzoriana et al.,
2017; Romagnoli et al., 2016; Snyder et al., 2014; Squiers et al., 2012; Tai et al., 2018;
Tuteja et al., 2013; Yau et al., 2015). In this sample, the perceived knowledge of
pharmacists who worked or studied outside the UAE did not differ from those who
worked or studied in the UAE. In addition, being a fresh graduate did not influence the
level of the perceived knowledge of pharmacists about genomics and
pharmacogenomics and that is in contrast with what Snyder et al. (2014) reported; that
new graduates had better knowledge in pharmacogenomics in comparison to senior
graduates. Pseudo-knowledge was observed as pharmacists in this sample were mixing
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between genomic medicine and genetic engineering or screening and that can be
attributed to the poor knowledge and the gap in the curriculum. This calls for
incorporating genomics and pharmacogenomics education more effectively in the
current training programs. Yau et al. (2015) assessed the practice of genomic medicine
and pharmacogenomics by pharmacists as well as their knowledge and attitude in a
systematic review and they concluded that pharmacists ought to be taught how to read
genetic test reports and act upon them. The research’s findings are in accordance with
that conclusion, as despite the positive attitude that pharmacists in this sample had
toward genomic medicine and pharmacogenomics, they ranked their knowledge level
as poor or fair.
The American Society of Health-System Pharmacists (ASHP) highlighted the
responsibilities, roles and functions of the pharmacist in the pharmacogenomics era
(American Society of Health-System, 2015). However, limited studies assessed
pharmacists’ health literacy skills and factors prominent to the adoption of
pharmacogenomics. A study by Romangnoli et al. (2016) used a qualitative method to
assess the resource requisite of the pharmacists in Pittsburgh, United States, and they
concluded that whenever a pharmacogenomics tool will be designed, pharmacist’s
requirements is an essential step to be factored in, particularly in terms of translation
of the genetic test. A gap was identified in the tools that pharmacists use to seek
information. Most pharmacists in this research identified internet surfing, Google and
YouTube as their main source of information, except for a few clinical pharmacists
who navigate databases and scientific journals and stated that the internet may have
unscientific information. It is worth mentioning that these skills are dynamic in nature
and are an integral component of the framework of the pharmacogenomics literacy of
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pharmacists. To bridge this gap, authorities and policy makers may provide official
clinical practice pathways and references for healthcare providers in the UAE.
Pharmacists in this research have agreed that the decision to implement genomics and
pharmacogenomics in the UAE is in the hands of stakeholders. A wide range of papers
discussed the role of stakeholders and the gaps that hinder the adoption of genomic
medicines (Bush et al., 2019; Snyder et al., 2014; Tai et al., 2018).
Fatalism is one of the emergent themes in this study; Elbarazi et al. (2017) had
investigated the influence of religion on opinions related to health in the UAE and they
highlighted the necessity of having a personalized set of religious values in decision
making (Elbarazi et al., 2017). Nevertheless, this research is the first to shed light on
the implication of religion on the adoption of genomic medicine among healthcare
providers. Pharmacists in this sample were advocates of genetic testing to their
offspring and they attributed that to their maternal and paternal instincts of protecting
their children; these findings are parallel to the findings of Hallowell et al. (2013) in
which participants value the genetic tests in promoting the health of their relatives,
particularly their children.
Pharmacists did not agree on the proper and ideal mechanism of implementing
genomic medicine and pharmacogenomics in the UAE. Some pharmacists advocated
a preemptive pharmacogenetic testing approach, which seeks proactive testing and
obtaining the results of the genetic test at the time of prescribing (Keeling et al., 2019).
On the other hand, other participants were advocates of the reactive pharmacogenetic
testing approach, in which specific drug–gene tests will be requested at time of
dispensing (Arwood et al., 2016). Pharmacists perceived that a multidisciplinary team
of a physician, pharmacist and genetic counselor may be the best approach to tackle
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pharmacogenomic communication in the light of the current scene of the lack of
knowledge, workload and shortage of personal (Wurcel et al., 2019).
Myriad studies postulated the feasibility of pharmacists’ role in implementing
pharmacogenomics at bed side and health settings. A pilot study by Bank et al. (2019)
in the Netherlands underscored the efficient role of community pharmacists in
recommending intervention based on the drug–gene of the patients, and these
recommendations were acknowledged by the clinicians in 88.7% of the patients (Bank
et al., 2019).
Stark et al. (2019a) advocated the global liability of transforming genomics into
healthcare. In their paper, they delineated the different implementation strategies taken
by 15 countries, namely: the UK, France, Australia, Saudi Arabia, Turkey, the US,
Estonia, Denmark, Japan, Qatar, Switzerland, the Netherlands, Brazil, Finland and
China. These strategies and initiatives can be tools for the adoption of genomic
medicine and pharmacogenomics in the UAE to avoid reinventing the wheel and
squandering resources.
Pharmacists in the UAE are thirsty for resources and tools to foster their competency
in genomics and pharmacogenomics. The Implementing GeNomics In PraTticE
(IGNITE Toolbox) is one of many open peer reviewed resources that consolidate the
knowledge and implantation efforts of pharmacists and other healthcare providers. The
Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines on
converting genetics results to actionable interventions (Cavallari et al., 2017a). This is
accompanied by the PharmGKB, which grants knowledge incorporated in pathways
(Thorn et al., 2013).
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Scholars are equipping healthcare providers with tools to overcome the gap in their
knowledge. Zarei et al. (2020) coined a web-based pharmacogenomics search
instrument for the pharmacogenomics of drugs used in anesthesia. The GenotypeTissue Expression (GTEx) Consortium is another resource (Keen & Moore, 2015).
Ziegelstein (2017), in his commentary, diagnosed personomics as the gap of the
adoption and evolution of personalized medicine. In consonance with this punch line,
it was hypothesized that the healthcare providers and, more specifically, pharmacists
are rooted in the personomics concept. Moreover, addressing their knowledge, attitude
and perception will reshape the face of medicine in the country (Ziegelstein, 2017).
As recommended by the 9th Santorini Conference conducted in Greece, establishing a
research link between academics and businesses will bridge the gaps and chasm in the
roadmap for full implementation of genomic medicine and pharmacogenomics
(Visvikis-Siest et al., 2018). These recommendations can guide the UAE in its strategy
for implementing genomic medicine and pharmacogenomics.
The strength of this research is that it is the first qualitative research to be conducted
among pharmacists in the UAE that discusses the adoption of genomics and
pharmacogenomics in the UAE. The qualitative nature of the research allows
researcher to dig deeper and enables a comprehensive picture. A limitation of this
research was lower representation of the community pharmacists; they declined the
participation in the focus group due to workload shifts and their difficulties in
obtaining manager approval. Another limitation is the lack of representation of all the
seven emirates of the UAE; despite the snowballing sampling technique, researcher
could not have enough representation from cities other than Abu-Dhabi city.
Researcher found difficulty in recruiting pharmacists to participate in the focus group
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discussions; 43 invitations were rejected, mainly due to lack of knowledge about the
topic.
4.2.3 PGLP Framework
In the era of personalized medicine, it is plausible to have a personalized framework
for genomics and pharmacogenomics literacy which is a tool for the adoption of
pharmacogenomics among pharmacists. The researcher factored the individual’s
factor of the pharmacists and their skills, knowledge, and attitude as well as the
sociocultural factors and demands as the input dependent. This PGLP framework can
guide the stakeholders in any country as it is comprehensive and systematic.
There is conflict among researchers about the definition of health literacy. For the
pharmacogenomics literacy, this research advocates the definition of Baker (2006) as
“the dynamic skills to work in the health care setting. These skills vary according to
the traits and key features of both individual and the health care system.” Baker (2006)
stated that health literacy is context specific and fluctuates depending on the type of
health problem, the provider and the setting (Baker, 2006). On the other hand, genetic
literacy has been defined as “adequate understanding and awareness of genomics
foundation to permit knowledgeable outcome” (Syurina et al., 2011).
In the literature, there is an aggregating evidence of the gap in knowledge of
pharmacogenomics among healthcare providers ( Abdela et al., 2017; Dodson, 2011;
Giri et al., 2018; Kim et al., 2020; Rahma et al., 2020b; Stanek et al., 2012; Tsermpini
et al., 2019) specifically pharmacists (AlEjielat et al., 2016; Elewa et al., 2015; Karuna
et al., 2020; Muzoriana et al., 2017; Rahma et al., 2020a; Tuteja et al., 2013; Adamu
Yau et al., 2015). Preponderance of literacy frameworks are dedicated to patients
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(Syurina et al., 2011). However, having a literacy framework for pharmacogenomics
dedicated for healthcare providers will systematically pave the knowledge gap. The
complexity and the multifactorial challenges of the health system coupled with the
multidimensional aspects of health literacy necessitate a comprehensive framework to
address literacy in pharmacogenomics (Qiang, 2003; Syurina et al., 2011).
Assuring a competent healthcare provider is one of the 10 essential public health wheel
of tasks deciphered by Institute of Medicine (Curry, 2005). It spurs empowering all
healthcare providers from all levels with ongoing knowledge. Literacy in
pharmacogenomics is challenged by the unprecedented advances in technology and
research in the field coupled by the need of lifelong learning (Owen, 2011; Romagnoli
et al., 2016; Syurina et al., 2011).
Researcher devoted the framework to pharmacists hence they are the hardcore of
pharmacogenomics, as articulated in the statement of The ASHP (American Society
of Health-System, 2015).
The health literacy skills framework captures a holistic approach toward literacy and
it takes into account individual and sociocultural influences; therefore, researcher
exploited it to conceptualize the Pharmacogenomics Genomics’ Literacy Framework
for Pharmacists (PGLP) (Squiers et al., 2012). Researcher tailored it and personalized
it to pharmacists in the light of the wealth of codes and data obtained from pharmacists
from focus group discussions (Rahma et al., 2020a). The PGLP framework tackled
pharmacogenomics’ genomics literacy through variety of lenses.
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4.2.3.1 How to use PGLP framework?
This framework will guide stakeholders in their mission of equipping pharmacists and
potentially genetic counselors, doctors and nurses with skills required for the adoption
and implementation of pharmacogenomics. It is consolidated based on a validated
theoretical framework for health literacy, which gives PGLP credibility.
PGLP is a personalized literacy framework for the adoption of pharmacogenomics in
the era of personalized medicine. It encompasses bundle inputs namely individual and
sociocultural factors and highlights the role of demand, skills, knowledge and attitude
of pharmacists and potentially other healthcare providers to learn and implement
genomics and pharmacogenomics and appeals to their beliefs and instincts.
PGLP strategizes the attempts of stakeholders to educate pharmacists about
pharmacogenomics taking in account their individual factors and tailoring modules to
meet their role, occupation, and capabilities, whether they are clinical pharmacists or
inpatient or outpatient or community pharmacists or a pharmacist setting in a
Pharmacy Therapeutic Committee (PTC) or Institutional Review Board (IRB).
Personalizing tuition to the type of patients they are serving whether oncology patients,
psychiatric, transplant, cardiology, metabolic or geriatric.
Stakeholders occupied by implementing pharmacogenomics in their countries should
not isolate their approach from the sociocultural factors incubating and nourishing
their infrastructure and resources. They have to tailor their map to their current
educational system, health system and cultures. They have to utilize media and call for
laws and policy. Moreover, they need to factor religion and literacy of the community.
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The demand will set the pace for the pharmacogenomics implantation and hence
educational efforts and utilization of PGLP framework.
Catalyzing the three dynamic pillars of skills, knowledge and attitude of pharmacists
and healthcare providers will be compelling formula for developing a cost-effective
personalized and profound modules and approaches. Knowing the pharmacists’ skills
will guide the stakeholders in purchasing platforms and databases and other resources
and will tailor orientation. Mapping the knowledge and attitude of the pharmacists will
help shaping the resources, workshops, seminars, and competencies. This PGLP
framework is comprehensive, and researcher theorizes that it will tailor the
implementation strategies in a standardized and systematic manner.
Individual inputs to literacy:
Both health literacy skills and PGLP framework embraced the individual traits as input
into literacy. Individuals’ inputs like age, education, power, roles, and capabilities are
traits that need to be acknowledged and factored in while designing any training in any
field and pharmacogenomics is not an exception. One uniform approach had been
abandoned and replaced by a more tailored and personalized approach that put learner
as the center and consider individuals’ inherited factors and capabilities to empower
them (Crown et al., 2020; Martins et al., 2020; McClaren et al., 2020a; Shuster et al.,
2020; Tsai et al., 2020). Many medical and health sciences colleges are embracing this
evidence-based shift in paradigm and putting learner in the center stage and tailor the
pedagogy according to their individual traits (Berlin et al., 2010; Gálvez-Peralta et al.,
2018; Garten & Altman, 2010; Lee et al., 2012; Patrinos & Katsila, 2016). In the
pharmacists’ cohort, researcher deciphered how diverse the pharmacists’ role, power,
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and capabilities. Pharmacists working as clinical pharmacists were more familiar with
pharmacogenomics than those in community settings. Pharmacists with children were
keener to learn about pharmacogenomics as they appreciate and foresee its value.
Stakeholders planning a workshop about pharmacogenomics to pharmacists, need to
know their audience regarding their demographic, role, occupation, prior knowledge,
and experiences. Researcher hypothesizes that this will be a cost-effective approach
(Assem et al., 2021; Nicholson et al., 2021; Ward et al., 2020). A study by Owusu‐
Obeng et al. (2014) scrutinized the role of pharmacists in the pharmacogenomics’ era
and aligned with this research’s findings. In their model, some of the individual’s input
required from pharmacists are skills in informatics, background in medication safety,
insight in medication‐use policies and procedures, education, and conquest of literature
assessment.
In the published implementation models of pharmacogenomics and in accordance with
research’s findings, clinical pharmacists were appropriately situated to implement and
lead clinical pharmacogenomics programs, as they own individual’s input that are
plausible such as expertise in pharmacodynamics, kinetics, genomics, informatics, and
patient care (Bain et al., 2018; Hicks et al., 2016; Owen, 2011; Owusu‐Obeng et al.,
2014; Schuh & Crosby, 2019b; Schwartz & Issa, 2017).
Demand or Stimuli:
Researcher adopted demand in the PGLP framework from the HLS framework as it is
the switch on button. The demand can originate from the patient and or the clinical
setting in a micro, meso and macro-levels (Schuh & Crosby, 2019a).
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The American Society of Health-System Pharmacists (ASHP) statements highlighted
the pharmacist’s patient-care loop. In their statement, patients were at the center-stage
for the demand for pharmacogenomics implementation (American Society of HealthSystem, 2015).
Skills:
Critical skills of accessing, understanding, appraising, and applying knowledge and
information are an essential dimension of health literacy and health literacy skills
(Freedman et al., 2009; Squiers et al., 2012; Syurina et al., 2011). A study by Peterson‐
Clark et al. (2010) pointed out that pharmacists scored a shallow general skills in
surfing online information and e-health. A randomized clinical trial by Basheti et al.
(2009) reported that the retention of the pharmacists’ skills was significantly improved
after training them on the proper technique of using inhalers and providing them with
printed materials and tools. These findings are in congruence with research’s findings
(Rahma et al., 2020a). It is pivotal to add skills to the PGLP framework; electronic
resources and databases are the mainstay of pharmacogenomics like Clinical
Pharmacogenetics Implementation Consortium (CIPC) (Caudle et al., 2014) and
PharmGKB (Thorn et al., 2005).
Knowledge:
Knowledge of pharmacists is a profound repertoire of literacy. It eluded the health
literacy skills framework; however, we advocate and anchor its impact on health
literacy in general and pharmacogenomics in particular. Breadth of studies highlighted
the gap in knowledge of genomics and pharmacogenomics among pharmacists and
other healthcare providers as well as the impact of this gap on implementation (Abdela
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et al., 2017; Albassam et al., 2018; AlEjielat et al., 2016; Berenbrok et al., 2019;
Karuna et al., 2020; Muzoriana et al., 2017; Nagy et al., 2020; Rahma et al., 2020a;
Rahma et al., 2020b; Tuteja et al., 2013; Yau et al., 2015). Knowledge is beyond prior
knowledge of basics of pharmacogenomics, it is a bundle of information concerning
benefit and applications, knowledge of the available resources, services and practices,
knowledge of the cost and insurance coverage, knowledge of the local, national, and
international guidelines. Researcher foresees it as a dynamic pillar that needs to be
addressed regularly by stakeholders planning literacy in pharmacogenomics and
genomics.

Knowledge

will

speed

the

implementation

and

adoption

of

pharmacogenomics in the practice setting of pharmacists. Pharmacists’ literacy and
competency in pharmacogenomics ought to be assessed and updated regularly
(American Society of Health-System, 2015; Benzeroual et al., 2012; Berenbrok et al.,
2019; Formea et al., 2013; Papastergiou et al., 2017). Therefore, this pillar and
component of the PGLP framework is vital. Credibility of the pharmacists has been
pointed out as being essential to the community ’trust or patients ’trust of any health
information (Nelson et al., 2009; Hesse et al., 2005; Squiers et al., 2012). Therefore,
pharmacists’ knowledge of pharmacogenomics will assert such trust from patients and
community (Rahma et al., 2020a).
Attitude:
Health skills literacy framework posed attitudes, feelings, incentive, and self-worth, as
mediators between health literacy and outcome (Squiers et al., 2012). In the PGLP
framework, researcher stressed attitude as an imperative cornerstone toward literacy
in pharmacogenomics. Studies have shown that attitude of pharmacists or other
healthcare providers or students is a leverage on implementing pharmacogenomics and
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genetic testing (AlEjielat et al., 2016; Assem et al., 2021; Dodson, 2011; Elewa et al.,
2015; Laskey et al., 2003; Martins et al., 2020; Olwi et al., 2016; Rahma et al., 2020c;
Roederer et al., 2012; Stanek et al., 2012; Tuteja et al., 2013; Weir et al., 2010; Yau et
al., 2015).
In line with the health literacy skills framework, researcher labeled a dynamic nature
to skills as well as the knowledge and attitude. Hence, these elements are
interconnected and influence each other and are influenced by the sociocultural inputs
as well.
Sociocultural influencers of literacy:
The sociocultural determinants of PGLP framework are more ample than the health
literacy skills framework as it incorporated 10 inputs tackling culture, community,
patient, media, religion, stakeholders, educational system, laws and ethics, health
systems and healthcare providers. Researchers conceptualize that these elements are
cross-roads for genomics and pharmacogenomics literacy. The World Health
Organization (WHO) apprehended the same sociocultural factors that were appointed
in this PGLP framework; Pang (2009) named the fragile health care delivery systems
as an obstacle to be addressed. Furthermore, WHO advises stakeholders to implement
the following strategy to pursue pharmacogenomics: efficient networks , society
confidence, embracing a multidisciplinary tactic to research, intensifying ethical and
regulatory contexts, and engaging all relevant stakeholders (Pang, 2009).
Pharmacists are not isolated from the community, health system or other healthcare
providers. Pharmacists in the cohort advocate a multidisciplinary approach to
implement pharmacogenomics. Studies favored this methodology. A study by
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Caraballo et al. (2017) employed a multidisciplinary task force of professionals to
strike a balance in the implementation of pharmacogenomics at the point of care.
Another study by Dunnenberger et al. (2016) concluded that a multidisciplinary
pharmacogenomics clinic can expedite the incorporation of pharmacogenomics into
clinical care.
The strength of this work is conceptualizing a novel, comprehensive and personalized
pharmacogenomics and genomics literacy theoretical framework tailored for
pharmacists. Moreover, PGLP framework is based on published health literacy skills
framework that was synthesized upon a number of literacy frameworks (Squiers et al.,
2012). Additionally, PGLP framework has been tailored to meet specific individual
and sociocultural factors pertaining to pharmacists and pharmacogenomics.
Furthermore, researcher added knowledge, attitude as new pillars inherited with
pharmacogenomics literacy. Another strength is building the PGLP framework using
mixed methods which added thoroughness and depth. Additionally, this framework
can be a platform to pharmacogenomics and genomics literacy to other healthcare
providers or even other health related literacy.
The PGLP framework is a theoretical framework that needs to be validated. Future
implementation research can validate this framework and extrapolate it to other
healthcare providers.
4.3 Assessing the Knowledge and Attitude of Students in UAE
The majority of medical and health science students in the UAE had a positive attitude
toward genomic medicine and PGx; they would consider having genetic testing done
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at some point in their life to find out their future risk of developing genetic diseases.
Nevertheless, they had a fair level of knowledge about genomic medicine and PGx.
Dearth of knowledge on genomic medicine and PGx is one of the identified barriers
and challenges for the full implementation of genomic medicine and PGx. Studies
denoted that healthcare providers had a gap in their knowledge about genomic
medicine and PGx (Kim et al., 2020; McCullough et al., 2011; Taber & Dickinson,
2014). Medical and health science students are the future adopters of genomic
medicine and pharmacogenomics. Therefore, it is crucial to identify the students’
knowledge and attitudes toward genomic medicine and PGx in an early stage so policy
makers can intervene and strategize the roadmap for the full implementation of
genomic medicine and PGx in the UAE.
Most of the students in the sample did not demonstrate a good level of knowledge in
the area of genomic medicine and pharmacogenomics, which could reflect the gap in
the educational landscape of genomic medicine and pharmacogenomics in the UAE.
This identified gap is aligned with what other investigators had identified in
undergraduate medical students in southeast Europe and the United Kingdom (Higgs
et al., 2008; Pisanu et al., 2014).
Researcher found significant statistical differences between the level of knowledge of
the undergraduates and the year of study. This can partly be attributed to the fact that,
based on the mapping of UAE universities’ curricula, genetic and PGx courses
available to the medical and health science students are incorporated starting from
second year. This mimics the trend of genetics and PGx education in the United States
and Canadian medical schools (Plunkett-Rondeau et al., 2015). Additional significant
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differences were found between the level of knowledge and engagement in a training
or educational activity pertaining to genomic medicine or PGx and with the completion
of an internship or study program abroad. This finding underpins the infancy of the
universities’ omics programs in the UAE and articulates the urgency in revisiting these
programs to avoid the bottleneck situation warned against by the International Society
of Pharmacogenomics in their recommendations to the deans of medical and health
sciences schools (Gurwitz et al., 2005).
Researcher anchored a positive prospect in terms of the principles of PGx in the cohort;
around 90% of the students articulated that genetic changes affect responses to drugs.
This aligns with the positive outcome reported by Talwar et al. (2019) in their
systematic literature review. By the same token, students in this sample and pharmacy
students in Jordan and West Bank of Palestine lagged behind in denoting the
pharmacogenomics’ recommendation of the FDA (Jarrar et al., 2019).
Medical and health science students in the UAE are united in terms of their attitudes
toward genetic tests under the same banner with medical and health science students
worldwide. In this sample, the majority of the students (82.7%) would consider having
genetic testing done at some point in their life to find out their future risk of developing
genetic diseases. In a study conducted by Laskey et al., (2003) among African
American and other marginal students, 95% of them endorsed genetic testing for
preventive care. Interrelating attitudes were found among college students in the
Kingdom of Saudi Arabia and Greece (Mavroidopoulou et al., 2015; Olwi et al., 2016).
Nevertheless, 74.7% of the students in this sample would only like to know their
susceptibility to diseases that have current interventions for protection and that
synchronized with the Common-Sense Model of Self-Regulation (CSM) framework
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for understanding illness self-management, in which students can formulate action
plans in response to the threat of genetic tests’ results (Cameron & Reeve, 2006;
Leventhal et al., 2016).
The overwhelming majority of the students in this sample (around 80%) selected the
physician to fill the role of explaining the report of the genetic tests to them, while
around 45% of them voted for the pharmacist. This can be a stereotype of the current
health system that the students had trained in as well as a reflection of their limited
knowledge. Research proposed a partnership between pharmacists, physicians, and
genetic counselors as a model to adjust for the gap in knowledge (Kennedy, 2018;
Mills & Haga, 2013). Students in the sample stated a myriad of legal and ethical
concerns and liabilities. They voiced concerns that the availability of genetic tests
could be problematic for insurance companies and future employers. These concerns
match those of students in the USA, KSA, Qatar and Greece (El Shanti et al., 2015;
Laskey et al., 2003; Mavroidopoulou et al., 2015; Olwi et al., 2016). A heuristic
qualitative study conducted in Belgium, explored the direct and indirect worries of
genetic tests, and concluded that legislative powers need to be clear and subtle to
relieve these concerns about genetic discrimination (Wauters & Van Hoyweghen,
2018).
The majority of students in this sample was optimistic about the future and believed
that medicine in the UAE will be more personalized. Most of them agreed that the
government should invest more money into its implementation and more time should
be dedicated towards tutoring PGx. These stands boost the sporadic effort to
implement personalized medicine in the UAE in particular and the GCC, Middle East
and North Africa (MENA) region in a wider spectrum. A study by Shah and Shaheen
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(2016) foresees the UAE as a fruitful landscape in the genomic era as the UAE is a
host to a substantial expat population which translates to versatility in phenotypes in
addition to the UAE locals and their unique signature genetic traits. Another study by
Mitropoulos et al. (2015) shed light on success stories on the implementation of
genomic medicine, and, in their article, they recounted PGx research that launched in
1996 in the UAE and led to the discovery of many novel variants.
Students in the UAE are eager for literacy in genomic medicine and PGx and they
highlighted workshops, seminars, and internship to be their preferred pedagogy. The
students ranked internet-based courses as their third preference in educational
approach, which can craft the strategy to remedy the current gap in knowledge.
Existing resources on the Internet consolidate this reciprocity of knowledge (Barh et
al., 2013; Berlin et al., 2010; Duong et al., 2020; Gálvez-Peralta et al., 2018; Gurwitz
et al., 2003; Hoehndorf et al., 2012; van den Boom et al., 2013). Moreover, researcher
explored the students’ perceived barriers to the full implementation of genomic
medicine and PGx in the UAE. Students in this sample ranked lack of training and
education as the first barrier. The breadth of research tackled this barrier. Ta et al.,
(2019) highlighted in their paper the robust role of PGx education as a panacea toward
generating well-informed clinicians who will champion personalized medicine. The
students also foresee lack of clinical guidelines, cost of testing, lack of infrastructure
as well as lack of community awareness as a bundle of barriers deterring the full
implementation of genomic medicine and PGx in the UAE. Corresponding research
studies tackled the same barriers and investigated strategies towards overcoming these
barriers (Knowles et al., 2017; Mitropoulou et al., 2020).
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Assessing the attitudes and knowledge of medical and health science students in the
UAE about genomic medicine and PGx is an added tool to the implementation kit
needed to construct a roadmap for the full implementation of genomic medicine and
pharmacogenomics in the UAE. It empowers stakeholders to tackle the gaps in
knowledge and conquer the barriers and challenges.
The inherited bias of information bias and selection bias will be a limitation that had
been accepted by previous studies. Snowball sampling is prone to selection bias or
community bias, unknown sampling population size, and hence difficulty in
calculating an accurate response rate. To address these limitations, researcher scanned
all the medical and health science universities in the UAE and employed random
selection sampling techniques. However, scarce representation of the Northern
Emirates had been detected and this might impact the generalizability of the findings.
4.4 Mapping the Current State of Genetics Testing Services in UAE
The knowledge of the genetics of diseases has been growing exponentially, creating
new opportunities for genetic testing, and incorporating such testing into clinical
practice (Burke et al., 2001). This has impacted the advancement of diagnostic tools
for genetic diseases, which has proven to be very useful for preventing, managing, or
treating these diseases. Also, it has proven useful for the timely management of certain
diseases, in which screening and early intervention have been effective for controlling
the symptoms and complications and improving the prognosis of some genetic
diseases (Burke et al., 2001). In the mapping, researcher sought to create a baseline of
the genetic testing landscape in UAE. Moreover, researcher attempted to examine the
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information provided on the website of the laboratories in UAE and compare it to the
onsite information provided by laboratory’s personnel.
Genomic medicine is defined as using an individual patient’s own genotypic
information for their clinical care (Manolio et al., 2013). Despite its great potential to
contribute to the advancement of clinical care, genomic medicine was restricted to
research purposes until 5 years ago. It has taken a long time for this knowledge to be
applied in clinical practice (Landry et al., 2018; Manolio et al., 2013). Globally, a range
of academic medical centers and integrated health systems have already initiated
programs to implement genomic medicine (Manolio et al., 2013).
Rapid progress has been made in identifying the molecular basis of human inherited
disorders. This has been driven by new technological developments that have
dramatically reduced the cost of genetic analysis. This has resulted in increased
numbers of genetic testing centers emerging in many parts of the world (Sagia et al.,
2011). The current population of the UAE is estimated to be 9,960,509. Nearly 75%
of the population of UAE is clustered on the northeast. The two main cities Dubai and
Abu Dhabi have more than 3 million residents each. All UAE citizens can access
private sectors but not vice versa. However, insurance companies do not fully cover
costs of genetic tests which is a concern with regard to accessibility and acceptability
(World Population Review, 2021; Nyika, 2009).
In the Gulf countries, including the UAE, there is a high frequency of consanguineous
marriage (estimated to be 12% – 70%), which is responsible for the high frequency of
genetic diseases. This includes, but is not limited to, hemoglobinopathies and inborn
errors of metabolism. Previously, in certain Gulf countries, molecular diagnostic
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samples were sent abroad for testing and analysis, but the results of significant
numbers of samples came back negative or inconclusive. This can be attributed to the
established differences in genetic profiles between the Gulf region and the West as
supported by a number of studies where novel and distinctive hotspots for diseasecausing mutations that are unique to the Gulf Arabian patients were identified.
Therefore, Gulf countries have adopted local strategies to develop and establish their
own accredited molecular diagnostic laboratories through research and development
(Zayed & Ouhtit, 2016).
In general, the findings indicate rapid growth in the field of genetic services provided
in the UAE, reflected by the rapid increase in the number of laboratories and the variety
of tests provided. The increased number of laboratories in Abu Dhabi and Dubai
clearly reflects the need for a broader range of health services due to the larger
population and greater cultural diversity in these two emirates in particular. There was
a general reluctance among the private laboratories to participate in the survey. The
same hesitance was also reported in a similar study from Greece (Sagia et al., 2011) .
This research indicated that prenatal testing appears to be the most required test across
the centers. This is expected given the high number of birth defects reported in the
UAE compared to the levels in other countries with similar rapidly developing health
services such as Malaysia, where clinical tests are in higher demand (Balasopoulou et
al., 2017).
Only six of the surveyed laboratories claimed to provide pharmacogenomic testing
among their services. This is a low level compared with that reported in similar studies
performed in Greece (61.5%) and Malaysia (15%) (Balasopoulou et al., 2017; Sagia
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et al., 2011). This is possibly due to a lack of awareness of the role of
pharmacogenomics in personalized medicine, resulting in its limited implementation
in patients’ management. In Greece, the relatively limited implementation was
attributed to discouragement from pharmaceutical companies as implementation of the
results can affect their profit margins (Sagia et al., 2011). The genetic tests and tools
offered in UAE are not comprehensive and may hinder genomics implementation in
UAE. According to Monte et al. (2012) myriads of omics screening and tools are vital
for the therapeutic safety and efficiency in pragmatic setting including genomics,
epigenomics, transcriptomic, proteomic and metabolic polymorphisms.
As genetic technology advances, the practices of genetic testing have become more
heterogeneous, with many different types of tests being added to the list of tests
provided to the public in different settings and for a variety of purposes (Balasopoulou
et al., 2017). A good example of this is increased demand for wellness and fitness tests,
which were advertised through the websites of 33% of laboratories in this research.
Researcher thinks that this is one of the repercussions of a growing focus on health
awareness issues and wellness in the media. This rise has occurred despite the fact that
such tests lack a robust evidence-base (Balasopoulou et al., 2017).
The results showed that among all DNA sources for genetic testing listed by the
different laboratories, blood samples were the most common, followed by saliva and
sputum, in agreement with studies performed elsewhere (Balasopoulou et al., 2017;
Sagia et al., 2011). Despite the debate in literature, it seems that physicians and the
general public still tend to believe that peripheral blood provides a more solid scientific
basis as a DNA source for genetic testing than other sources (Sagia et al., 2011).
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The genetic services provided by the genomic centers are mainly directed to clinical
services through hospital referrals. Complete genetic counseling services are available
in 8 of the 15 laboratories providing counseling. Complete genetic counseling is
defined here as the presence of a certified genetic counselor/clinical geneticist that
waives the need for referring stakeholders to another place to interpret the reports and
act on the consequences of the results. As most of the surveyed laboratories deal
directly with hospital referrals, this can explain the absence of complete counseling
services, which was also reported by Sagia et al. (2011) in Greece. The fact that only
1 of 27 laboratories provides information about consent forms raises serious ethical
concerns about privacy, confidentiality, anonymity of individual tests, and the fate of
the genetic material. Similar concerns have been raised about genetic testing practices
in Greece and Malaysia (Balasopoulou et al., 2017; Kechagia et al., 2014; Sagia et al.,
2011).
Most of the laboratories, as per the questionnaire survey, stated that they maintain high
standards and keep a positive reputation among the public by maintaining
accreditation, giving a sense of reliability and accuracy of their test results. However,
this did not match our findings from examining the websites of these laboratories. Only
40% clearly stated the type of accreditation and the accredited body on their websites.
In addition, only 4 of 27 laboratories have been certified for the provision of genetic
testing services, specifically ISO-15189 and/or ISO-17025. The rest of the laboratories
were accredited by different accreditation bodies, including Royal College of
Pathologists of Australia/National Association of Testing Authorities, College of
Canadian and American Pathologists (4 laboratories) and Joint commission
international (2 laboratories). Other labs stated they are accredited with ISO with no
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other specifications. The status of accreditation renewal on the companies’ webpages
could not be tracked.
The findings highlighted a discrepancy between the data collected by the two adopted
methods and that raised a red flag. The discrepancy was noticed in types of services
provided, DNA sources, type of genetic counseling provided and the updated status of
the relevant websites. Genomic medicine is a new field to the community of the UAE,
and no studies have evaluated the genomic literacy of the population of the UAE. Thus,
the community and health professionals may be misled by the information advertised
in the websites of those laboratories, especially since some of the laboratories are not
accredited by accreditation bodies which is another red flag. A study by Sabatello et
al. (2019) concluded that society has some understanding of genetic vocabulary but
has gaps in the interpretation of its constructs. A recent study by Bukini et al. (2020)
highlighted the correlation of low genomic literacy with consenting to genomic tests
and the need to execute more techniques to enhance the public’s understanding of
genetic tests and preserve their safety and privacy. Another recent study by Comess et
al. (2020) voiced the need for empowering investigators and public health society with
artificial intelligence methodologies to bridge gap and translate data from in silico to
bedside. Stakeholders in UAE must tackle this challenge to fully implement genomics
in the country.
The results showed that different types of health insurance are accepted by most of the
laboratories covered in the survey. Most of these centers provide services for which
the cost is partly covered by health insurance, while very few have services fully
covered by health insurance.
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By mapping the data using an internet search, it was clear that most laboratory websites
lack critical information, which might be a concern for patients and clinicians. This
includes information about legal issues, sample storage, consent forms,
standardization of tests, and costs. Researcher believes that written consent and
ensuring ethical and legal principles including autonomy, confidentiality, privacy, and
equity should be mandatory for all laboratories to protect both parties. Public debates
about the ethics of developments in human genetics research has a complex history. In
an attempt to distance present practice from past abuses, debate in Europe and USA
has been focused on the implications of developments in genetics for individuals rather
than populations and societies. The debate has led to the emergence of three principles:
consent, privacy, and confidentiality. The genetics ethics state that genetic information
should be only obtained from people who have given genuine consent—meaning
information has been communicated appropriately and consent has been given freely.
Confidentiality in genetic testing means that genetic information should not be
communicated to others or used for new purposes without the person’s consent.
Privacy in the context of genetic testing is understood as a person’s right to not be
obliged to disclose information about his or her genetics characteristics (Thomas,
2004).
The strength of the research is being the first attempt of mapping the genetic services
in the UAE and having a baseline of the genetic services landscape in UAE. To ensure
accuracy of the data gathered from the laboratories on their services, researcher
adopted two methods for collecting data: a web survey and an onsite survey.
It is difficult to draw a definitive conclusion based on the information gathered from
the survey, since some laboratory managers were either selective in which questions
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in the survey they responded to or did not know the definitive answers to some
questions. There was a general reluctance among the laboratories to participate in the
survey, leading to incomplete plotting of the genetic services in UAE. Additionally,
participants did not provide detailed information about their services which hindered
the mapping. The websites’ lack of data on last updated information and the dynamic
nature of the environment of genomic services in UAE are limitations to this mapping.
4.5 Establishing a Stakeholders’ Matrix of Power and Interest
Stakeholders in healthcare systems are the major team players and mapping their role,
power, interest, and stance is a critical consideration for implementing genomic
medicine and pharmacogenomics (Mitropoulou et al., 2020). This will support shaping
the roadmap of genomic medicine and pharmacogenomics in the UAE. Supporting
standard policies will set up the stage for robust systems in the country.
Role of stakeholders in operationalizing genomic medicine and pharmacogenomics in
healthcare and educational systems has been studied extensively. Mitropoulou. et al.
(2020) stated that mapping the views of stakeholders paves the road for standardizing
national polices. In a recent qualitative study, Best et al. (2020) concluded that
pinpointing areas of discrepancies or cohesions among stakeholders will guide them
in meeting their needs. The literature review carried out by Roberts et al. (2017)
identified the role of stakeholders as a prospect for implementing genomics medicine.
The qualitative nature of the research allowed researcher to dig deep in the stance and
interest of stakeholders in UAE. Most of the stakeholders in this research ascertained
the clinical demand of genomic medicine in UAE. They aligned this demand with the
high prevalence of consanguinity in UAE, the high burden of genetic diseases, the urge
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to utilize the genomic technology to personalized medications, and the increased
awareness among physicians about the power of genetic services that motivated them
to demand genomic medicine. These rationalizations are backed by research conducted
in UAE, for instance, Denic et al. (2013) associated consanguinity with the prevalence
of β-Thalassemia in Abu Dhabi. Another study by Al-Jasmi et al. (2012) concerning
the burden of Lysosomal storage recessive disorder, concluded that UAE had 40-fold
higher prevalence compared to western countries and is linked to consanguinity in
UAE. Al‐Gazali and Ali (2010) reviewed the mutation of single gene disorders and
reported that UAE ranked sixth in accordance with the prevalence of birth defects, and
they attributed that to the norm of consanguinity.
The positive stance of stakeholders in UAE toward the clinical demand of genomic
medicine in UAE is comparable to other stakeholders in the world. In their analysis of
stakeholders in Greece, Mitropoulou et al. (2014) reported similar findings; though in
their study, the Ministry of Health and public healthcare insurance funds had opposite
stances.
Infrastructure is one of the robust pillars for the implementation of genomic medicine
and pharmacogenomics (Mitropoulou et al., 2020). Many of the stakeholders in UAE
favored building an internal infrastructure in the country over the current norm of
sending and processing genetic samples abroad. They expressed the fact that UAE is
a wealthy country and can afford building this infrastructure. Interestingly, one of the
interviewed stakeholders was responsible for building an internal capacity in UAE and
their first project is the Genome Program to sequence Emirati reference genome. The
stakeholder agreed that having an internal infrastructure will troubleshoot any issues
related to privacy, extra cost, and the delay in receiving the results. Whereas those
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stakeholders working as Chief Executive Officers and other administrative roles
preferred to wait until a demand is able to bring return on investment. That is in line
with the stakeholders in Greece who voiced resources as one of the obstacles and
challenges for full implementation of genomic medicine and pharmacogenomics
(Mitropoulou et al., 2014).
There has been other projects to sequence the human genome in UAE as well as its
neighboring countries: Kuwait, Saudi Arabia, and Qatar (Al-Ali et al., 2018).
However, the stakeholders warned that the scattered and fragmented nature of these
projects did not add value to the target of having UAE database or even GCC database.
Evidence from other studies underscored the issue of fragmentation and recommended
having a governance committee with proactive measures (Cornel et al., 2012).
Most of the stakeholders in this sample viewed genomic medicine and
pharmacogenomics as cost-effective. One of the stakeholders disclosed that they are
in the process of studying this in UAE and has approval from the institutional review
board to do so. This demeanor leverages the implementation of genomics medicine
and pharmacogenomics in UAE as numerous research provided evidence pertaining
the cost-effectives of genomic medicine and pharmacogenomics (Fragoulakis et al.,
2019; Girardin et al., 2019; Kasztura et al., 2019; Stark et al., 2019c; Zhang et al.,
2019).
However, a stakeholder working in an insurance company had an opposite stance
about the cost-effectiveness of genomic medicine and pharmacogenomics in UAE.
This attitude raises a red flag. Reimbursement has been identified by Implementing
GeNomics In PracTicE (IGNITE) network as one of the seven key drivers of
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genomic sustainability (Levy et al., 2019). Levy et al. (2019) stated that embracing
genomic medicine is challenged by evidence considered necessary for payers to
vindicate reimbursement. A study by Hess et al. (2015) was in line with research’s
findings and they justified the attitude of insurance companies that they are viewing
pharmacogenomic tests as experimental not clinical. Further research is needed to
analyze this attitude and uncover its explanation to overcome this obstacle in its
infancy stage in UAE.
The debate about the best approach for implementing genomic medicine and
pharmacogenomics is a hot topic in research (Hart et al., 2019; Leary et al., 2019;
Marrero et al., 2020; Nallaseth, 2019). The researcher articulates this in the interview
guide. The majority of the stakeholders in UAE favored preemptive approach which
seeks testing proactively once in lifetime and having the results of the genetic test
ready at time of prescribing over the gene-specific approach. Only the two genetic
counselors in the cohort were skewed toward gene-specific approach because they
anticipated the dilemma of incidental findings (Lannoy et al., 2019).
On the same theme of genetic testing, most of the stakeholders in UAE are opposing
online direct-to-consumer kits. They attributed that to lack of awareness among the
community in UAE, lack of regulation and the missing piece of counseling by genetic
counselors that are not offered by most direct-to-consumer kits. These attributes had
been addressed in research. Schleit et al. (2019) discussed a case of a false negative
result and how it poses harm not only for the person taking the test but also to their
relatives. Direct-to-consumer is not yet licensed in UAE; however, stakeholders are
occupied with health and safety of the UAE community and voiced the need to have
regulations in place to protect and educate consumers. Moreover, they proposed the
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alternative of accredited clinic-based tests with affordable prices, which are coupled
with genetic counseling service (Mitropoulou et al., 2014; Mitropoulou et al., 2020;
Schaper et al., 2019; Schleit et al., 2019; Tandy-Connor et al., 2018; Weedon et al.,
2019).
On the verge of the implementation of genomic medicine and pharmacogenomics in
UAE, some of the stakeholders are occupied with ethical and legal concerns whereas,
few stakeholders have not thought about it. These concerns have been consolidated in
literature, such as: confidentiality of the results of genetic test in the cloud era,
insurance discrimination and employer discrimination (Bélisle-Pipon et al., 2019;
Dove et al., 2015; Jooma et al., 2019). These findings are in line with the concerns of
stakeholders in Greece (Mitropoulou et al., 2014), and USA (Bélisle-Pipon et al.,
2019). One of the stakeholders foresees the need to modify the consent process and
adopt a dynamic consent process instead. This is a trajectory that requires enforcing
laws and legislation to protect privacy, confidentiality, and autonomy of the patients
(Manson, 2019; Meagher et al., 2020; Tindana et al., 2019). Overall, the researcher
considers this a pressing need to address before it becomes a barrier (Mitropoulou et
al., 2020).
An imperative exploration from the interview of stakeholders is the list of anticipated
barriers and challenges for the full implementation of genomic medicine and
pharmacogenomics in UAE. Identifying these risk variables gives the stakeholders a
vantage point to proactively overcome these barriers. Addressing these risks by the
experts will pave the way to the full implementation of genomic medicine and
pharmacogenomics in UAE (Rastogi & Trivedi, 2016; Walters & Kitchin, 2009).
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Implementing the strategies dictated by the Mendelow’s business model will allow the
systematic implementation of genomic medicine and pharmacogenomics. It will
facilitate saving time and resources by engaging the key players (promoters and
defenders) as well as engaging and satisfying the latent stakeholder (Anney, 2014;
Elsaid et al., 2017; Gottschalk, 1999; Kuzmin & Khilukha, 2016; Mendelow, 1981).
This research is the first attempt to explore the attitude and stance of the stakeholders
in the UAE. The qualitative methodology allowed mapping the power/interest matrix
of Mendelow’s model which is a substantial footstep for achieving the full
implementation of genomic medicine and pharmacogenomics in UAE.
Similar to other qualitative studies, the shortcoming of generalization is the inheritance
limitation in this research. However, researcher sets the stage for conducting
quantitative studies to satisfy generalization. Another limitation is lack of
representation of the media, pharmacists, religious authority, and other stakeholders.
Nevertheless, researcher was able to map various stakeholders representing different
sectors of the UAE. Researcher insured the credibility, reliability, and quality of the
research by ensuring the Lincoln and Guba (1986) evaluation criteria: triangulation,
respondent validation reflexivity, peer debriefing and audit trail, as well as using
validated tools and models from the business arena.
In summary, the assessment of university curricula resulted in “genetics” being
included in the majority of universities syllabus. PGx was taught in six universities but
only for Pharmacy majors. The mean knowledge score of the surveyed healthcare
providers was 5.2 (± 2.3) out of nine, which shows a fair level of knowledge. However,
92% showed a positive attitude regarding availability of genetic testing. The top
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identified barrier for implementation for genomics and PGx was the cost of testing
(62%), followed by lack of training or education of genomics and PGx (58%) and lack
of health insurance coverage (57%). Moreover, the mean knowledge score for medical
and health sciences students was 5.4 (± 2.7). Regarding genetic and genomic services,
prenatal testing was the most offered genetic service among the laboratories included
in the research, and blood samples was the main sample type for genetic testing
followed by saliva. There was no standardization of the accreditation bodies, health
insurance coverage. Most of the interviewed stakeholders emphasized the clinical
demand for genomic medicine in UAE. However, many were less inclined to articulate
the need for PGx at present. Most of stakeholders were in favour of building
infrastructure for better genetic services in the country. However, stakeholder from
health insurance sector had a contradicting stance about the cost-effectiveness of
genomic medicine. The majority were concerned with the legal and ethical aspects of
genomic medicine and had an opposing stance on direct-to-consumer kits.
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Chapter 5: Conclusion
The conclusion of this research will be presented as a synopsis of what was found in
each pillar of the research. Furthermore, the implications of the findings will be
presented as the roadmap for the full implementation of genomic medicine and
pharmacogenomics in UAE.
5.1 Research Implications
This research set the stage for the stakeholders occupied with implementing genetic
testing and PGx in the UAE. Healthcare workers are the front-liners and the champions
of the implementation strategies. Therefore, mapping their knowledge, attitudes, and
concerns toward genetic testing and PGx will direct the framework for
implementation. Crossing and bridging the chasm of knowledge will steer the
implementation. Researcher therefore recommends launching Continuing Medical
Education (CME) accredited workshops presenting case studies and blended learning
for healthcare providers. Researcher urges collaboration between academia and
healthcare to utilize experts in the field, seeing as most healthcare workers in the UAE
have not studied pharmacogenomics as part of their education. The positive attitude of
healthcare workers will facilitate and guide the implementation strategies by
identifying multidisciplinary champions. Researcher commends the integration of
genetic counselors in the implementation modules to bridge the current gap in
knowledge and ability to counsel patients. Researcher urges the stakeholders to declare
and implement laws to protect the privacy and confidentiality of genetic test results to
avoid discrimination by insurance companies. Researcher proposes streamlining and
benchmarking the workflow, algorithms, and guidelines. Researcher advocates better
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utilization of technology and attributing the electronic decision support to back up
healthcare workers in the UAE.
Moreover, the assessment of the knowledge and attitudes of students of medical and
health sciences schools in the UAE captures the gaps and harnesses measures to
address these gaps. Students of today are the champions of personalized medicine
tomorrow. Stakeholders in the UAE must strive to acquaint their students with up-todate knowledge of genomic medicine and PGx. Researcher recommends updating the
curriculum of the medical and health sciences under the supervision of the experts in
the field and in line with accreditation bodies. Researcher proposes stand-alone courses
in genomic medicine and pharmacogenomics for both under- and post-graduate
medical and health science students. Researcher recommends initiating a rapport
between academia and health setting to impute knowledge and translate knowledge
into practice.
Mapping the educational environment of genomics and PGx in UAE is a heuristic
stage that will galvanize the implementation trajectory. The positive attitude along
with the interest of the stakeholders in academia is a well-aimed arrow in the flight of
implementation. The researcher recommends the following 11 strategies with regard
the educational environment of genomics in UAE:
1. Having a standardized curriculum of genomics and PGx for each health
science fields (medicine, pharmacy, nursing, dental, pathology… etc.).
2. Using the blended teaching approach to recruit experts in the field that can
teach courses online.
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3. Benchmarking with the international universities and organizations for
collaboration and accreditations.
4. Blending the laboratory components in the curriculum as literatures prove it
efficient.
5. Imputing ethical, legal aspects of genomics and PGx in the curriculum.
6. Adopting “Train the trainer” strategy.
7. Embarking on the basics of genomics and PGx in elementary schools using
innovative pedagogy.
8. Fostering the collaboration between academia and healthcare setting to
produce research and databases.
9. Spanning the residency and fellowships opportunities to include genomics,
PGx, bioinformatics, and genetic counseling.
10. Mandating the stand-alone courses of genomics and PGx in the curriculum for
both undergraduates and postgraduates.
11. Establishing national accreditation counsel to train, educate and license
healthcare providers.
There has been rapid growth of genetic services in the UAE because of the rapid
economic growth and standardization of healthcare; however, the private genetic
services appear to lack an appropriate regulatory framework, which is also the case in
some European countries including Greece. A wide variety of high-quality certified
genetic services are provided by different centers and are mostly directed to clinical
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care, but not toward research. These centers are mainly concentrated in Dubai and Abu
Dhabi. Some form of counseling (complete/partial) service is provided by 51.8% of
the genetic centers. By mapping the data using an internet search, it was clear that most
laboratory websites lack critical information, which might be a concern for patients
and clinicians. This includes information about legal issues, sample storage, consent
forms, standardization of tests, and costs. Researcher believes that written consent and
ensuring ethical and legal principles including autonomy, confidentiality, privacy, and
equity should be mandatory for all laboratories to protect both parties.
Researcher also recommends that laboratories put some effort into updating and
maintaining their websites. We are in an era of wide integration of technology, and
researcher thinks that keeping the public informed is a civic duty for everyone in the
field of genetic testing. Moreover, the present research highlighted the potential lack
of genetic counseling services, bioinformatics analysis, and DNA bio-banking on the
market, which is essential for overall genetic profiling and disease prevention.
Researcher foresees these findings as the launching point for establishing a strategy
for the implementation of genomic medicine and pharmacogenomics in UAE. This
will facilitate the construction of a roadmap for the full implementation of genomic
medicine and pharmacogenomics in the UAE with potential applicability to many
healthcare systems around the world. The periodic mapping of stakeholders in UAE is
a key element in the roadmap. Researcher recommends building on these findings by
conducting a quantitative research and replicating it on a different timeline to capture
the dynamic stance and interest of stakeholders in UAE.
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5.2 Roadmap for the Full Implementation of PGx in UAE
The gathered data from the mixed method approach captivated the root causes of the
delay of the implementation of genomic medicine and pharmacogenomics in UAE.
These gaps and root causes are presented in the Ishikawa fishbone diagram (Figure
21).

Impediment of the
implementation of genomic
medicine and PGx in UAE
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Figure 21: Root causes of the hindered implementation of PGx in UAE
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Based on the results tackling the spectrum of public health genomics in UAE, The,
researcher declares that the answer to the research questions, is that UAE is in the
midway in terms of implementing genomics and PGx. There are fragmented attempts
to tackle this field, manifested in the growing interests of adding genomics in the
curriculum, offering masters in genetic counseling, building infrastructures, hosting
workshops in genomics and pharmacogenomics targeting healthcare providers,
starting the Emirati reference genome projects as well as motivating stakeholders to
get on board, however solid strategy and clear roadmap is needed to save resources
and harvest outcomes. Researcher conceptualized a roadmap for the implementation
of genomic medicine and pharmacogenomics in UAE (Figure 22). It was constructed
based on all the results and findings of the mixed method approach of this research
and based on the bundle of root causes that reside in the infrastructure, educational
system, healthcare system, healthcare providers, and stakeholders. It combines both
bottom-up and up-bottom approach.
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Figure 22: Roadmap for the full implementation of genomic medicine and PGx
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This roadmap will facilitate, guide, and strategize the initiatives and proposals to
implement genomic medicine and pharmacogenomics not only in UAE but in other
neighboring countries as well. It tackles multi-pillars that had been identified by
researchers and stakeholders around the world in concordance with the public health
aspects. The components of the roadmap span over educational environment, the
healthcare

systems

and

infrastructures,

the

stance

of

stakeholders

and

community/patients. This roadmap can be the backbone for all the stages and phases
of implementation: exploration, installation and both initial and full implementation of
personalized medicine. Moreover, the roadmap can be tailored to meet the objectives,
resources, mission, and vision of the stakeholders in UAE or any other country.
The future directions of this research are the continuous and periodic assessment of
the pillars of the roadmap in terms of knowledge, attitude, needs, power, and interest.
Hence, the findings presented in this research are a baseline that can be a point of
reference for the proactive implementation strategy. Additionally, the researcher
requests to assess the knowledge, attitude, perception and the genetic literacy of the
community and patients in UAE to strategize and assort the implementation resources
and approaches. Researcher calls investigators to validate the PGLP framework and
the road map for the full implementation of genomic medicine and pharmacogenomics
in UAE. Moreover, the researcher anticipates the role of artificial intelligence to bridge
the gap between science, knowledge, and application. Artificial intelligence tools will
act as a safeguard and safety net for healthcare providers and will streamline the
process. Moreover, it will allow up-to-date access and utilization of research. Training
local IT experts in bioinformatics will speed the implementation process and ought to
be a priority. Additionally, marrying the artificial intelligence with the UAE reference
genome and basics of pharmacology will host the discovery of targeted therapy and
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will give a face to personalized medicine for UAE nationals and the Arab world. Other
disciplines of OMICS like epigenomics, metabolomics must be explored too to ensure
a holistic approach to implementation and avoid barriers and wastage of time, money,
and resources.
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Appendices
Appendix A: Participant Information Sheet
Study Title: Assessing the knowledge, Attitude and perception of Genomic Medicine
and Pharmacogenomics among healthcare providers and patients in the UAE"
Invitation to Participate:
Dear Participant…
We are seeking your kind participation in filling in a questionnaire to help us identify
the current status and future needs for genetic testing, genomic medicine and
pharmacogenomics in the UAE. The questionnaire is short and will not take more than
15 minutes. We appreciate your support and cooperation. Please note that this is an
anonymous questionnaire where at no stage your name and identity will be revealed
to anyone.
We greatly appreciate your time and support
Purpose of the study:
Public health genomics is a recent interdisciplinary aspect in public health comprising
the use of genetic epidemiology, biostatistics, health policy, health education, and
state-funded programs focused on surveillance and prevention of heritable disorders
as well as provide the necessary set up needed to achieve the ultimate aim of improving
population health. The underlying driving force behind this discipline is the
phenomenal improvement in our understanding of the human genome and its relevance
to human health and disease. This understanding led to numerous medical and public
health applications including in diagnosis, therapy and prevention of ill health. In this
proposal, we aim to evaluate the current status of the knowledge and facilities for
utilizing genomic medicine and pharmacogenomics in the UAE and construct a
roadmap to implementing genomic medicine in the clinic with the aim of improving
the public health of the UAE nation.
Why have I been chosen?
This study aims to survey health care workers, medical related students as well as the
public
Do I have to take part?
It is absolutely voluntary to take part in this study. You to decide whether or not to
take part. If you do decide to take part you will be given this information sheet to
keep and be asked to sign a consent form. You can withdraw your participation at
any time and even after you have given the consent. A decision to withdraw at any
time, or a decision not to take part, will not affect the standard of care you receive.
What will happen to me if I take part?
This is a one off 5-10 minutes survey through questionnaire, all information obtained
will be handled with the utmost degree of confidentiality.
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Principal Researchers Contact details:
Azhar Talal , PhD candidate UAEU ,Institute of public health , Tawam Hospital,
Pharmacy Department, 0501126098
Definitions
GENETIC TESTING: The use of genetic material (DNA) for we diagnosis of genetic
and other human conditions
GENOMIC MEDICINE: The use of genetic information of an individual for their
diagnosis, treatment and other relevant applications
PHARMACOGENOMICS: The use of genetic and genomic information of the
individual for the prescription of their medications.
You will be given a copy of the information sheet and a signed consent form to keep.
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Appendix B: Consent Form

Please read carefully the information sheet and consent form before signing
Project title: Assessing the knowledge, Attitude and perception of Genomic
Medicine and Pharmacogenomics among healthcare providers and patients in
the UAE"
Researchers:
Miss. Azhar Talal Al-Rahma, PhD Student at the Institute of Public Health,
College of Medicine and Health Sciences. Telephone: 0501126098. Email:
201280026@uaeu.ac.ae
You will be asked to provide or deny consent after reading the information
sheet.
1

I confirm that I have read and understand the information sheet dated
(Version) for the above study and have had the opportunity to ask questions.

2
3

I understand that my participants is voluntary and that I am free to withdraw
I understand that if I withdraw from the study it will not adversely affect my
healthcare or employment
I understand that my data will be kept confidential and in a safe place
I agree to take part in the above study

4
5

Name of Participant

Date

Signature

Name of Researcher Taking Consent

Date

Signature
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Appendix C: Questionnaire for Healthcare Providers
We are seeking your kind participation in filling in the below questions about
genomic medicine and pharmacogenomics. The questionnaire is short and will not
take more than 15 minutes. We appreciate your support and cooperation. Please note
that this is an anonymous questionnaire where at no stage your name and identity
will be known to anyone.

As an INCENTIVE you are given a chance to get a FREE registration for the third
workshop of GENOMIC MEDICINE and Pharmacogenomics organized by Golden
Helix Foundation and UAEU next February 2019 , all you have to do is to send me
an e-mail, which will appear in the space at the end of this survey
Do you agree to participate ?

o Yes
o No
Gender:

o Male
o Female
Your nationality
________________________________________________________________

Your facility is operated by:

o Government
o Private
o Semi-government
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Location of your facility :

o Abu Dhabi
o Al-Ain
o Ajman
o Fujairah
o Ras al-Khaimah
o Sharjah
o Umm al-Quwain
o Dubai
Type of facility:

o Tertiary care Hospital
o Secondary care Hospital
o Health Clinic
o Other ________________________________________________
How old are you? (Age in years)
________________________________________________________________
Total years of experience:
________________________________________________________________
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Your occupation is:

o Consultant
o Hospitalist
o Surgeon
o Specialist
o Attending Physician
o Primary Physician
o Resident
o Nurse
o Dentist
o Inpatient Pharmacist
o Pharmacy Technician
o Outpatient Pharmacist
o Pharmacy supervisor
o Clinical Pharmacist
o Other: (please specify)
________________________________________________
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Location of Facility:

o Rural
o Urban
Did you practice outside United Arab Emirates ?

o No
o Yes, please name countries you practice in
________________________________________________

Choose the best answer that suits your qualifications (you can choose more than one
answer)

o Bachelor
o Master
o PhD
o Board certified
o Diploma
o Other ________________________________________________
In general, to what extent are your opinions and decisions influenced by religion?

o Greatly influenced
o Somewhat influenced
o Not influenced
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How much your decision to go for genetic testing would be affected by your
traditions and cultural customs ?

o Greatly influenced
o Somewhat influenced
o Not influenced
Have you or anyone close to you ever had any experience with genetic issues? For
example, having a heritable disease in the family, or taking a genetic test?

o YES
o NO
Have you completed Pharmacogenomics/ Pharmacogenetics related training or
education?

o Yes
o No
Type of the course:

o Stand alone course on Pharmacogenomics /Pharmacogenetics
o As part of other course
o Online course
o Other ________________________________________________
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Choose the correct answer for the following statements about genetics &
Pharmacogenomics:
True

False

Do Not
Know

Humans have 48
chromosomes?

o

o

o

Adenine (A) only
pairs with cytosine
(C) and Thymine (T)
only pairs with
Guanine (G)?

o

o

o

Pharmacogenomics
seeks to individualize
therapy based on
patient’s genetic
profile?

o

o

o

Genetic changes can
cause adverse
reactions?

o

o

o

Pharmacogenomics
testing is
recommended by
FDA for certain
drugs?

o

o

o

Genetic changes can
affect the patient’s
response to certain
drug?

o

o

o

Genes can be
activated or
deactivated by other
genes?

o

o

o

Every cell of the
body contains the
whole genome?

o

o

o

Environmental
factors, such as
cigarette smoke, can
affect gene activity?

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree
with the following statements?
Strongly Somewhat
agree
agree

Neither
Somewhat
agree nor
disagree
disagree

Strongly
disagree

At some point in my
life, I might consider
having a genetic test
to find out my risk
of developing
various genetic
diseases

o

o

o

o

o

I am glad that
genetic tests can be
ordered on the
internet

o

o

o

o

o

I am glad that
genetic tests are
available so that
people with a family
history of serious
genetic disease can
find out if they are
at risk

o

o

o

o

o

The availability of
genetic tests for
insurance companies
and future
employers is
problematic.

o

o

o

o

o

I am generally
positive towards
genetic testing and
think the
government should
invest more money
into its development

o

o

o

o

o

I would like to
participate in genetic
research

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree
with the following statements?
Neither
Strongly Somewhat
Somewhat
agree nor
agree
agree
disagree
disagree

Strongly
disagree

I would like to donate
my genetics materials
for bio-bank

o

o

o

o

o

If I were diagnosed
with cancer, I would
consider having my
genes analysed in
order to help chose a
cancer treatment with
the fewest side effects

o

o

o

o

o

If I had a family
history of diabetes I
would consider having
my genes analysed in
order to help me make
lifestyle choices and
decisions about
interventions that may
prevent diabetes from
developing

o

o

o

o

o

I would NOT be
willing to get my
whole genome
analysed, because I
worry about issues of
confidentiality

o

o

o

o

o

I am skeptical toward
pharmacogenomics
because of the
possibility of getting
information about my
genes that is unrelated
to the treatment

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree
with the following statements?
Strongl Somewhat
y agree
agree

Neither
agree
Somewhat
nor
disagree
disagree

Strongly
disagree

I believe that, in the
future, medicine will
be more personalized

o

o

o

o

o

I think that more time
should be devoted for
the teaching of
pharmacogenomics
in the course of study

o

o

o

o

o

I would you be
interested in
attending a
pharmacogenomics
course and/or
educational seminar

o

o

o

o

o

I believe that
pharmacogenomics
could be exploited by
employers, insurance
companies..etc to
discriminate certain
population groups or
patients

o

o

o

o

o

I would like only to
know my
susceptibility to
diseases that have
current intervention
for protection

o

o

o

o

o

Genetics and Genetic
tests are involved in
my current work.

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree
with the following statements?
Strong
ly
agree

Neither
Somewhat
agree
Somewhat
agree
nor
disagree
disagree

Strongly
disagree

Pharmacogenomics
and it' tests are
involved in my
current work.

o

o

o

o

o

The results of genetic
tests will affect the
medical care of my
patients in terms of
medications,
diagnosis,
appointments…etc.)

o

o

o

o

o

The expense of
genetic &
pharmacogenomics
tests should be
covered by insurance
companies.

o

o

o

o

o

I could explain the
results of genetics
and
pharmacogenomics
tests to my patients
without translation.

o

o

o

o

o

My undergraduate
studies at the
University provided
me with sufficient
knowledge on
genetics &
pharmacogenomics.

o

o

o

o

o

Policy and
procedures as well as
legal framework do
exist in the field of
genetic tests in UAE.

o

o

o

o

o
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Which type of education do you prefer to learn about Pharmacogenomics/
Pharmacogenetics? Please tick all that apply

o Workshops or seminars
o Internet based learning activities
o Self-directed learning
o blended learning (joint e-learning and onsite training)
o Other ________________________________________________
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Which of the following do you think are barriers for the implementation of
pharmacogenetic /Pharmacogenomics testing in U.A.E ? Please tick all that apply

o Shortage of personnel
o Lack of clinical guidelines on Pharmacogenomics/ Pharmacogenetics practice
o Lack of testing services
o Lack of training or education
o Cost of testing
o No clinical need
o Insurance coverage
o No law for confidentiality of results
o Other ________________________________________________
Which of the following sample you may provide for Pharmacogenomics/
Pharmacogenetics testing ? Please tick all that apply

o Blood
o Saliva
o Buccal Swap
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Have you ever advised any of your patients to undertake a genetic test?

o Yes
o No
o Not Applicable
Choose which test (Check all that applies):

o A genetic test (e.g. to control a hereditary disease).
o A cytogenetic test (e.g. for dysmorphology and or mental retardation syndromes).
o A pharmacogenomic test (e.g. to reduce significantly the chances of developing
side effects and or to control response to a medication).

o Other ________________________________________________
Have you had any patients who asked about undertaking a genetic test in the last two
years?

o Yes
o No
o Not Applicable
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Have you had any patients who asked your advice about the results of a genetic test
in the last two years?

o Yes
o No
o Not Applicable
What is the most reliable source of information regarding genetics &
pharmacogenomics? (you can choose more than one answer)

o Databases
o The leaflet of the medication
o Scientific Journals
o Google
o YouTube
o Lexicomp
o Up to Date
o Micromedx
o Other ________________________________________________
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Who do you think should provide counseling to genetic/pharmacogenetic testing and
results?

o Physician
o Pharmacist
o Genetic counselor
o Nurse
o Other ________________________________________________
The present state of Genomic Medicine and Pharmacogenomics in UAE is:

o Very good
o Good
o Adequate
o Poor
o I do not know
If you wish to get a FREE registration to the third Genomic medicine and
Pharmacogenmic workshop organized by GoldenHelix foundation and UAEU in
February 2019 , please put your email here or you can simply email me at
201280026@uaeu.ac.ae
________________________________________________________________

Thank you for your valuable time, you really helped me and helped the future of
health in UAE.
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Appendix D: Questionnaire for the Medical and Health Sciences Students
We are seeking your kind participation in filling in the below questions about
genomic medicine and pharmacogenomics . The questionnaire is short and will not
take more than 5 minutes . We appreciate your support and cooperation. Please note
that this is an anonymous questionnaire where at no stage your name and identity
will be known to anyone.

As an INCENTIVE you are given a chance to get a FREE registration for the third
workshop of GENOMIC MEDICINE and Pharmacogenomics organized by Golden
Helix Foundation and UAEU next February 2019 , all you have to do is to send me
an e-mail in the space at the end of this survey

Do you agree to participate ?

o Yes
o No
Gender:

o Male
o Female
Your nationality
________________________________________________________________
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Type of your University:

o Government
o Private
o Semi-government
Location of your university:

o Abu Dhabi
o Al Ain
o Fujairah
o Sharjah
o Umm al Quwain
o Ajman
o Ras Al Khaimah
o Dubai
You are studying for which degree?

o Bachelor
o Master
o PhD
o Other (please specify)______________________________________________
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Your year of study?

o First Year (1)
o Second Year (2)
o Third Year (3)
o Forth year (4)
o Fifth year (5)
o Sixth Year (6)
o Other (7) ________________________________________________
Your main field of study:

o Medicine (1)
o Pharmacy (2)
o Laboratory (3)
o Nursing (4)
o Other (5) ________________________________________________
How old are you? (Age in years)
________________________________________________________________
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Did you complete an internship training abroad OR study any course abroad?

o Yes
o No
Can you please specify which COUNTRY
________________________________________________________________
Can you please specify what was the COURSE or type of internship?
________________________________________________________________
In general, to what extent are your opinions and decisions influenced by religion?

o Greatly influenced
o Somewhat influenced
o Not influenced
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How much your decision to go for genetic testing would be affected by
your traditions and cultural customs

o Greatly influenced
o Somewhat influenced
o Not influenced
Have you or anyone close to you ever had any experience with genetic issues? For
example, having a heritable disease in the family, or taking a genetic test?

o Yes
o No
Have you completed Pharmacogenomics /Pharmacogenetics related training or
education?

o Yes
o No
Type of the course:

 Stand alone course on Pharmacogenomics /Pharmacogenetics
 As part of other course
 Online course
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Choose the correct answer for the following statements about genetics &
pharmacogenomics:
True

False

Do Not know

Humans have 48
chromosomes?

o

o

o

Adenine (A) only
pairs with cytosine
(C) and Thymine (T)
only pairs with
Guanine (G)?

o

o

o

Pharmacogenomics
seeks to individualize
therapy based on
patient’s genetic
profile?

o

o

o

Genetic changes can
cause adverse
reactions?

o

o

o

Pharmacogenomics
testing is
recommended by
FDA for certain
drugs?

o

o

o

Genetic changes can
affect the patient’s
response to certain
drug?

o

o

o

Genes can be
activated or
deactivated by other
genes?

o

o

o

Every cell of the
body contains the
whole genome?

o

o

o

Environmental
factors, such as
cigarette smoke, can
affect gene activity?

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree with
the following statements?
Neither
Strongly Somewhat
Somewhat
Strongly
agree nor
agree
agree
disagree
disagree
disagree
At some point in
my life, I might
consider having a
genetic test to
find out my risk
of developing
various genetic
diseases

o

o

o

o

o

I am glad that
genetic tests can
be ordered on the
internet

o

o

o

o

o

I am glad that
genetic tests are
available so that
people with a
family history of
serious genetic
disease can find
out if they are at
risk

o

o

o

o

o

The availability of
genetic tests for
insurance
companies and
future employers
is problematic

o

o

o

o

o

I am generally
positive towards
genetic testing
and think the
government
should invest
more money into
its development

o

o

o

o

o

I would like to
participate in
genetic research

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree with
the following statements?
Strongly
agree

Somewhat
agree

Neither
agree nor
disagree

Somewat
disagree

Strongly
disagree

I would like to
donate my
genetics materials
for bio-bank

o

o

o

o

o

If I were
diagnosed with
cancer, I would
consider having
my genes
analysed in order
to help chose a
cancer treatment
with the fewest
side effects

o

o

o

o

o

If I had a family
history of diabetes
I would consider
having my genes
analysed in order
to help me make
lifestyle choices
and decisions
about
interventions that
may prevent
diabetes from
developing

o

o

o

o

o

I would NOT be
willing to get my
whole genome
analysed, because
I worry about
issues of
confidentiality

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree with
the following statements?
Strongly
agree

Somewhat
agree

Neither
agree nor
disagree

Somewat
disagree

Strongly
disagree

I am skeptical
toward
pharmacogenomic
s because of the
possibility of
getting
information about
my genes that is
unrelated to the
treatment

o

o

o

o

o

I believe that, in
the future,
medicine will be
more personalized

o

o

o

o

o

I think that more
time should be
devoted for the
teaching of
pharmacogenomic
s in the course of
study

o

o

o

o

o

I would you be
interested in
attending a
pharmacogenomic
s course and/or
educational
seminar

o

o

o

o

o

I believe that
pharmacogenomic
s could be
exploited by
employers,
insurance
companies..etc to
discriminate
certain population
groups or patients

o

o

o

o

o
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On a scale from strongly disagree to strongly agree, to what extent do you agree with
the following statements?
Strongly
agree

Somewhat
agree

Neither
agree nor
disagree

I would like only
to know my
susceptibility to
diseases that
have current
intervention for
protection

o

o

o

o

o

I would prefer
that the
PHARMACIST
to explain to me
my genome
report

o

o

o

o

o

I would prefer
that the
PHYSICIAN to
explain to me
my genome
report

o

o

o

o

o

Somewat
disagree

Which type of education do you prefer to learn about Pharmacogenomics
/Pharmacogenetics? Please tick all that apply

o Workshops or seminars
o Internet based learning activities
o Self-directed learning
o During internship year
o Other ________________________________________________

Strongly
disagree
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Which of the following do you think are barriers for the implementation of
Pharmacogenomics /Pharmacogenetics testing in U.A.E ? Please tick all that apply

o Shortage of personnel
o Lack of clinical guidelines on Pharmacogenomics /Pharmacogenetics practice
o Lack of testing services
o Lack of training or education
o Cost of testing
o Other ________________________________________________
Which of the following sample you may provide for Pharmacogenomics
/Pharmacogenetics testing? Please tick all that apply

o Blood (1)
o Saliva (2)
o Buccal Swap (3)
As an INCENTIVE you are given a chance to get a FREE registration for the third
workshop of GENOMIC MEDICINE and Pharmacogenomics organized by Golden
Helix Foundation and UAEU next February 2019 , all you have to do is to send me
an e-mail at 201280026@uaeu.ac.ae
________________________________________________________________
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Appendix E: Onsite Laboratories Questionnaire
Name of the laboratory : ……………
Location: ……………
1.

2.

Are you providing a genetic service in your lab?
A. Yes
B. No

What type of genetic service do you offer?
1. Paternity test
8. Molecular microbiology analysis
2. Family tree analysis
9. Immunologic microbiology
3. Ancestry analysis
10. Cytogenetics (FISH/Chromosomal
breakage)
4. Prenatal testing
11. Mitochondrial DNA
5. Pharmacogenomic testing
12. Health and wellness (fitness, skin
care )
6. Whole Genome sequencing
13. Other: ……………
7. Genomic screening

3. What are the DNA sources used in your lab?
1. Blood
12. Urine
2. Plasma
13. CSF
3. Serum
14. Nasal swabs
4. Saliva/ sputum
15. Throat/pharyngeal swabs
5. Buccal swab
16. Rectal swab
6. Tissue (bone/bone marrow/
17. Genital swab
placenta/embryo)
7. Seminal stains/semen
18. Bronchoalveolar lavage fluid
(BAL)
8. Cigarette butts
19. Other: ……………
9. Hair
10. Items of everyday use
11. Stool
12. Amniotic fluid
4. Do you have a genomic bank?
A. Yes
B. No
5. Do you have bioinformatics analysis?
A. Yes
B. No
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6.
A.
B.
C.

Who are your stakeholders?
Only directly to clients
Only through medical referrals ( Hospitals/ clinics/doctors)
Both A & B

7. Is genetic counseling available at your center?
A. Yes
B. No
8. If genetic counseling is available at your center, is it limited or complete?
A. Limited B. complete
9. Regarding the genetic counseling service – if available-:
A. The counselor is available at the center
B. We refer the patients to an outside counselor
10. Do you consider the information on you website complete and representative of
your service?
A. Yes
B. No
C. I don’t know
11. How frequent do you update the information on your website?
A. Every few months ( less than six months)
B. Every 6 months – 1 year
C. Every 1-2 years
D. More than that
12. Do you have a personal who is responsible for updating your website?
A. Yes

B. No

13. Are the services costs available on your website?
A. Yes
B. No
C. I don’t know
14. Do you have information about the legal issues on your website?
A. Yes
B. No
C. I don’t know
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15. Do you have information regarding the privacy of each case on your website?
A. Yes
B. No
C. I don’t know
16. Do you have information about the sample storage available on your website?
A. Yes
B. No
C. I don’t know
17. Do you have information regarding the consent available on your website?
A. Yes
B. No
C. I don’t know
18. Is your lab covered by health insurance?
A. Fully covered
B. Partially covered C. No
19. Is your lab accredited?
A. Yes
B. No
20. If your lab is accredited, please list the accreditation parties
A.
B.
C.
D.
21. Where does the processing of your specimens take place?
A. Local
B. Samples are sent abroad
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Pharmacogene selection:
22. How are the genes aggregated for testing?
A. Single gene
B. Disease specific panel
C. Broad panel testing
D. I do not know

23. Can the laboratory provide customized panel of genes?
A. Yes
B. No
C. I do not know

Logistics:
24. What is the turnaround time?

25. Are samples used for research purposes?
A. Yes
B. No
C. I do not know

26. Is there any KPI in your lab?
A. Yes
B. No
C. I do not know
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Reporting of results:
27. How are the results returned to a provider/patient?
A. Through system
B. Through written report
C. Through website
D.I do not know.
E.Other : specify please : ……………

28. Are the results easy to interpret for a provider/patient?
A. Yes
B. No
C. I don’t know

29. Is their evidence for each recommendation available in the report?
A. Yes
B. No
C. I don’t know

30. What type of evidence you use to support your recommendations?
A.
B.
C.
D.
E.

American guidelines.
Canadian guidelines.
Dutch guidelines.
Other: specify……………
I don’t know

31. What educational materials are available to aid in discussion of the results? (You
can choose more than one answer)
A. Brochures
B. Videos
C. Posters
D. Online resources
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Test cost and reimbursement:

32. Does the laboratory bill patient insurance directly?
A. Yes
B. No
C. I do not know.
D. Other: ……………

33. What patient financial assistance programs does the laboratory provide?

34. Does the laboratory provide a maximum cost for the patient?

A. Yes
B. No
C.I Do not know

Thank you so much for your time and help
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Appendix F: Topic Guide for Pharmacists’ Focus Group Discussion
Introduction:
Welcome to UAEU and thank you for accepting the invitation to participate in this
first focus group in UAE to address Pharmacogenomics and genomic medicine. Your
opinions and thoughts are valuable and will help us construct the road map to the
implementation of genomic medicine and pharmacogenomics in UAE.
My name is Azhar Talal and this is/are my colleague(s)
……………………………..
The aims of the focus group:
In the coming 2 hours we will discuss:
1- Your Knowledge toward Genomic medicine and pharmacogenomics
2- Your experiences and attitude with Pharmacogenomics/genetics
training/education and its application in your practice.
3- Your perceived barriers of implementation of genomic medicine and
pharmacogenomics in UAE.
Can I get your permission to tape the discussion, so I can get to it later for the
transcribing and analysis? (If yes, switch it on)
I want to emphasis that there is no right or wrong answers, you can disagree with
each other, and you can change your mind. Please feel comfortable saying what you
want.
Discuss procedure:
My colleague will be taking notes, so I do not oversight anything you have to say,
because your opinion matters.
Anonymity:
In spite of being recorded, I would like to promise you that the discussion will be
anonymous. The tapes will be locked and once transcribed will be erased. The
transcribing will not allow linkage to you or to the name of the area of your practice.
The participants of this focus group and I would appreciate if you refrain from
discussing what we will bring on the table today to other members outside the focus
group.
Ground rules:
The only rule here is that ONE person speaks at a time. You may feel that you want
to interrupt to say something important, though I value all your inputs, but I will be
thankful if you please wait until he/she finishes. You can write your comment in a
piece of paper so you don not forget it, and discuss it when no one is talking.
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As I said there is no right or wrong answers, you can disagree with each other, and
you can change your mind. You do not have to speak in any particular order. Please
feel comfortable saying what you want.
Your opinion matters to me and will help shape the future of genomic medicine and
pharmacogenomics in UAE.
Does anyone have any questions?
OK, let us begin.

Participant introduction:
I would like everyone to introduce themselves. Can you tell us your name?
Topics for discussion:
We will discuss the following topics:
1-

Your Knowledge toward Genomic medicine and pharmacogenomics

2Your experiences and attitude with Pharmacogenomics/genetics
training/education and its application in your practice.
3Your perceived barriers of implementation of genomic medicine and
pharmacogenomics in UAE.
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Appendix G: Interview Guide for Pharmacists
Research Title: Knowledge, attitudes of registered pharmacists in UAE toward
genomic medicine and pharmacogenomics and their perceived barriers of its
implementation

1. Demographic questions

 Gender
 Year of Graduation
 Nationality
 In which Emirates you work?
 In which section/setting you work?
 Type of employer (Government, private, university, retail)
 How many years have you been in practice?
 Are you studying for board or degree? and what are you studying?
Did you study in UAE or abroad?

Knowledge of registered pharmacists in UAE toward Genomic medicine and pharmacogenomics
2. Can you explain genomic
2.a. Is it true or false that: patient’s genetic profile may influence response
medicine and/ or
to drug therapy?
pharmacogenomics?
2.b. Do you know that the package insert for warfarin includes a warning
about altered metabolism in patients who have specific genetic variants?
2.c. Do you agree that Genetic determinants of drugs response change over
a person’s lifetime?
2.d. Is it true or false that: pharmacogenomics can identify drug-drug
interactions?
2.e. Is it true or false that: pharmacogenetics testing is currently available
for most medications?
2.f. Is it true or false that: Human has 24 chromosomes?
2.g. Is it true or false that: Adenine (A) only pairs with cytosine (C) and
Thymine (T) only pairs with Guanine (G)?
2.h. Is it true or false that: Pharmacogenomics testing is recommended by
FDA for certain drugs?
2.i. What does a poor metabolizer phenotype indicate?
-Lower drug safety because of poor metabolism.
-Good drug efficacy because of poor metabolism
2.j. Is it true or false that: Every cell of the body contains the whole
genome?
2.k. Is it true or false that: Environmental factors, such as cigarette smoke,
can affect gene activity?
2.l. Is it true or false that: Genetic determinants of drug response change
over a person’s lifetime?
Pharmacogenomics/genetics training/education and application in practice
3.a Did you study Genomic medicine or pharmacogenomics?
3.b. Did you apply pharmacogenomics (drug selection, dosing, monitoring, counselling) for a patient in your
practice setting?
3.c. As far as you know, do you have pharmacogenomics testing at your work?
3.d. Did you attend any conference or workshop about pharmacogenomics?
3.e. How would you rate your current understanding of pharmacogenomics (poor, fair, good, very good,
excellent)?
3.f. Where do you obtain information on genomic and pharmacogenomics?
3.g. Are you competent to interpret the warning in Warfarin leaflet about altered metabolism in patients
who have specific genetic variants if a patient asks you?
3.h. Which type of education do you prefer to learn about pharmacogenomics ? workshop? E-Learning?
University? Scientific articles?
3.i.Do you think that more time should be devoted for the teaching of pharmacogenomics in the course of
study?
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Attitudes of registered pharmacists in UAE toward genomic medicine and pharmacogenomics
4.Tell me about your attitude 4.a. In your opinion, how likely is it that pharmacogenomics testing will
toward genomic medicine
help to decrease the number of adverse drug reactions?
and pharmacogenomics:
4.b. In your opinion how likely is it that pharmacogenomics will help to
decrease the cost of developing new drugs?
4.c. Do you know anyone with genetic condition?
4.d. Do you feel that you are adequately informed about the availability of
genetic testing and its application in the context of drug therapy?
4.e. Do you think that the pharmacist should be the one who counsel
patients about genomic testing? Or we are not equipped to do so and should
leave it to the physician or genetic counsellor?
4.f. Do you rely on package leaflet (inserts) for information regarding
genetic testing and the prediction of response to drugs?
4.g. Do you think that pharmacogenomics test will benefit patients by:
-improving drug effectiveness.
-Reducing drug toxicity.
-Increasing patient’s understanding of their therapy.
-Improving patient’s adherence to therapy.
-Control drug therapy expenditures.
-Will not benefit the patients at all.
4.h. Do you think that insurance companies should cover the cost of
pharmacogenomics tests? Or you think there should be criteria for coverage
based on age, comorbidities and type of insurance card?
4.i. As a pharmacist, do you think that all pharmacists should be required to
have some knowledge of pharmacogenomics?
4.j. In your opinion , who should counsel the patient about their DNA
reports ? pharmacist ? physician? Genetic counselors?
4.k. Do you think there is a need to have laboratory facilities in UAE that
can do and analyze DNA analysis?
4.l. In general, to what extent are your opinions and decisions influenced by
religion?
4.m. Have you or anyone close to you ever had any experience with genetic
issues? For example, having a heritable disease in the family, or taking a
genetic test?
4.n. Will you consider having a genetic test to find out your risk of
developing various genetic diseases?
4.o. Are you glad that genetic tests can be ordered on the internet?
4.p. would like to participate in genetic research or donate to biobank?
5. Perceived barriers of implementation of genomic medicine and pharmacogenomics in UAE

5.Tell me what are the
barriers for adopting
genomic medicine and
pharmacogenomics in UAE

5.a. How concerned are you that unauthorized persons may gain access to
the results of genetic test or pharmacogenomics testes?
5.b How concerned are you that the results of genetic test or
pharmacogenomics testes can cause discrimination by employers and or
insurance companies?
5.c. How do you think the community in UAE will react to
pharmacogenomics and genomic medicine?
5.d. In your opinion what are barriers for the implementation of
pharmacogenomics in your practice setting?
-Shortage of personnel
-Lack of guidelines
-Lack of testing services
-Lack of training or education
-Cost of Testing

Comments
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Questions for the Retail Pharmacist
6.Views on DTC KIT
6.a. Do you sell DTC?
6.b. Do you think that DTC need FDA approvals?
6.c. Do you imagine that one day in the future each patient coming to your
pharmacy will have his /her pharmacogenomics analysis uploaded in an
electronic chip , so it can be guide your choice of the right medications and
dose ?

Concluding question:
Of all the points that we addressed today, what is the most important point you
would like to highlight about constructing a road map for the implementation of
Pharmacogenomics and genomic medicine in UAE?
Is there any other information that you think would be beneficial for me to know?
Conclusion:
My colleague and I cannot thank you enough for coming today and for opening up
and sharing your valuable opinions. I hope you found the discussion interesting.
If there is anything you are un satisfied with, please let me know either now or later.
I would like to emphasis again that all your comments and opinions will be
anonymous.
Before you leave, please hand in your completed demographic questionnaire.
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Text of e-mail invitation:
Dear Esteemed Pharmacist:
You are invited to participate in a focus group for a research project on the
Implementation of Genomic medicine and pharmacogenomics in UAE.
The project is called Establishing the Roadmap for Genomic Medicine and
Pharmacogenomics in the UAE
It is part of my PhD studies at United Arab Emirates University and has been
approved by their Ethics committee.
I am asking you to take part in this focus group because you have valuable insight
and experience that will help shape the future of pharmacogenomics in UAE.I have
asked nine other pharmacists to join us in the discussion and I will be assisted by 1-2
colleagues.
DATE: Saturday 15 December 2018
TIME: 11:00 AM
DURATION: 2 hours
LOCATION: UAEU, CMHS, the campus near Tawam hospital, male entrance,
ground floor, institute of public health, Room: IPH-GE108.
You will need to sign at the entrance to gain visitor access, and there will be signs to
guide you to the venue as well as refreshments.
Confidentiality
Please note that your name and any identifying information you share with us will
remain confidential. Your responses will be summarized along with other responses
and used collectively to help guide decision-making. No names or identifying
information will be used when compiling this information.
Consent
There is no obligation to participate in this focus group. You may refuse to
participate or withdraw at any time and it will not affect your practice in any way.
I do very much hope that you will agree to take part and looking forward to seeing
you on Saturday 15 December 2018.
Please email me back or call me on my mobile (0501126098) to confirm your
attendance.
Yours,
Azhar Talal
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Appendix H: Interview Guide for Stakeholders
Q1. Can you tell me about yourself? Your qualifications and area of practice
Q2. Do you apply GENETIC testing in your practice setting?
Q3. Do you apply GENOMIC testing in your practice setting?
Q4. Do you apply pharmacogenomics (drug selection, dosing, monitoring, counseling)
for a patient in your practice setting?
Q5. As far as you know, do the testing carried at your hospital lab or abroad?
Q6. Do you think there is a need to have laboratory facilities in UAE that can do and
analyze DNA ?
Q7. Do you know how to read genome sequencing report?
Q8. Do you think that more time should be devoted for the teaching of Genomic
medicine and /or pharmacogenomics in the course of study?
Q9. In your opinion how likely it is that pharmacogenomics will help to decrease the
cost of treatment?
Q10. Do you think that the pharmacist should be the one who counsel patients about
genomic testing? Or you think the physician should counsel the patient?
Q11. Do you see a future were genetic counselor set with patients and their families
and discuss susceptibility for diseases and life style modifications based on genome
sequencing?
Q12. How do you think that pharmacogenomics test will benefit patients?
Q13. Do you think that insurance companies should cover the cost of
pharmacogenomics and or genomic tests?
Q14. Are you going to depend on pharmacists to intervene based on
pharmacogenomics?
Q15. Have you or anyone close to you ever had any experience with genetic issues?
For example, having a heritable disease in the family, or taking a genetic test?
Q16. Will you consider having a genetic test to find out your risk of developing various
genetic diseases?
Q17. Are you glad that genetic tests can be ordered on the internet? Why?
Q18. Do you like to participate in genetic research or donate to biobank?
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Q19. How concerned is you that unauthorized persons may gain access to the results
of genetic test or pharmacogenomics testes?
Q20. How concerned is you that the results of genetic test or pharmacogenomics testes
can cause discrimination by employers and or insurance companies?
Q21. How do you think the community in UAE will react to pharmacogenomics and
genomic medicine?
Q22. In your opinion what are barriers for the implementation of pharmacogenomics
in your practice setting?
Q23. Of all the points that we addressed today, what is the most important point you
would like to highlight about constructing a road map for the implementation of
Pharmacogenomics and genomic medicine in UAE?
Q24. Can you share with me an experience in which you used genomic medicine or
pharmacogenomics?
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